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Abstract
Stereotactic ablative body radiotherapy (SABR) is the standard of care for inoperable earlystage non-small cell lung cancer (NSCLC) patients. However, thoracic tumours are
susceptible to respiratory motion and, if unaccounted for, can potentially lead to dosimetric
uncertainties. Respiratory gating is one method that limits treatment delivery to portions of
the respiratory cycle, but when combined with intensity-modulated radiotherapy (IMRT),
requires rigorous verification. The goal of this thesis is to optimize respiratory gated IMRT
treatment planning and develop image-guided strategies to verify the dose delivery for
future early-stage NSCLC patients.
Retrospective treatment plans were generated for various IMRT delivery techniques,
including fixed-beam, volumetric modulated arc therapy (VMAT), and helical
tomotherapy. VMAT was determined the best technique for optimizing dose conformity
and efficiency.
A second treatment planning study that considered patients exhibiting significant tumour
motion was conducted. Respiratory ungated and gated VMAT plans were compared.
Significant decreases in V20Gy and V50%, predictors for radiation pneumonitis and
irreversible fibrosis, respectively, were observed.
The predominant uncertainty of respiratory gating lies in the ability of an external surrogate
marker to accurately predict internal target motion. Intrafraction triggered kV imaging was
validated in a programmable motion phantom study as a method to determine how
correlated the internal and external motion are during ungated and gated VMAT deliveries
and to identify potential phase shifts between the motions.
KV projections acquired during gated VMAT delivery were used to reconstruct gated conebeam CT (CBCT), providing 3D tumour position verification. Image quality and target
detectability, in the presence of MV scatter from the treatment beam to the kV detector,
was evaluated with various imaging parameters and under real-patient breathing motion
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conditions. No significant difference in image quality was observed for the CBCT
acquisitions with or without the presence of MV scatter.
This thesis explores the benefits of combining respiratory gating with IMRT/VMAT for
the treatment of early stage NSCLC with SABR, and evaluates advanced on-board imaging
capabilities to develop dose delivery verification protocols. The results of this thesis will
provide the tools necessary to confidently implement a respiratory gated radiotherapy
program aimed at improving the therapeutic ratio for early-stage NSCLC.

Keywords
lung cancer, respiratory motion, respiratory gating, intensity modulated radiation therapy
(IMRT), volumetric modulated arc therapy (VMAT), stereotactic ablative body
radiotherapy (SABR), flattening filter free (FFF), , intrafraction imaging, cone-beam CT
(CBCT).
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Chapter 1
“The purpose of education is to replace an empty mind with an open one”
– Malcom Forbes

1

Introduction

1.1 Lung Cancer
Cancer has recently surpassed cardiovascular disease as the leading cause of death in most
countries1. In Canada, cancer accounted for 29.9% of all deaths compared to 19.7% from
heart disease in 20112. More specifically, lung cancer is the leading cause of cancer death
with a five-year survival rate of only 17% and 20,600 deaths estimated in 20152. Lung
cancer can be further subdivided into two main groups, small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC), with 85% of all lung cancer diagnosed in the latter
category. SCLC is a fast progressing disease and typically initiates in the centre of the
lung3. NSCLC is subdivided into adenocarcinoma, where growth starts in the glandular
cells in the outer part of the lung, squamous cell carcinoma, which initiates in squamous
cells lining the bronchus, and large cell carcinoma, which can grow anywhere in the lung
and exhibits rapid progression. Patients are classified based on the TNM staging system,
that describes the characteristics of the tumour, node, and metastasis (Table 1-1). Earlystage (T1-2, N0) NSCLC where lesions are localized and have not metastasized to regional
lymph nodes, account for approximately 14% of the total lung cancer4. Effective treatment
options for these lesions are either surgery, radiation therapy, or both. In this thesis, we
focus on contemporary radiation therapy techniques.
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Table 1-1: The TNM staging of NSCLC. Table adapted from Edge et al. 2,5
Stage
Tumor (T)
Occult Carcinoma TX
0
Tis
IA
T1a,b
IB
T2a
IIA
T2b
T1a,b
T2a
IIB
T2b
T3
IIIA
T1a,b T2a,b
T3
T4
IIIB
T4
Any T
IV
Any T

Nodal (N)
N0
N0
N0
N0
N0
N1
N1
N1
N0
N2
N1, N2
N0, N1
N2
N3
Any N

Metastasis (M)
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M1a,b

5-year survival

49%
45%
30%

31%
14%

5%
1%

T denotes tumour size:
x: Primary tumour cannot be assessed, tumour proven by presence of malignant cells but not visualized by
imaging or bronchoscopy
is: Carcinoma in situ
1: Surrounded by lung or visceral lung without bronchoscopic evidence of invasion more proximal than lobar
bronchus.
1a: Tumor 2 cm or less in greatest direction
1b: Tumor more than 2 cm but less than 3 cm in greatest direction
2: Tumor has any of: involves main bronchus, 2 cm or more from carina; or invades visceral pleura; associated
with atelectasis, or obstructive pneumonitis that extends to the hilar region but does not involve entire lung
2a: Tumor more than 3 cm but less than 5 cm in greatest direction
2b: Tumor more than 5 cm but less than 7 cm in greatest direction
3: Tumor more than 7 cm or one that directly invades any of: parietal wall, chest wall, diaphragm, phrenic
nerve, mediastinal pleura, parietal pericardium; or tumour in the main bronchus less than 2 cm distal to the
carina but not involving the carina; or associated atelectasis or obstructive pneumonitis of the entire lung, or
separate tumor nodule(s) in the same lobe
4: Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent
laryngeal nerve, esophagus, vertebral body, carina, separate tumour nodules in a different ipsilateral lobe
N denotes extent of regional lymph nodes spread
0: No regional lymph node metastasis
1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes,
including involvement by direct extension
2: Metastasis in ipsilateral mediastinal and/or sub-carinal lymph nodes
3: Metastasis in: contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, and
supraclavicular nodes
M denotes distant metastases
0: No distant metastasis
1: Distant metastases
1a: Separate tumour nodule(s) in a contralateral lobe, tumour with pleural nodules or malignant pleural
effusion
1b: Distant metastasis (in extrathoracic organs)
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1.2 Treatment Strategies for Early-Stage NSCLC
1.2.1

Surgical Resection

Surgical resection through lobectomy or sublobar resection, remains the standard of care
in treatment of early-stage NSCLC patients. Lobectomy provides superior outcomes over
sublobar resection with improved local control and extended overall survival (OS)6.
Estimated 3-year OS for lobectomy is 79% and 80% for local and nodal recurrence free
survival7, respectively. Although surgical resection has shown promising outcomes, it is
often precluded due to significant co-morbidities, poor cardiac function, or decreased
pulmonary reserve exhibited by the patient.

1.2.2
1.2.2.1

Radiation therapy
Conventional Radiation Therapy

Options for early-stage NSCLC patients deemed inoperable or who refuse to undergo
surgery are radiation therapy, or observation without cancer specific treatment. In external
beam radiation therapy, the tumour is targeted using high energy x-rays. However, some
dose is deposited to normal tissue along the x-ray beam paths to the tumour, as
demonstrated for a sample patient in Figure 1-1.

Figure 1-1. Colour wash of the dose distribution for an early-stage NSCLC patient. The
prescription dose was 54 Gy (absorbed energy per unit mass, J/kg). The purple colour
depicts the low dose deposited along the paths of the beams.
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In deciding the prescription dose and dose distribution, the goal of radiation therapy is to
provide the optimal tradeoff between targeting the tumour to increase tumour control
probability (TCP), while reducing normal tissue complication probability (NTCP)8.
Conventional three-dimensional conformal radiation therapy (3D-CRT) is delivered with
a prescribed tumour dose of 60 Gy or more delivered over the course of six weeks, in 30
daily fractions. The fractionation scheme of 2 Gy per fraction resulted in low NTCP, but
unfortunately, outcomes of such conventional fractionations also yielded low TCP and
overall survival, leading inoperable patients to forego any treatment options9,10. Dose
escalation to early-stage NSCLC lesions has been shown to provide improved TCP11,12, but
the increase in fractionation dose is associated with increased dose to normal lung, and
potential worsening of NTCP.
Dosimetric lung parameters used to predict radiation induced lung toxicities are the percent
volume of lung receiving 20 Gy or more (V20Gy), the absolute volume of lung receiving
50% of the prescription dose (V50%), and the mean lung dose (MLD)13–15. Treatment
planning requires maintaining these dosimetric parameters as low as possible to help avoid
potential radiation-induced lung toxicities.

1.2.2.2

Stereotactic Ablative Body Radiotherapy (SABR)

Over the past decade, stereotactic ablative body radiotherapy (SABR), a hypo-fractionated
treatment technique imitating the surgical knife in ablating the tumor with a high dose of
radiation delivered within a two-week period, has been implemented in the clinic16.
Outcome studies for SABR have revealed impressive 3-year local control rates upwards of
90%17–21. More recently, a study concluded SABR as a viable treatment option in operable
early-stage NSCLC patient, with 3-year OS, and local or nodal recurrence free survival of
95% and 86%, respectively, surpassing surgical outcomes of 79% and 80%, respectively 7.
SABR treatment prescriptions vary based on organs at risk (OAR) in proximity to the
target; lesions located adjacent to the chest wall are prescribed 55 Gy in five fractions,
lesions located within 2 cm of the mediastinum are prescribed 60 Gy in eight fractions, and
centrally located lesions are prescribed 54 Gy in three fractions, spanned over one or two
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weeks. Conventional treatment for NSCLC includes a prescription dose of 60-66 Gy in 30
daily fractions (or 6 weeks).

1.2.2.3

Intensity Modulated Radiation therapy (IMRT)

Treatment with intensity modulated radiation therapy (IMRT) in SABR leads to
improvement in target dose conformity and reduction in toxicities to normal tissue22.
Treatment is optimized by reducing the objective function based on set objectives for the
target and normal tissue sparing. Intensity gradients of dose are created by modulating the
fluence of incident beams using a computer controlled multi-leaf collimator (MLC) to
produce beam segments within each treatment beam. Efficiency in IMRT can be improved
by incorporating automated treatment planning to set the beam geometry, create regions of
interest to aid treatment planning, and to determine optimization objectives (Appendix A).
There are different modalities to deliver IMRT that can be classified into: fixed beam
IMRT (FB-IMRT)22,23, volumetric modulated arc therapy (VMAT)24,25, and helical
tomotherapy (HT)26–28. FB-IMRT implies the gantry is held stationary (per beam) while
all segments required to modulate the beam are delivered. The FB-IMRT group can be
further subdivided into step-and-shoot and sliding window techniques. In step-and-shoot
delivery, the beam intensity pattern is the weighted summation of all its segments. During
each segment, the MLC leaves remain stationary. In sliding window delivery, the MLC
leaves transition during irradiation. VMAT treatments are designed using a broad treatment
beam as the gantry rotates, simultaneously varying gantry speed, dose rate, and MLC leaf
positions25. Modulation is dynamically achieved as the gantry rotates in an arc. Equally
spaced positions along the arc are initially coarsely sampled (Figure 1-2A) followed by
added sampling points equally spaced between previous points until desired spacing in
sampling points is achieved (Figure 1-2)25. Another rotational IMRT modality, HT
delivery, is a slice-by-slice treatment delivery using a fan beam, a binary MLC, and
synchronizing couch motion through the bore, to gantry rotation during treatment. In the
clinic, there is a lack of consensus on which IMRT technique is optimal for radiotherapy
planning in SABR22–24,26. Chapter 2 of this thesis compares these various treatment options
and techniques.
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Figure 1-2. Continuous treatment beam and MLC motion in VMAT is modeled as static
source positions initially coarsely spaced (a). During treatment planning optimization,
sampling points are added midway between previous points (b, c). The next sample set are
added starting at the beginning of the gantry range (d). Additional samples are continuously
added until the desired sampling frequency of gantry rotation is reached. Adapted from
Otto25

1.2.2.4

Dose Calculation Algorithms

With increasing complexity of treatment planning and delivery, as in IMRT, the dose
calculation algorithm selected during treatment planning is an important step to ensure
quality of treatment plan. There are multiple dose calculation algorithms available, where
Monte Carlo technique is considered the gold standard. Monte Carlo technique is a
randomized statistical method to determine the probability of certain events occurring. In
radiation therapy planning, for a large number of histories, the path of a particle is
simulated by using knowledge of the probability of photon and electron interactions29,30.
However, Monte Carlo based dose algorithms require long computational times. Other
dose calculation algorithms modelled include collapsed cone convolution (CCC), and
Acuros XB.
In convolution-based dose calculation algorithm, the modelled primary energy fluence is
projected through the medium. The total energy released per unit mass (TERMA) is
calculated at each voxel based on the mass attenuation coefficient of the medium and the
primary fluence. The dose distribution is calculated by convolving TERMA with the dose
point spread function, or kernels, at each voxel. Dose point spread functions are modelled
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using Monte Carlo for a homogeneous phantom. Dose heterogeneity corrections are
required to account for different densities. Dose calculation time is reduced from voxel
based in convolution, to a set of arrays, or cones, in CCC to be convolved with TERMA31,32.
CCC is applied clinically in all IMRT treatment delivery techniques described above.
Acuros XB dose algorithm is based on a solution to the linear Boltzmann transport equation
and directly handles the effects of tissue heterogenity33,34. The linear Boltzmann transport
equation describes primary and secondary particle interactions as they travel through a
medium. Acuros XB dose algorithm treatment planning results in similar dose distribution
from Monte Carlo based algorithms for small fields with tissue heterogeneity, as in earlystage NSCLC35-37. Both, CCC and Acuros XB dose algorithm, are applied in Chapter 2 of
this thesis.

1.3 Respiratory-Induced Target Motion
In the treatment of thoracic cancer, interfractional changes include patient’s weight loss,
tumour growth or shrinkage, and variations in respiratory motion pattern, and
intrafractional motion includes cardiac, muscular and respiratory breathing motion.
Respiratory motion induces variability in target position for both interfraction and
intrafraction conditions.
Respiratory breathing is comprised of involuntary and voluntary physiological
mechanisms. In quiet breathing, the alveolar pressure, or the intrapulmonary pressure, is
controlled by the diaphragm and intercostal muscles, Figure 1-3. During inhalation, the
diaphragm, a dome-shaped muscle, contracts and descends, while the external intercostal
muscles contract, and move the rib cage upwards and outwards. This allows a decrease of
alveolar pressure relative to the atmospheric pressure, and air flows into the thoracic cavity.
During expiration, the diaphragm muscle relaxes and ascends, and the intercostal muscles
move downwards and inwards, simultaneously. The alveolar pressure increases relative to
barometric pressure and air will flow out of the thoracic cavity.
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Figure 1-3. Diagram displaying the process of quiet breathing. Adapted from Silverthorn
et al.38
The individual lungs are enclosed by the visceral pleura, and an outer membrane, the
parietal pleura, surrounds the thoracic cavity maintaining separation from the mediastinum.
The space in-between the visceral and parietal pleura creates the intrapleural space and
helps keep the lungs inflated through the intrapleural pressure. Trans-pulmonary pressure
is the difference between the alveolar pressure and the intrapleural space, typically about 3 mmHg38. Pneumothorax, or collapsing of the lung, occurs if trans-pulmonary pressure
drops to zero, causing fluid or air to fill the intrapleural space.
The elasticity required to aid in exhalation and the lung tissue viscoelasticity causes an
increase in the volume at the same pressure during inhalation, leading to lung hysteresis.
This can lead to variabilities in the respiratory motion.
The diaphragm is the most important muscle in quiet breathing accounting for 60% to 75%
of lung volume changes. The contraction and relaxation of the diaphragm can lead to an
increase in motion magnitude of proximal tumours, primarily in the superior-inferior (SI)
direction. The intercostal muscles connect adjacent ribs and help enlarge the chest cavity
in the anterior-posterior (AP), and lateral direction to allow more airflow38. In thoracic
cancers, the lesion will move in conjunction with respiratory breathing motion. A study by
Yu et al39 has reported a median tumour motion of 4.2 mm in the SI direction for earlystage NSCLC. For lesions located in the lower lobes, a median tumour motion of 9.2 mm
in the SI direction was observed39. Respiratory motion is unpredictable and variable
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between patients and within the same patient over the course of treatment40–45. Therefore,
different techniques have been developed to monitor breathing patterns during irradiation.

1.3.1

Motion-Induced Dosimetric Uncertainties

In the presence of motion, the static dose distribution to the target will be blurred,
potentially causing under-dosage to the tumour and over-dosage to surrounding normal
tissue. In a single IMRT fraction, the impact of intrafraction motion can result in errors up
to 18% to 20% compared to the intended static target dose46–48. IMRT-defined radiation
fields are not exclusively restricted by the primary collimators, but are defined by moving
MLC leaves. The motion of the target is independent of the motion of the MLC leaves
allowing for the potential of the target to unintentionally move in and out of these gradients.
The lack of synchronicity between the MLC leaves and tumour motion causes an “interplay
effect” and is not accounted for in radiation treatment planning systems. As radiation fields
become more modulated, the potential for errors due to the interplay effect increases. Over
the course of treatment, studies have shown that the interplay effect may average out for
conventional fractionations, causing an estimated 2% error47,49. However, lung SABR
treatments are often limited to three to eight fractions, resulting in less opportunity for the
interplay effect to average out. On the other hand, individual SABR treatments are longer,
due to the increased dose per fraction, reducing the interplay effect on tumours that move
by up to 1-cm50–54.
Respiratory motion management is required for patients exhibiting large tumour motion
amplitudes, highly modulated fields, and fast beam delivery54. According to the AAPM
task group 76 on respiratory motion effects in radiation therapy, respiratory management
techniques are advised for tumour motion greater than 5 mm to help reduce uncertainty in
dose delivery and normal tissue toxicity55. Respiratory motion can expose surrounding
healthy tissue to radiation and increase the risk of radiation-induced pulmonary toxicities56–
58

. Two common toxicities associated with lung cancer radiotherapy are radiation

pneumonitis, an early adverse effect, and irreversible fibrosis, a late effect 13,59,60, further
investigated in Chapter 3.
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1.3.2

Motion Artifacts in CT Image Acquisition

The precision of dose delivery relies on an accurate representation of a patient’s internal
anatomy depicted by computed tomography (CT) imaging. A stationary subject is assumed
during CT simulation, and respiratory motion hinders image quality by causing imaging
artifacts in thoracic CT61–64. During acquisition of an image slice, variability in respiratory
phase causes slice displacement artifacts in the reconstructed CT volume. Tumour
movement in-between the image slice acquisitions, inflicts geometric uncertainties in the
reconstructed CT volume61, as shown by Figure 1-4.

Figure 1-4. Respiratory motion induced imaging artifacts in CT. A) Target motion as CT
slices are acquired, B) Distorted reconstructed volume representation. Adapted from Balter
et al.61
Severity of imaging distortions are related to the sampling time per slice, slice thickness,
gantry speed, respiratory motion period and amplitude, and size of the lesion. The resulting
target volume exhibits geometric uncertainties i.e. shrinking or lengthening of the target,
and discontinuities in the edge geometry (Figure 1-5). Respiratory motion induced artifacts
from CT simulation are manifested as tumour and normal tissue delineation errors. These
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distortions can adversely affect treatment plans, dose calculation accuracy, and in turn,
treatment delivery.

A.

B.

C.

D.

E.

Figure 1-5. Reconstructed CT volume images with respiratory motion induced artifacts;
A. True geometry for the static spherical object; B-E. Different artifacts obtained by
standard axial CT scanning. Adapted from Rietzel et al63.
Respiratory motion is more problematic for images acquired on a treatment machine for
patient setup guidance before treatment, referred to as “on-board imaging”. The slow
rotation speed in on-board CT imaging causes substantial respiratory induced artifacts,
such as blurring, doubling, streaking, breakup, and distortions65–69 (Figure 1-6).

Figure 1-6. Respiratory induced artifacts in on-board CT imaging. The image on the left
is static square-shaped phantom, and the magnitude of motion applied to the phantom in
the SI direction (or up and down direction) increases from left to right. Adapted from Song
et al68.
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1.4 Respiratory Motion Management Techniques
Respiratory motion should be considered during both CT simulation and treatment
delivery. The impact of respiratory motion in early-stage NSCLC can be limited through
breath-hold methods, tumour immobilization, respiratory tumour tracking, and respiratory
gating. Reduction in target motion results in smaller treatment field sizes, and potentially
reduced normal tissue toxicity. A brief overview of each method will be provided in the
following subsections while respiratory gating will be explained in greater detail in section
1.5.

1.4.1

Motion-Encompassing Methods (4D-CT)

Respiratory motion introduces imaging artifacts and hinders accurate localization of the
tumour and internal structures acquired during 3D-CT simulation. Large margins for the
tumour can be incorporated to ensure full target coverage for the observed range of motion,
but cause greater risk of radiation induced toxicities to normal tissues. Imaging techniques
that allow for better visualization of the envelope of target motion, and permit more
accurate margins are required.
Four-dimensional CT (4D-CT) is the most common approach that integrates organ motion
into the acquisition of the CT dataset to facilitate treatment planning63,70–73. Here,
volumetric image data is acquired at different respiratory phases by oversampling each
slice position in synchrony with a respiratory breathing signal (Figure 1-7). Helical and
cine acquisition mode are two techniques utilized to acquire 4D-CT dataset74. Slice
positions in helical 4D-CT are oversampled by reducing the pitch, or reducing the ratio of
the scanning table translation per gantry rotation. In cine mode, sequential CT data is
acquired over a full breathing cycle at fixed scanning table positions.
During 4D-CT acquisition, the respiratory motion of an external surrogate labelled with
infrared reflective markers is tracked using an infrared camera. The external surrogate is
placed between the xyphoid process and umbilicus, and records the AP motion of the
abdomen surface. Respiratory phase is determined from the respiratory signal and the
image data acquired simultaneously is tagged according to the corresponding respiratory
phase (Figure 1-7B). Retrospectively, all acquired image data are sorted into different
12

phase bins (Figure 1-7A). If a respiratory trace is divided into ten bins, the 0% phase
represents the end inhalation, 10% - 40% phase represent mid exhalation, 50% phase
represents the end exhalation, and 60% - 90% phase represents mid-inhalation. A 3D-CT
volume reconstructed from image data acquired from a single phase, represents a 3D
volumetric image at one respiratory phase bin. A 4D-CT dataset is the collection of the 3DCT volumes reconstructed from all phases.

B.

A.

Figure 1-7. 4D-CT phase-sorting process. In this simplified example, the acquired CT
images are sorted into only four distinct bins (A) based on respiratory phase of the
respiratory signal (B). Adapted from Vedam et al71.
In early-stage NSCLC, 4D-CT imaging can facilitate target delineation to provide a
representation of target excursions caused by full breathing motion. The gross target
volume (GTV), can be contoured in each of the phases of the 4D-CT, where the union of
all the phases represents the internal target volume (ITV), as shown in Figure 1-8.
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Figure 1-8. 4D-CT image displays the gross target volume (GTV) in the end-inhalation
(A), end-exhalation (B), the internal composite target volume (ITV) in green with the
planning target volume (PTV) in yellow (C). Adapted from Glide-Hurst et al75.
However, delineating the GTV and all OARs in all of the 4D-CT phases substantially
reduces workflow efficiency. Instead, post-processing tools can derive 3D-CT datasets to
provide a representation of the target. A time-averaged intensity CT image is generated
from the average voxel value across the breathing cycle image data acquired to represent a
blurred volume. Maximum intensity projection (MIP) 4D-CT is derived by fusing the 3DCT volumes of the different respiratory phases based on the maximum intensity of each
voxel76–78. In MIP images, the high density tumour appears brighter than low density
lung63. MIP 4D-CT is useful for peripheral tumours but delineation of tumours in proximity
to the chest wall, mediastinum, or diaphragm becomes more difficult.
For SABR, 4D-CT dataset acquisition for treatment planning aids in determining the
mean79, and range of tumour motion80. Improved delineation of the tumour and critical
structures mitigates potential target misses, especially for tumours exhibiting large
magnitude of motion81.
The disadvantage of using motion-encompassing methods includes irradiating larger target
volumes and, as a consequence, larger normal lung volumes. In tumours exhibiting motion
greater than 5 mm, other methods to minimizing tumour motion during treatment delivery
can yield significant normal tissue sparing55.
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1.4.2

Breath-hold Methods

A method to minimize target volumes during treatment is through control of respiratory
breathing either voluntarily or by an occlusion valve

55,82

. An occlusion valve is used in

active breathing control (ABC), where air flow to the patient is temporarily blocked at endinhalation, immobilizing the lung and stalling target motion83,84. The treatment beam
irradiation is enabled once the target has been immobilized according to the desired tidal
volume. Another common breath-hold technique uses deep inspiration breath-hold (DIBH)
where the patient voluntarily controls his or her breathing while interactively observing
their respiratory trace82,85–88. Prior to treatment, the patient is coached through quiet
breathing followed by two breathing periods of slow deep inspiration and expiration prior
to the breath hold, as in Figure 1-985. This provides reproducible motion control at endinhalation. In both techniques, the breath is held for 10 – 20 seconds for every iteration.
Respiratory motion is tracked during treatment using spirometry, surface markers, or an
external surrogate. Regardless of the technique used for breath-holding during treatment
(ABC or DIBH), the same management technique should be also used during CT
simulation.
Motion management through the use of breath-hold at deep-inspiration provides tumour
immobilization and the added benefit of a reduced lung density that enhances tumour
contrast and visualization85.

15

Figure 1-9. Deep inspiration breath-hold (DIBH) consists of slow quiet breathing session
followed by a reproducible deep breath hold. Adapted from Hanley et al85.
DIBH relies on active participation of the patients but inoperable NSCLC patients treated
with SABR often exhibit poor pulmonary function and are often fragile, making breathhold a very challenging task. Another limitation during breath-hold is that some patients
exhibit continuous diaphragm oscillatory motion, leading to fluctuations in tumour
position55.

1.4.3

Tumour Immobilization Methods

The magnitude of respiratory motion during treatment and CT simulation can be minimized
mechanically by forced shallow breathing. Abdominal compression is the most common
approach where a body frame with pressure plate is applied to the patient’s abdomen to
limit diaphragm motion89-91. The maximum possible pressure a patient can comfortably
manage is pressed against the abdomen. The position and pressure applied during CT
simulation, is recorded to provide reproducible setup during each treatment fraction.
While attempting to minimize respiratory motion, abdominal compression is not well
tolerated by patients92. Studies have shown a statistically significant increase in
interfractional variation of tumour position for SABR lung patients treated with abdominal
compression methods90,92,93.
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1.4.4

Respiratory Tumour Tracking Methods

In the above techniques, large margins are required to encompass the target as it moves
during full respiratory motion, or suppressing tumour motion through breath-hold and
abdominal compression causes discomfort to the patients that may be intolerable. In
respiratory tumour tracking, the patient breathes freely and target margins are reduced by
tracking the tumour motion within the radiation beam94. Safe incorporation of respiratory
tracking requires monitoring of the tumour trajectory, and compensation for the tumour
motion geometrically and dosimetrically.
The motion trajectory of the target can be acquired through imaging, such as fluoroscopy,
for lesions located centrally in the lung where normal structures will not obstruct visibility;
however, lesions located adjacent to normal tissue (diaphragm, mediastinum, and chest
wall) will lack visibility. Fiducial markers are high atomic number metals, typically gold
pellets, and can provide high contrast when implanted within the lesion of interest using a
percutaneous or bronchoscopic implanting technique. Three or more fiducial markers are
required to allow for measurements of rotation and translation between the markers55. The
position of fiducial markers within the tumour, is determined using imaging or from an
emitted radiofrequency (RF) signal. However, placement of fiducial markers is an invasive
procedure, and can be susceptible to migration during treatment. External surrogates on the
chest can be used alternatively to account for breathing motion if the correlation with
tumour trajectory motion can be verified.
The radiation beam mechanically follows the tumour using MLC tracking95,96 or a robotic
linear accelerator with six degrees of freedom97–99. However, delays in linear accelerator
reposition once motion coordinates are determined can occur; in the case of MLC tracking,
time delays of 200 ms or more occur100. There are additional time delays for determining
the coordinates of the tumour in the images. Position predictive algorithms based on
previously acquired motion trajectory are used to prospectively adapt the radiation beam.
These algorithms assume periodicity of motion from planning to treatment delivery101. As
mentioned in section 1.3.1, respiratory motion may exhibit both inter- and intra- fractional
variability42,45,102.
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Radiation treatment planning requires computation of dose distributions in all the
respiratory phases of the 4D-CT dataset because of geometric displacements and lung
density changes. The relationship between respiratory phase and the tumour motion
trajectory, adapts the treatment dosimetrically103.
A summary of the different motion management techniques is provided in Table 1-2.
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Table 1-2. Summary of the different methods of respiratory management and variations in intra- and inter-fraction motion.
Abbreviations: BH: breath-hold, ABC: active breathing control, SD: standard deviation, LR: left-right, AP: anterior-posterior, SI:
superior-inferior, DIBH: deep inspiration breath-hold, *includes setup error, 3D—3-dimensional error, mDIBH moderately deep
inspiration breath-hold. Adapted from Keall et al55.
Motion
Management
Technique
Breath-hold

Advantages

-

Limited
tumour
motion

-

-

Reduced lung
density

-

-

Does not
require
specialized
software and
hardware

-

Tumour
Immobilization

Disadvantages

-

Study

May require
patient active
participation
Patient exhibit
continuous
diaphragm
motion

Efficient due
to continuous
treatment
beam during
breath hold
Limit tumour
motion

-

Not well tolerated
by patients
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Mitigation
Method

Intra-fraction Inter-fraction
variation (cm) variation (cm)

Cheung et
al104

BH at
inspiration with
ABC

-

SD: 0.18 LR,
0.23 AP, 0.35
SI

Dawson et
al105

BH at exhalation
with ABC

SD: 0.25

SD: 0.44

Remouchamps et
al106

mDIBH with
ABC

Mean: 0.14

Mean: 0.19

SD: 0.17

SD: 0.22

Mean: 0.1

Mean: 0.25

SD: 0.09

SD: 0.16

Mean 3D: 0.7
Range: 0.2–
1.1

Mean 3D:
0.49* Range:
0.4–0.8*

Hanley et
al85

DIBH

Negoro et
al107

Abdominal
compression

-

Respiratory
Tracking

Respiratory
gating

-

Patient is free
breathing

-

Treatment
time is not
limited

-

Adapts to the
full 3D
motion

-

Limit tumour
motion

-

Patient is free
breathing

Significant
interfraction
variation

-

Requires periodic
respiratory
breathing

-

Mechanical delay
uncertainties

-

Increased
treatment time

-

89

Abdominal
compression

-

SD: 0.33 LR,
0.34 AP, 0.44
SI

Bissonnette
et al90

Abdominal
compression

Mean 3D:
0.24

Mean 3D: 0.3

Mampuya
et al93

Abdominal
compression

-

SD: 0.21 LR,
0.19 AP,
0.31 SI

Hoogeman
et al108

Robotic linear
accelerator

SD: 0.19 LR,
0.25 AP,
0.19 SI

-

Ford et
al109

Gating at
exhalation with
RPM

Mean: 0.26

Mean: 0.0

SD: 0.17

SD: 0.39

Wagman et
al110

Gating at
exhalation with
RPM

Mean: 0.20

-

Wulf et al

Internal target
and external
surrogate
correlation
uncertainty
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1.5 Respiratory Gating Methods
Respiratory gating also allows the patient to breath freely, and the treatment beam is
triggered only within a predetermined portion of the breathing cycle111–116. In respiratory
gating, the portion of the breathing waveform where the treatment beam is activated, is
coined the “gating window”. The gating window is predetermined according to the stable
portion of the breathing cycle, most often during the end-exhalation period. The respiratory
motion within the gating window is considered as the residual motion117. The respiratory
gating efficiency, or duty cycle, is defined as a percentage of the “beam on” time to total
treatment time112. The gating window is determined based on a tradeoff between limiting
residual motion, and optimizing the duty cycle to reduce overall treatment time. A subset
of the 4D-CT dataset corresponding to the respiratory phases within the intended gating
window are averaged to form the subset average 4D-CT dataset that is used for treatment
planning. The subset average 4D-CT incorporates the residual motion within the gating
window. The ITV, in this case, is generated based on the blur of the target volume in the
subset 4D-CT. Planning and set-up uncertainties are included in the planning target volume
(PTV) by the addition of a margin to the ITV, in early-stage NSCLC 5 mm margin is
used117. The result is a significant reduction in the target margins compared to conventional
free breathing ungated radiotherapy and as a result, reduced normal tissue irradiation111.
Internal respiratory gating, similarly to respiratory tracking, is facilitated through the use
of fiducial markers118. Originally developed by Mitsubishi Electronics Co. (Tokyo, Japan),
internal gating defines the gating window through fluoroscopic detection of fiducial
markers during treatment. Position of the fiducial markers is identified during treatment in
three dimensions using four sets of diagnostic x-ray imaging systems. Within the gating
window, the x-ray kV acquisition pulses are interlaced with the treatment MV pulses to
avoid scatter from the MV reaching the fluoroscopic detectors. As mentioned previously,
implantation of the fiducial markers is an invasive procedure generally not well tolerated
by inoperable SABR patients.
External respiratory gating relies on surrogate signals of a respiratory motion, and is a noninvasive alternative method for respiratory gating applicable to almost all patients 55. The
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external surrogate is an infrared reflective plastic box (Figure 1-10A) placed between the
xyphoid process and the umbilicus, to maximize the AP motion. During 4D-CT acquisition,
a mark is tattooed on the patient’s skin to ensure reproducible placement of the external
surrogate box during treatment. Infrared markers on the surrogate box have fixed nonsymmetric positions to facilitate observation of potential misalignment during geometric
calibration. The displacement of the external surrogate box is detected by the position
sensors with the in-room infrared camera (Figure 1-10B) generating a respiratory trace.

Figure 1-10. Respiratory gating external surrogate box with infrared markers (A) and
infrared Polaris Spectra NDI camera that tracks the markers (B).
Prior to each treatment session, the starting phase of the respiratory trace is matched to the
corresponding phase in the reference trace, recorded during 4D-CT acquisition (Figure
1-11) and used in treatment planning. Irregularities between 4D-CT acquisition and
treatment session breathing traces can be reduced through respiratory breathing training. If
the recorded waveform period does not match the reference waveform, the treatment beam
is triggered “off” and will not be allowed to begin.
In Figure 1-11, the gating window is dictated by the upper and lower gating thresholds. If
the thresholds are set to the same range, system will consider the gate as fully open and
beam holding will not occur.
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Figure 1-11. Respiratory chart demonstrating the gating window (yellow shaded area)
defined by the upper and lower gating thresholds (blue and orange lines, respectively). The
reference trace from the 4D-CT acquisition is demonstrated by the green waveform, and
the treatment waveform is displayed by the black waveform. Adapted from VitalBeam
imaging manual119.

1.5.1

Amplitude Gating

Amplitude gating is based upon the displacement of the external surrogate box as a
representative metric of the tumour at a certain position (Figure 1-12)116. The total
displacement in the respiratory signal is the position difference between end-inhalation and
end-exhalation. The respiratory waveform shown in Figure 1-12 displays the amplitude, or
motion above the baseline, versus time. The gating window, shown by the highlighted
yellow area in Figure 1-12, is defined as a window of displacement (solid line) allowed
from end-exhalation.
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Figure 1-12. Amplitude based respiratory gating waveform. The solid black curve
represents the waveform trace as a function of time, whereas the dashed black lines
represent the recurring respiratory phase (0 to 2π radians) as a function of time. The upper
and lower thresholds are displayed by the blue and orange lines, respectively. The gating
window is shown in the shaded yellow area.

1.5.2

Phase Gating

A sinusoidal pattern is used to approximate the real-patient waveform and analyze the
respiratory waveform. Phase values of a full breathing cycle (0 to 2π radians) are converted
into percent and divided into 10 equal bins ranging between 0% to 100%119. In the “needle
diagram” (Figure 1-13A) the end-inhalation is represented by 0% and end-exhalation by
50%. Inhalation occurs when the needle is in the left half of the dial (50%-100%), whereas
exhalation occurs in the right half of the dial (0%-50%). In phase gating, the gating window
is represented by two angular positions (dashed line) of the respiratory waveform (Figure
1-13B)116.
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Figure 1-13. Phase based respiratory gating waveform: A) Needle diagram representing
cyclic phase where the orange tick mark represents the entry to the gating window, and the
blue tick mark represents the exit of the gating window; B) Displacement waveform as a
function of time is shown in the solid black line, whereas the dashed black lines represent
the respiratory phase as a function of time. The entrance and exit of the gating window are
displayed by the orange and blue lines, respectively. The gating window is shown in the
shaded yellow area.

1.5.3

Learning Respiratory Motion

For both amplitude gating and phase gating, the respiratory waveforms are analyzed for
reproducibility. Raw data points from the external surrogate box are converted into a
smooth wave using polynomial fitting119. The end-inhalation and end-exhalation are
attained through a peak and trough detection to produce an estimate of the breathing
respiratory period. Each peak is assigned at 0%, with succeeding peak assigned at 100%.
A fixed value for end-exhale is not assigned but it is estimated to be around 50%. The
respiratory phase of end-exhalation depends on the pattern of the breathing cycle, in
respiratory traces exhibiting longer inhalation than exhalation, end-exhalation will occur
at phases <50%, whereas, respiratory traces exhibiting shorter inhalation than exhalation,
end-exhalation will occur at phases >50%.
Patient breathing characteristics are measured during the learning period that lasts for four
complete breathing cycles. Within the learning period, respiratory motion is required to be
periodic in order to provide a reproducible breathing trace. Fast breathing peaks in the
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learning period, defined as less than 1.5 seconds between consecutive inhalation or
exhalation peaks, or 0.5 seconds between inhalation and exhalation peak, are ignored and
not included in the motion characteristics analysis. The average end-exhale position is
measured over the learning period and assigned as the baseline value. The baseline value
is set to zero in the respiration chart and is only updated if re-learning of the breathing trace
is required. The respiratory trace acquired during 4D-CT is used as a reference and relearned if necessary, prior to every treatment session.
The periodicity of respiratory breathing trace is measured by calculating a phasedisplacement scattergram (Figure 1-14). Predictive filters are employed to correct for
irregular, non-periodic breathing by setting a threshold for the beam “on”120. The predictive
filter aids in restricting inaccurate treatment delivery by triggering the beam “off” when
the motion does not match the 4D-CT reference values within a predefined tolerance. In
respiratory gating, the treatment beam is paused if respiratory position falls outside of the
gating window, or if the motion periodicity falls outside of the predictive filter margins.

Figure 1-14. Characterizing periodicity in respiratory breathing trace. Examples for a
regular and irregular breathing cycles are shown. A sample gating window is displayed for
amplitude (blue shaded) and phase (red shaded) gating with a 40% duty cycle.
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1.5.4

Respiratory Gating Limitations

The respiratory gating window is optimized based on a tradeoff between duty cycle and
residual target motion. As duty cycle is minimized, treatment session times are increased.
Increased treatment time may cause intrafractional setup errors due to potential movement
from patient discomfort. Patient throughput on the treatment machine is also reduced by
increased treatment times. Studies have indicated potential reduced tumour control for
treatments that require longer than 20 mins122,122. This becomes increasingly important
with the combination of high dose per fraction SABR prescriptions, with respiratory gating.
Respiratory phase analysis relies on a sinusoidal approximation, leading to substantial
inconsistencies for patients that exhibit irregular respiratory motion (Figure 1-14). Phase
calculations are based on preceding breathing cycles so that inconsistencies between
breathing cycles will produce incorrectly defined respiratory phases. By comparison,
amplitude gating has demonstrated less variability when respiratory motion lacks
periodicity123–125.
The large uncertainty in external respiratory gating lies in the accuracy of an external
surrogate marker to predict the internal motion of the tumour. The magnitude of
displacement between the external surrogate and tumour motion does not need to be the
equal but must be correlated. However, correlation is contingent on the external signal
phase predicting the internal tumour respiratory phase. The inability to observe tumour
motion directly leads to uncertainties in the displacement and phase relationship between
the surrogate and the tumour126.
The internal and external correlation is disrupted or lost completely by transient and
continuous changes in respiratory motion breathing or instability in oscillatory mechanical
systems55,127. Lack of correlation can cause the radiation beam to trigger incorrectly in parts
of the breathing cycle (Figure 1-15). The external surrogate and internal target correlation
is further investigated in Chapter 4 of this thesis.
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Figure 1-15. Comparison of the internal and external motion without a phase shift (a), and
with a phase shift (b). The red lines indicate beam exposure times that are out of synchrony
with the target motion. Adapted from Keall et al55
Respiratory gated treatments are susceptible to inter-fraction variability in tumour and
external surrogate relationship, requiring relearning of periodicity before each fraction. The
risk of baseline variations increases with treatment time leading to the tumour movement
outside the gating window128. Intrafractional variation can cause discrepancies in dose
delivery with some targets being on the verge of under-dosage129,130.

1.6 High Dose Rate Gated SABR
1.6.1

TrueBeam Linear Accelerator

The Varian TrueBeamTM (Varian Medical Systems, Palo Alto, USA) linear accelerator
(LINAC) is a recent technical development that allows for the integration of respiratory
gating with VMAT and is the subject of Chapters 3-5. Respiratory-gated VMAT provides
the ability to safely combine the normal tissue sparing capabilities of respiratory gating to
superior treatment efficiency achieved through VMAT131. In respiratory gated VMAT, the
interplay effect contributes insignificantly to dose delivery errors due to minimal residual
motion, although increased motion irregularity in patients treated with gated VMAT has
shown to negatively affect the intended dose distribution50,132.
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Treatment delivery efficiency is improved by removing the flattening filter to enhance dose
rate. The flattening filter is located prior to the monitor chambers and succeeding the target
and primary collimators. The distribution of photons after the target is strongly forward
peaked, and the conical shaped flattening filter is used to obtain a uniform dose distribution
at a referenced depth. However, the role of the flattening filter is negligible for SABR
treatments due to the associated small field sizes (Figure 1-16). The advantage of flattening
filter free (FFF) beams is an increase in photon fluence allowing for higher treatment dose
rates (monitor units (MU) per minute). For example, a 10 MV FFF x-ray beam has a peak
dose rate of 2400 MU/minute, and a 6MV FFF beam has a peak dose rate of 1400 MU/min.
A conventionally flattened beam, on the other hand, has a peak dose rate of only 600
MU/minute133. The application of FFF beams in SABR treatments has significantly
improved efficiency134–136 while radiobiological properties are maintained137. Increased
efficiency in treatment times reduces potential intrafraction errors from patient movement,
as has been observed for treatment session times lasting more than 30 minutes138.

Figure 1-16. Axis dose profile at different depths in water, comparing flattened beams (A),
and FFF beams (B). The dose rates have been renormalized at a central depth of 2 cm.

Another feature of TrueBeam linac is the “Research Mode” interface that allows a
knowledgeable user to program motion trajectories of major accelerator components.
Research Mode provides access to the user to go beyond clinically approved modalities
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and investigate novel treatment and imaging techniques in a non-clinical setting139–143. The
user formulates specific axes of motion for each of the imaging and treatment delivery
trajectories, such as gantry, collimator, on-board kV imaging source and detector, etc, as a
function of cumulative dose, written in extensible markup language (XML).

1.6.2

Pre-Treatment Verification

As radiotherapy planning and delivery is becoming increasingly complex, dose delivery
verification (i.e. quality assurance) are even more necessary.

For respiratory gated

radiotherapy, verification of the intended gating window and the relationship between the
external surrogate motion and internal tumour motion is required during treatment delivery.
Image-guided radiation therapy (IGRT) has therefore been implemented prior and during
treatment to facilitate patient set-up, detect patient deformation from CT-simulation to
treatment delivery, and for dose verification.
Prior to treatment delivery, on-board imaging (OBI) or the electronic portal imaging device
(EPID) can be used to facilitate patient set-up and ensure there are not any significant
deformations in patient anatomy between the plan and the delivery session (Figure 1-17).
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kV source

MV source

kV detector

MV detector

Figure 1-17. Varian TrueBeam mounted on-board imaging (red squares) and electronic
portal imaging detector (orange square).
The EPID uses the MV beam to acquire a single image of the patient for setup verification.
Patient bony anatomy landmarks on the image can be used to guide patient alignment. High
energy photons reduce the overall noise in MV images144. However, poor image contrast
from the MV energy x-rays hinder soft tissue and, often, bony anatomy visualization.
On-board kV imaging, achieves contrast superior to images acquired with an MV source145.
The TrueBeam LINAC allows acquisition of a pair of orthogonal respiratory gated kV
radiographs. During respiratory gated patient setup, these planar images are compared to
digital reconstructed radiographs (DRR) generated from the planning CT dataset145,146.
The TrueBeam LINAC allows for kV fluoroscopy. The ability to also acquire a respiratory
trace simultaneously with the external marker block brings forth real-time monitoring and
correlation of visible lung structures. The position of the tumour can be determined as a
function of time. If the visibility of the tumour is poor, another moving anatomic surrogate,
such as the diaphragm, can be used to define the relationship of internal motion with the
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external surrogate motion. The gating window should be adjusted if a consistent time delay
of 0.5 sec or greater exists between internal and external surrogate motion55. To limit
radiation dose during continuous imaging, the imaging voltage and current can be lowered,
at the cost of image quality.
Continuous kV imaging acquired at multiple gantry angles allows for generation of a
volumetric cone-beam CT (CBCT)138. Volumetric CBCT permits soft tissue matching with
the treatment planning CT. There are two different types of filter applied to modify the kV
energy spectrum, in order to improve image quality. A 0.89 mm titanium filter is applied
to remove low-energy x-rays in the beam. Whereas, the bowtie filter is an aluminum shaped
filter applied to compensate for greater attenuation by the patient at center field, and reduce
patient skin dose. In full-fan CBCT, using a full-bowtie filter, the FOV is limited by the
detector size. In scans where patient size surpasses the detector size, such as thoracic scans,
half-fan CBCT scanning technique is used. In half-fan CBCT, using the half-bowtie filter,
the FOV width is increased by offsetting the position of the detector and scanning only half
of the patient for part of the rotation and offsetting the position of the detector in the
opposite direction for the remainder of rotation. The shifted projections are retrospectively
stitched together.

1.6.3

Intrafraction Treatment Verification

Pre-treatment verification aids in diminishing inter-fractional uncertainties. However,
intra-fractional uncertainties are still persistent during SABR lung treatments128 and can
inhibit treatment delivery accuracy if not accounted for.
Acquiring MV portal imaging during treatment can allow for a dosimetric and real-time
verification of radiation dose delivery. The EPID can acquire beam’s-eye-view (BEV)
projections throughout treatment. Either a “single shot” image can be acquired or a
synchronized MV, or cine loop, can be used to acquire continuous readout of images
between beam pulses147. Both provide a utility to verify the target is within the gating
region. For dosimetric verification using unsynchronized MV, the EPID can be operated
in integrated mode and continuously reads out and assimilates acquisitions, resulting in a
single image representing the total dose delivered per beam. These images can be used to
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reconstruct the 3D dose distribution for comparison to the planned dose distribution;
deviations in the accumulated dose could be accounted for in subsequent fractions148. MV
imaging using FFF beams during treatment provides shaper images compared to standard
flattened beams, due to a reduction in primary head scatter149.
A technique to combine kV and MV imaging for intra-treatment verification in VMAT and
fixed beam IMRT is discussed by Ren et al139. For clinical respiratory-gated delivery
verification, kV imaging can been triggered prior to or at the exit from the gating
window150–152. However, triggered kV imaging is limited in examining residual motion
inside the gating window. Geometrical verification and residual motion analysis can be
investigated through kV fluoroscopy during treatment153. Fluoroscopic imaging acquired
during respiratory gated SABR treatment provides additional intrafraction information at
the cost of additional imaging dose. Also, the ability to trigger fluoroscopic imaging only
within the gating window is not possible in current clinical mode of operation. Therefore,
longer treatment times associated with respiratory gated SABR, make this application
impractical due to the significant increase in imaging dose to the patient and the strain on
the x-ray tube. In chapters 3 and 4 of this thesis, respiratory gated kV imaging is
investigated using Research Mode of operation.
The image quality of in-treatment fluoroscopy is significantly reduced due to patient scatter
of the treatment beam to the kV detector154. The percent of the scatter dose from the
isocenter to the detector ranges between 0.0154% to 0.0174% for 10 cm by 10 cm field
size with a 10 MV beam (Appendix B)155. Different groups have investigated removing the
MV contribution to the kV detector through readout of unexposed kV frames156, and
interlacing kV projections between MV pulses157,158.

1.7 Research Questions and Hypothesis
The aim of this research is to optimize and improve radiation treatment planning and
delivery using state of art technologies for early-stage NSCLC patients treated with SABR.
SABR fractionation schemes consist of high doses (54 Gy - 60 Gy) delivered in only a few
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fractions (3–8), requiring very high precision in sparing normal tissue and dose target
conformity to the target. However, respiratory motion is the major roadblock in treatment
accuracy. High dose SABR treatment delivery lessens potential averaging of respiratory
motion uncertainties, as observed in conventional dose fractionations, and therefore
escalates consideration of the moving target.
Respiratory gating can mitigate the effects of respiratory motion, while the combination of
respiratory gating with VMAT using high dose rate delivery of FFF beams can increase
treatment efficiency. However, additional uncertainties are introduced in respiratory gated
VMAT by the additional degrees of freedom, such as the gantry rotation and variable dose
rate. Respiratory gating window will lead to multiple stops of the gantry motion, causing
ramping up-and-down of the dose rate when entering and exiting the gating window. These
potential uncertainties introduced in dose delivery must be studied. Advanced on-board
imaging protocols in TrueBeam Research mode can be generated to provide intrafraction
verification of respiratory gated VMAT. The following questions were articulated to
address these concerns:


Which IMRT delivery technique optimizes dose distribution and delivery for earlystage NSCLC patients?



Will respiratory-gated VMAT reduce the potential for radiation induced normal lung
toxicity?



Can we safely use intra-treatment kV imaging for delivery verification of respiratory
gating?

The answer to these questions can be summed up under the hypothesis of this thesis:
Simultaneous real-time kV imaging during radiation treatment delivery will improve
the precision of respiratory gated VMAT for early-stage NSCLC such that the
expected benefits can ultimately be realized clinically.
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1.8 Research Objectives
The goal of this thesis is to validate and improve respiratory gated treatment planning and
delivery for early-stage NSCLC patients with SABR. More specifically, the focus of this
thesis is to investigate treatment planning using high dose rate IMRT and respiratory gated
VMAT, and to verify treatment delivery with real-time on-board gated kV imaging
synchronized to the treatment beam. The breakdown of the research objectives to attain
this goal are formulated as:


To compare various IMRT treatment techniques by determining which provides the
optimal trade-off between treatment efficiency and dose conformity in early-stage
NSCLC treated with SABR.



To assess the reduction of radiation induced lung toxicities, pneumonitis and fibrosis,
by the combination of respiratory gated VMAT in early-stage NSCLC patients
exhibiting significant tumour motion.



To determine if on-board kV imaging can be used as a tool to ensure that the motion
of the external surrogate used for respiratory gating correlates well with internal
target motion using patient specific waveforms during respiratory-gated VMAT
treatment delivery.



To investigate imaging parameters in intrafraction CBCT by using gated kV
fluoroscopy acquired during respiratory-gated and ungated VMAT.

1.9 Thesis Roadmap
1.9.1

Chapter 2 - Dosimetric planning comparison of IMRT
techniques for early stage non-small cell lung cancer with
SABR

Retrospectively, radiation treatment plans for ten patients with early-stage NSCLC were
computed with eight various IMRT modalities: 1) Three FB-IMRT methods; 2) Two
VMAT methods; and 3) Three Tomotherapy methods. The goal of this work was to
determine which modality provided the optimal trade-off between dose conformity and
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treatment efficiency. Dosimetric parameters including dose conformity (minimum PTV
dose, conformity indices of the PTV etc), dose volume histogram metrics (maximum dose
to healthy structures, mean lung dose, contralateral V5Gy, etc), and treatment efficiency
(MLC degradation, treatment delivery time, etc) were compared amongst each of the
treatment planning techniques. This chapter is adapted from a research paper entitled
“Comprehensive dosimetric planning comparison for early stage non-small cell lung
cancer with SABR: fixed-beam IMRT versus VMAT versus tomotherapy” by Xhaferllari
I, El-Sherif O, and Gaede S. in press at the Journal of Applied Clinical Medical Physics

1.9.2

Chapter 3 - The potential for respiratory-gated VMAT to
reduce normal lung toxicity in SABR patients

In this chapter, respiratory gated VMAT is compared theoretically to ungated VMAT for
20 early-stage NSCLC patients exhibiting significant breathing-induced tumour motion.
Dosimetric parameters (V20Gy and mean lung dose) corresponding to early induced lung
toxicities, such as pneumonitis, and (V50%) corresponding to late induced lung toxicities,
such as fibrosis, were calculated for all retrospective treatment plans. This chapter is
adapted from research paper entitled “Dosimetric planning study of respiratory-gated
volumetric modulated arc therapy for early-stage lung cancer with stereotactic body
radiation therapy” published in Practical Radiation Oncology vol. 5 (3): pp. 156-61 (2015)
by Xhaferllari I, Chen JZ, MacFarlane M, Yu E, Gaede S.

1.9.3

Chapter 4 - The use of on-board kV imaging during respiratory
gated VMAT delivery to evaluate the correlation between
tumour motion and external surrogate motion in patientspecific waveforms

Correlation of the internal target motion and the external surrogate marker motion was
investigated using different real-patient breathing waveforms in free breathing ungated,
amplitude gated and phase gated conditions. In this chapter, on-board gated fluoroscopy
during VMAT was investigated as a tool to correlate the external marker motion with
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internal target motion, and to calculate pre-determined simulated phase shifts. This work
was performed using the TrueBeam Research mode and a programmable respiratory
motion phantom. This chapter is based on a research paper entitled “The use of on-board
kV imaging during respiratory gated VMAT delivery to evaluate the correlation between
tumour motion and external surrogate motion in patient-specific waveforms” by
Xhaferllari I, El-Sherif O, Stevens T, Gaede S to be submitted to the Medical Physics
journal.

1.9.4

Chapter 5 – Investigation of image quality of intrafraction cone
beam CT for 3D verification of respiratory-gated VMAT
delivery

Despite MV degradation of image quality, intra-fractional kV CBCT during SABR VMAT
treatment delivery was investigated as a volumetric dosimetric verification method.
Imaging parameters to optimize image quality and target delineation were explored.
Respiratory motion artifacts were studied by using a programmable respiratory motion
phantom embedded with multiple sized spheres under free breathing ungated, amplitude
gated, and phase gated conditions. The contents of this chapter are in preparation for a
submission entitled “Investigation of image quality of intrafraction cone beam CT for 3D
verification of respiratory-gated VMAT delivery” by Xhaferllari I, Dekker K, Hajdok G,
Gaede S to Physics in Medicine and Biology journal.

1.9.5

Chapter 6 - Conclusions and Future Work

In this final chapter, an overview of the important findings and conclusions of the thesis
are summarized. Main limitations from Chapters 2-5 are discussed. The thesis concludes
with potential topics of interest that can further build upon this work.
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Chapter 2

2

Dosimetric planning comparison of IMRT techniques for
early stage non-small cell lung cancer with SABR

This chapter is adapted from a research paper entitled “Comprehensive dosimetric planning
comparison for early stage non-small cell lung cancer with SABR: fixed-beam IMRT
versus VMAT versus tomotherapy” accepted in the Journal of Applied Clinical Medical
Physics by Xhaferllari I, El-Sherif O, and Gaede S.

2.1 Introduction
Cancer is the leading cause of death worldwide, with non-small cell lung cancer (NSCLC)
being the most common cause of cancer related mortality1. In the treatment of early-stage
NSCLC, surgical resection is considered the standard of care2. However, some patients are
deemed medically inoperable due to age, decreased pulmonary reserve, cardiac function,
or significant co-morbidities3. Medically inoperable patients, as well as patients unwilling
to undergo surgery, have the option to be treated using stereotactic ablative radiotherapy
(SABR). SABR is a hypofractionated technique where a very high ablative dose per
treatment is delivered in few fractions, normally three to eight. Therefore, tumor
conformality and sparing of normal tissue is increasingly crucial with SABR in comparison
to conventional fractionation. SABR treatments are computed using multiple beam angles
to achieve sharp dose gradients needed to spare healthy tissue. Outcome studies have
shown SABR has an overall survival of 41.2% compared to 66.1% for patients who
undergo lobectomy at five years, meanwhile, local control at three years has improved with
SABR, 87.8%, compared to lobectomy resection, 85%2.
Although non-coplanar three-dimensional conformal therapy (3D-CRT) remains a popular
technique for delivering SABR, intensity modulated radiation therapy (IMRT) has become
increasingly popular due to the ability to improve dose conformality and reduce toxicities
to normal tissue4. There are various techniques available to compute IMRT: fixed beam
(FB)4,5, volumetric modulated arc therapy (VMAT)6, and helical tomotherapy (HT)7. FB
involves holding the gantry fixed in each beam direction as each segment of the beam,
formed using a multi-leaf collimator (MLC), is delivered. FB can be accomplished by step49

and-shoot delivery (SS) and sliding window (SW). VMAT techniques deliver radiation
using gantry rotation up to 360ᴼ around the patient while simultaneously varying gantry
speed, leaf motion, and dose rate8. Both FB and VMAT can be optimized using direct
machine parameter optimization (DMPO) capable with the Pinnacle3 treatment planning
system (Philips Medical Systems, Fitchburg, USA) and Acuros XB (AXB) v11.3 dose
calculation algorithm capable with the Eclipse treatment planning system (Varian Medical
Systems, Palo Alto, USA). HT delivery is accomplished by synchronizing couch motion
through the bore to the gantry rotation; intensity modulation is attained by a thin fan beam
of various sizes and binary multi-leaf collimator 9, and most recently with dynamic jaws10.
Lung SABR treatment plans consist of small fields with substantial heterogeneity from the
high density tumour and the low density lung. Dose calculation algorithms available in
commercial products vary in accuracy of dose computation11,12. The dose calculation
algorithm available with Pinnacle3 and TomoTherapy treatment planning systems is
collapsed cone convolution13, and in Eclipse treatment planning system, AXB is employed
14

.

The goal of this retrospective planning study was to provide an extensive comparison of
the various FB, VMAT, and HT techniques for delivering IMRT based treatment for earlystage NSCLC patients with SABR. This study will conclude which technique and vendor
provides the highest dosimetric benefit by comparing indices for the region of interest and
organs at risk.

2.2 Material and Methods
2.2.1

Patient selection and contouring

A total of ten patients with medically inoperable early-stage NSCLC were enrolled in this
retrospective planning study. These patients were chosen based on criteria of motion
greater than 0.5 cm, and internal target volume (ITV) in the range of 4.4 - 53.1 cm3, as
typically observed in NSCLC SABR treatment cases. Patient specific characteristics,
including staging, lesion location, and target volumes are shown in Table 2.1.
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Table 2-1. General patient demographics

Patient

Stage

ITV size

PTV size

(cm3)

(cm3)

Tumor location

1

T1bN0M0

RLL*

Central

17.2

47.3

2

T1aN0M0

RLL

Peripheral

4.8

22.5

3

T2aN0M0

RLL

Central

22.6

58.8

4

T2aN0M0

RLL

Peripheral

35.2

78.0

5

T2aN0M0

RLL

Central

27.7

69.5

6

T2aN0M0

RLL

Peripheral

53.1

106.0

7

T1aN0M0

RML§

Peripheral

16.2

42.8

8

T2aN0M0

RML

Central

48.8

103.8

9

T2bN0M0

LLL‡

Central

40.9

92.2

10

T1aN0M0

LULll

Peripheral

4.4

17.9

Abbreviations: *RLL-Right Lower Lobe; §RML-Right Middle Lobe; ‡LLL-Left
Lower Lobe; llLUL- Left Upper Lobe
Four-dimensional computed tomography (4D-CT) scans, reconstructed into 10 phases,
were acquired for each patient using Varian’s Real-time Position Management (RPM)
system (Varian Medical Systems, Palo Alto, CA) in the Philips Brilliance Big Bore CT
scanner (Philips Medical Systems, Cleveland, OH). The gross target volume, (GTV), was
contoured on each of the ten respiratory phases and motion encompassing internal target
volume, (ITV), was created by summing the ten individual GTVs. Consecutively, the

51

planning target volume (PTV) was created by adding a 5 mm expansion to the ITV in the
untagged average 4D-CT. Target volumes and contours of the critical structures were
imported onto the untagged average 4D-CT and employed for treatment planning across
different techniques.

2.2.2

Treatment Planning

For each patient, eight treatment plans were optimized: three FB, two VMAT, and three
HT plans; for 80 treatment plans total. A dose of 54 Gy in three fractions was prescribed
for each patient. To ensure target coverage and provide normalization, 95% of the PTV
must be covered by the prescription isodose (RTOG 0618)15.
FB plans were computed by separate board certified dosimetrists who specialize in Eclipse,
and Pinnacle treatment planning. Prior to FB planning, the dosimetrists were instructed to
use nine-eleven coplanar beams in each of their plans to have the highest quality plan
attainable. For each patient, two SS plans, with a maximum allowed segments of 33 and
100 to represent low modulation (SS-LM) and high modulation (SS-HM), respectively,
were retrospectively planned in Pinnacle3 v9.1 treatment planning system, and the dose
was calculated using collapsed cone convolution. The SW plans were generated by a
different board certified dosimetrist than the SS plans using Eclipse treatment planning
system; therefore, SW was composed of nine to eleven coplanar beams and did not have
the same beam arrangement as SS. All the FB plans were recomputed using 10X flattening
filter free (FFF) beams to optimize the efficiency of expected treatment delivery, and SW
was recomputed using AXB dose algorithm version 11.3. Once recomputed, each of the
plans was validated to ensure they are clinically acceptable, and if needed, the plans were
re-optimized.
SA treatment plans were generated by employing clinically used Pinnacle host script via
Pinnacle3 planning system with collapsed cone convolution, and RA treatment plans were
computed with a clinically approved protocol in Eclipse planning system with AXB dose
calculation algorithm. Two partial arcs were used depending on the location of the lesion
in the lung to avoid overdosage to the contralateral lung. According to the clinical script,
the SA plans consisted of two 225⁰ beam arcs with the dimensions of 180.1⁰- 45⁰ clockwise
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and 45⁰ - 180⁰ counterclockwise if the lesion was located in the right lung, or 315⁰-179.9⁰
clockwise and 180⁰-315⁰ counterclockwise if the lesion was located in the left lung.
Whereas, the RA plans were computed using two 210⁰ beam arcs with the dimensions of
180.1⁰-30⁰ clockwise and 30⁰-180⁰ counterclockwise if the lesion was in the right lung,
and 330⁰-179.9⁰ clockwise and 180⁰- 330⁰ counterclockwise if the lesion was situated in
the left lung. Both partial arcs were generated using 10X FFF beam energy and a maximum
2400 MU/min dose rate.
All FB and VMAT techniques were prepared utilizing FFF beams to maximize efficiency
in these hypofractionated deliveries. FFF beams allow for safe treatment delivery with dose
rates up 2400 MU/min, significantly reducing treatment time16,17. Clinical assessment of
utilizing FFF beams to treat early-stage NSCLC patients with SABR have demonstrated
early local control rates upwards of 89%17.
The three HT plans with varying beam fan width of 1 cm, 2.5 cm, and 5 cm (HT-1cm, HT2.5cm, and HT-5cm respectively) were generated by a board certified dosimetrist using
HiART TomoPlan 3.1.1 (Accuracy Inc, Sunnyvale, CA). For the patients in this study, a
0.172 pitch and 1.3 modulation factor were used. All HT plans were designed using a 6X
beam with 600 MU/min dose rate and optimized with inverse planning based on least
squares optimization method. The dose was calculated by employing collapsed cone
convolution algorithm18,19.
Pinnacle, Eclipse and HT treatment planning systems have different optimization methods,
as well as varying cost functions. The planning constraints cannot be set the same between
the different planning systems to achieve highest dose computation results within each
treatment planning system. However, all plans computed in this study were clinically
acceptable and satisfied SABR protocol20,21.

2.2.3

Plan Comparison

The dose distribution from planning in all the different techniques and one set of contours
were transferred to MiM v.5.6.5 (MiM Software Inc., Cleveland, OH) for analysis
purposes. The independent software allows for consistent and unbiased plan evaluation
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based on dose volumetric histogram (DVH) parameters by using the same sampling
algorithm. Parameters that characterize dose conformality, DVH statistics, and treatment
delivery efficiency were obtained and compared. Further analysis to identify main
difference amongst fixed beam, VMAT and HT was performed by grouping the most
clinically appropriate plans SS-LM and SS-HM plans, RA and SA VMAT plans, and HT2.5cm and HT-5cm plans. SW and HT-1cm were not included in the combined group
analysis due to their inherent lack of efficiency18,22.

2.2.3.1

Dose conformality

To evaluate dose fall-off from the PTV to normal tissue, the maximum dose at least two
centimeters from the PTV, D2cm, was calculated. For the PTV, the maximum and mean
dose have been computed, and the conformality index was calculated for the 95% (CI95%),
80% (CI80%), and 50% (CI50%) isodose levels according to the RTOG model defined by:
𝐶𝐼𝑅𝐼 =

𝑉𝑅𝐼
𝑇𝑉

Where VRI represents the volume covered by the reference isodose and TV is the volume
of the PTV23.

2.2.3.2

DVH statistics

The maximum point dose (Dmax) to nearby critical organs at risk (OAR), such as the
esophagus, spinal cord, heart, trachea, and proximal bronchus, was compared amongst all
patients. Lung toxicity parameters analyzed include the absolute volume of normal lung
covered by 50% of the prescription or more (V50%), predictive of fibrosis24, the mean dose
to the normal lung (MLD), the normal lung receiving 5, 10, 20, 27 Gy or more (V5Gy, V10Gy,
V20Gy, V27Gy, respectively), and contralateral lung receiving at least 5, or 10 Gy (V5GyC,
V10GyC, respectively).

2.2.3.3

Treatment delivery efficiency

The intensity gradients in IMRT planning were acquired using multiple MLC based control
points. Increased modulation induces increased MLC travel, potentially causing a
devaluation of the MLC track, requiring more frequent replacement. The total MLC travel
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was compared between all fixed beam and VMAT plans. The total monitor units required
for each treatment technique was analyzed to evaluate treatment efficiency. The treatment
delivery time was simulated for each beam of the fixed beam and VMAT plans based on
the dose rate for each segment. Plan automation, available with TrueBeam linear
accelerators, was assumed to calculate time for gantry rotation in the FB treatment plans.
Meanwhile, the treatment delivery time in HT treatment plans was estimated based on the
pitch and monitor units, available in the DICOM header of the radiation plan dose files.

2.2.4

Statistical Analysis

All dosimetric parameters compared in this study were summarized by their respective
means and standard deviation. Statistical analysis was performed in IBM SPSS v.20 (IBM
SPSS Statistics for Windows, Armonk, NY) using Shapiro-Wilk normality tests followed
by one-way analysis of variance. The data significantly deviates from a normal distribution
if Shapiro-Wilk test was less than 0.05, and the null hypothesis was rejected. If the
distribution was considered not normal, a non-parametric test, Kruskal-Wallis one-way
analysis of variance, was utilized to find significance; followed by a Wilcoxon-MannWhitney test to find between-subject significance. Whereas, the data was considered
normally distributed if the Shapiro-Wilk test was greater than 0.05 and the null hypothesis
was accepted. For normally distributed parameters, a one-way analysis of variance
(ANOVA) was computed to find significance followed by a Tukey’s post hoc test to check
for between-subject significances.

2.3 Results
Dose distribution for the eight various IMRT techniques compared in this study are
displayed in Figure 2-1 for one patient, and the corresponding DVH of the PTV and normal
lung tissue, the lung tissue minus the ITV, are provided in Figure 2-2. In the axial slice for
all HT plans (Figure 2-1), the contralateral lung is covered by the 5 Gy or higher isodose
volume. As the width of the fan beam in HT increases to the 5 cm plan, an increase in the
low dose spillage is noticed in the superior-inferior direction shown in the coronal slice.
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Figure 2-1. Dose distributions of the axial and coronal slice for each of the eight different
planning techniques for patient 4, from top left to bottom right: SS-LM FB, SS-HM FB,
SW FB, SA, RA, HT-1cm, HT-2.5cm, and HT-5cm.
HT planning achieved dose homogeneity in the PTV surpassing other techniques, as can
be observed in the cumulative DVH (Figure 2-2); however, for SABR treatment, dose
uniformity and lack of hot spots within the target is not an essential priority for ablative
radiotherapy. Although hypoxic regions are irradiated with all IMRT techniques, the
increased heterogeneity within the PTV is regarded as clinically desirable, and provides
the ability to deliver inherently higher doses to potential hypoxic regions25–27.

56

Figure 2-2. Cumulative DVH for patient 4 for the PTV (solid lines) and the normal lung
tissue (dashed lines) obtained from the eight techniques used. All plans are normalized
such that 95% of the PTV receives 54 Gy or more.
Table 2.2 summarizes the average and standard deviation (SD) of the ten patients for each
of the parameters described in this study. Parameters for dose conformality, DVH related
statistics, and treatment efficiency amongst different planning modalities are displayed
along with between- and within-subject significance. Although every plan met the SABR
COMET criteria20, all HT techniques showed a significance decrease in the PTV Dmax and
mean dose compared to all other modalities in this study. This is further supported by the
dose homogeneity seen in the PTV in Figure 2-2. On the contrary, there was a significant
increase in conformality index, CI80%, CI50%, observed for the HT-5cm plan compared to
all other modalities, other than HT-2.5cm for CI50; RA&SA plans resulted in the most
conformal dose to the PTV. A significant increase in contralateral V5Gy was observed for
all HT plans (p=0.002) compared to SS and VMAT. A significant increase in mean lung
dose was attained for the HT-5cm plan (p=0.002). In both scenarios, RA&SA achieved the
lowest values.
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Table 2-2. Mean values ± standard deviation of all parameters compared. A p-value < 0.05 determines significance.
SSLM

SS-HM

SW

RA

SA

HT-1 cm

HT-2.5
cm

HT-5 cm

pvalue

73.8 ±
4.1f,g,h

65.8 ±
23.2f,g,h

71.7 ±
3.3f,g,h

71.2 ± 3.8
f,g,h

74.3 ±
2.9f,g,h

62.9 ±
2.4a,b,c,d,e

63 ±
5.8a,b,c,d,e

64.1 ± 7.4 a,b,c,d,e

<
0.001

Mean dose
(Gy)

62.6 ± 1.9

62.5 ± 1.9

f,g,h

f,g,h

62.5 ±
1.4f,g,h

62 ± 1.5 f,g,h

61.4 ±
1.2f,g,h

58.7 ±
1.8a,b,c,d,e

58.6 ±
3.4a,b,c,d,e

58.8 ± 4.1 a,b,c,d,e

<
0.001

D2cm (%)

58.6 ± 8

58.4 ± 6.8c

62.4 ±
5.5b,d

53.2 ± 4.3
c,e,h

60.5 ± 6d

57.2 ± 6

58.7 ± 6.6

60.9 ± 6.7d

< 0.05

CI95%

1.28 ±
0.08h

1.28 ± 0.08h

1.3 ± 0.09

1.23 ±
0.09f,g,h

1.23 ±
0.06f,g,h

1.37 ±
0.13d,e

1.35 ±
0.14d,e

1.43 ± 0.19a,b,d,e

< 0.01

CI80%

1.96 ±
0.23h

1.97 ± 0.24h

1.88 ±
0.18h

1.78 ± 0.2h

1.89 ±
0.19h

1.96 ± 0.21h

2.07 ±
0.31

2.35 ±
0.47a,b,c,d,e,f

< 0.01

CI50%

4.75 ±
0.77h

4.73 ± 0.77h

4.75 ±
0.72h

4.31 ± 0.75h

4.56 ±
0.84h

4.43 ± 0.57h

4.92 ±
0.83h

6.03 ± 1.38*

< 0.05

Cord

Dmax(Gy)

14.3 ± 4

13.3 ± 3.9

15.8 ± 7.1

11.2 ± 3.2

11.2 ± 1.4

13.9 ± 5.2

13.7 ± 5.5

13.8 ± 5.2

> 0.05

Bronchus

Dmax(Gy)

13.2 ± 9.3

13.4 ± 8.7

15.5 ±
10.8

16.2 ± 9.2

17 ± 11.1

17.2 ± 11.9

18.7 ±
13.9

19.6 ± 14

> 0.05

Esophagu
s

Dmax(Gy)

14.1 ± 6.3

14.1 ± 6.2

16.2 ± 8.5

14.9 ± 5.5

16.2 ± 6.4

15.6 ± 5.4

14.1 ± 3.9

14.4 ± 5.7

> 0.05

Heart

Dmax(Gy)

14.5 ± 6.4

15 ± 6.7

17.9 ± 7.6

17.1 ± 7.2

18 ± 6.4

19.2 ± 10.9

18.4 ±
11.3

17.6 ± 10.2

> 0.05

Trachea

Dmax(Gy)

2.4 ± 5.2h

2 ± 4.3h

1.5 ± 2.7

1.1 ± 2.1h

1.5 ± 2.6

1.4 ± 2.4

1.7 ± 2.4

2.7 ± 3a,b,d

> 0.05

Total lung

MLD (Gy)

4.8 ± 1.3h

4.8 ± 1.3 h

4.9 ± 1.4 h

4.7 ± 1.2 h

4.6 ± 1 h

5.1 ± 1.3 h

5.8 ± 1.6

7.1 ± 1.7a,b,c,d,e,f

< 0.01

V50% (cm3)

191 ± 78

189 ± 80

185 ± 77

172 ± 66

173 ± 67

179 ± 75

200 ± 83

250 ± 108

> 0.05

PTV

Dmax (Gy)
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V50% (%)

4.1 ± 1.6

4 ± 1.6

4 ± 1.5

3.7 ± 1.4

3.7 ± 1.3

3.8 ± 1.6

4.3 ± 1.7

5.3 ± 2

> 0.05

V20Gy (%)

6.3 ± 2.3

6.2 ± 2.2

6.2 ± 2.4

5.9 ± 2.2

6 ± 2.1

5.9 ± 2.3

6.7 ± 2.6

8.3 ± 2.9

> 0.05

12.9 ± 4.6

12.8 ± 4.4 h

14.3 ± 5

13.9 ± 4.4

h

14.1 ± 4.8

16.7 ± 6

20.7 ± 7a,b,e

< 0.01

23.7 ± 6.9 h

24.7 ± 7.7
h

22.9 ± 6.8 h

22 ± 6.2g,h

29 ± 8.2 h

33.4 ±
9.1e

40.8 ± 11.8

h

a,b,c,d,e,f

<
0.001

V10Gy (%)

0.9 ± 1.7

0.8 ± 1.4

2.8 ± 4.1

0.4 ± 1

0.4 ± 0.7

1.4 ± 2

1.5 ± 2.1

1.9 ± 2.5

> 0.05

V5 Gy (%)

7.9 ±
6.6f,g,h

8.4 ± 6.1f,g,h

10.8 ± 8

6.6 ± 7.6f,g,h

7.4 ± 7f,g,h

18.9 ±
10.9a,b,d,e

19 ±
11.2a,b,d,e

21 ± 15.2a,b,d,e

< 0.01

1184 + 341 b

960 +
310b

N/A

N/A

N/A

<0.00
1

V10Gy (%)

V5 Gy (%)
Cont. lung

Efficiency

h

23.5 ± 6.9

MLC
Motion (cm)

837 + 509

Monitor
Units

3823 ±
792b,c,d,f,g

4946 ±
1226a,c,e,f

8288 ±
3412a,b,d,e,f

4782 ±
655a,c,e,f

4023 ±
678b,c,d,f

11208 ±
1510a,b,c,d,e,h

7047 ±
4407a

5457 ± 3451f

<
0.001

Delivery
time (min)

2.5 ± 0.3*

3 ± 0.5*

4.4 ±
1.4a,b,d,e,f,g

2±
0.3a,b,c,f,g,h

1.9 ±
0.2a,b,c,f,g,h

13.2 ±
1.8a,b,c,d,e,h

8.3 ±
5.2a,b,c,d,e

6.4 ± 4.1a,b,d,e,f

<
0.001

b

3170 +
1475a,c,d,e

12.3 ± 2.7

1279 + 563 b
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To further emphasize estimated treatment delivery time amongst all techniques, a
significant increase was observed in all HT, and SS plans compared to SA; however, a
statistically significant difference is not found between RA&SA (p=.393) (Figure 2-3).

Figure 2-3. The mean estimated treatment delivery time for each treatment planning
technique over all patients.
In the overall MLC travel comparison, SS-HM required significantly more MLC motion
than all other modalities compared, as shown in Figure 2-4. SA resulted in the lowest MLC
travel time, and therefore, least amount of potential degradation on the MLC track,
compared to all other techniques, albeit, significance was not detected.
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Figure 2-4. Box plot of the total MLC traveled in each plan in millimeters for all treatment
modalities compared. For each plot, the median is displayed by the central line, the upper
and lower border of the rectangle represent the 75th and 25th percentile or interquartile
range, and the whiskers represent the extreme data points not considered outliers. Outliers
were illustrated by ‘o’ and significance was shown by ‘*.'
In the two VMAT techniques, RA displayed significantly superior D2cm, dose fall-off
parameter, to SA (p= 0.011), whereas total monitor units significantly increased (p=0.043).
However, VMAT showed improved overall treatment quality and efficiency compared to
all other modalities with SA achieving optimum efficiency.
Further analysis to identify main differences amongst fixed beam, VMAT and HT was
completed by grouping the SS-LM and SS-HM plans, RA and SA VMAT plans, and HT2.5cm and HT-5cm plans (Table 2.3). SW and HM-1cm treatment plans were not included
in this analysis based on poor performance in efficiency parameters, while dose distribution
was not improved, as observed in Table 2.2. A significant reduction in maximum dose to
the spinal cord was observed in the VMAT plans (p=0.017) compared to the SS. Although
not statistically significant for the remainder of the parameters, a reduction was found
between SS and VMAT (other than esophagus, bronchus and heart). When comparing SS
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to HT, target conformality (CI95%) significantly improved in the SS plans (p=0.015), at the
cost of the target mean and maximum dose which was significantly reduced in the HT plans
(p<0.001). Similarly, target mean and maximum dose (p<0.001) showed a significantly
reduction in the HT plans compared to the VMAT plans while all three target conformality
parameters significantly improved with VMAT (p<0.05 for all). In the DVH parameters,
maximum dose to the trachea and normal lung, V10Gy and V5Gy, contralateral lung V5Gy,
and mean lung dose significantly reduced using both the SS and VMAT treatment planning
compared to HT. These differences show that patients treated with SS or VMAT may be
less susceptible to radiation-induced lung toxicities compared to HT treated patients.
Estimated treatment delivery time was significantly reduced with VMAT plans compared
to all other techniques (p<0.001).
Table 2-3. Significance for each parameter studied between grouped SS, VMAT, and HT
(significance identified when p<0.05).
p-value
SS &
VMAT

SS & HT

VMAT &
HT

Dmax (Gy)

0.957

<0.001

<0.001

Mean dose (Gy)

0.213

<0.001

<0.001

D2cm (%)

0.978

0.168

0.152

CI95%

0.058

0.015

<0.001

CI80%

0.117

0.055

<0.001

CI50%

0.176

0.083

0.003

Cord

Dmax(Gy)

0.017

0.507

0.323

Bronchus

Dmax(Gy)

0.611

0.218

0.742

Esophagus

Dmax(Gy)

0.686

0.993

0.755

Heart

Dmax(Gy)

0.152

0.552

0.552

Trachea

Dmax(Gy)

0.626

0.004

0.020

Total lung

MLD (Gy)

0.561

0.005

0.001

V50% (cm3)

0.779

0.369

0.113

V50% (%)

0.756

0.341

0.093

PTV
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Cont. lung

Efficiency

V20Gy (%)

0.918

0.247

0.119

V10Gy (%)

0.990

0.002

0.002

V5 Gy (%)

0.898

<0.001

<0.001

V10Gy (%)

0.778

0.091

0.044

V5 Gy (%)

0.204

<0.001

<0.001

MLC Motion

0.123

N/A

N/A

Monitor Units

0.607

0.516

0.787

Delivery time (min)

<0.001

<0.001

<0.001

2.4 Discussion
In this study, all 80 IMRT plans generated conformal dose distributions and provided
clinically acceptable plans according to the guidelines of RTOG 0618 and our in-house
protocol based on SABR-COMET. Various IMRT planning techniques for treating SABR
were compared to conclude which IMRT modality is propitious by proving the most
favorable dose conformality, DVH parameters and treatment efficiency. In this study,
VMAT planning, RA and SA, provided for the optimal trade-off in treatment efficiency
and dose coverage. The inherent rotational nature of VMAT and tomotherapy treatment
planning optimization allows for greater degrees of freedom compared to fixed beam and,
therefore, should lead to higher quality radiation therapy treatment plans. Furthermore, the
application of a broad beam in VMAT compared to a thin fan beam in tomotherapy, led to
significantly improved treatment delivery efficiency. In treatment planning studies, Pareto
efficiency should be achieved using multi-criteria optimization to ensure accurate planning
comparison28. However, this technique was not available during the course of this study.
To overcome the lack of multi-criteria optimization, each treatment plan was computed by
a certified dosimetrist or by the application of a clinically acceptable protocol.
Several other studies have investigated the role of different IMRT treatment techniques in
the treatment of early stage NSCLC with SABR to reduce lung toxicities29,30. Kannarunimit
et al.29 compared three SABR treatment techniques robotic surgery, RA and HT plan for
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treatment of central lung with SABR. They concluded that HT and VMAT provided more
efficient treatment delivery and higher target dose homogeneity while robotic surgery and
VMAT provided a lower risk of radiation-induced lung pneumonitis, with VMAT yielding
the lowest risk in cases of large PTV coverage. During hypofractionated radiation
treatment, sharp dose gradients outside the PTV are desirable, hot spots in the center of the
PTV are invoked to aid a dose fall off outside the PTV25–27. Alluding to dose homogeneity
parameters not being included in the study, where traditionally HT planning excels. The
findings on the reduction of radiation-induced pneumonitis during VMAT plans by
Kannarunimit et al. were further supported by our study where RA and SA demonstrated
the lowest risk of radiation pneumonitis by having the lowest MLD and V20Gy values. A
significant reduction in MLD was found when grouping both VMAT techniques and
comparing to HT (p<0.001); however, no significant difference was found between the two
VMAT techniques31. For further analysis of radiation-induced lung toxicity, our study
investigated the reduction in the risk of fibrosis amongst the different treatment planning
techniques (V50%); VMAT achieved reduced V50% values. However, the differences in V50%
were not found to be statistically significant.
Weyh et al.30 compared RA, HT and fixed beam for SABR treatment to lesions in the
peripheral lung to conclude RA and fixed beam plans were equivalent but the reduction in
treatment time with RA makes them more preferable. This study has supported their work
and furthermore, our results demonstrate a decrease in all normal lung DVH parameters in
RA and SA, albeit not significant. Weyh et al. executed their study in eight patients for a
total of 24 treatment plans, whereas this study expands on validating different treatment
methods within FB, VMAT and HT compromising of 80 treatment plans. Treatment plans,
in both Weyh et al.

30

and Kannarunimit et al. 29, were generated using traditional beams

with flattening filter (FF) and analytical anisotropic algorithm (AAA) dose calculation
algorithm. Whereas in this study, FFF beams were utilized in all linear accelerator based
plans. Studies have shown that FFF treatment planning provides equivalent dose
distribution to FF beams while significantly reducing treatment delivery time and
increasing dose distribution conformity16. AXB dose calculation algorithm, computed in
this study for Eclipse treatment planning in RA and SW plans, has been shown to generate
treatment plans comparable to x-ray voxel Monte Carlo (XVMC) developed by
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BrainLab14. Moreover, AXB allows for faster computational time to XVMC, while
maintaining higher accuracy when dealing with tissue heterogeneity in the lung compared
to AAA.
An important parameter when considering IMRT treatment, degradation of the MLC
carriage due to MLC motion required during treatment delivery. The jaw opening in the
field sizes in all treatment plans ranged between 4-cm to 9-cm to surround the PTV but
limit MLC motion. Even though a significance was only found when comparing each of
the techniques to SS-HM, within the VMAT techniques, there was a reduction in MLC
motion for the SA in nine of ten patients compared to RA. SA based treatment planning
could result in a longer lifespan of the MLC carriage.
The limited number of patients used in this study may have led to insufficient statistical
power to show significance between some of the parameters analyzed. The statistical power
of 0.76 was measured using ANOVA repeated measures in G-power v.3.1.9.232.
Although other various treatment modality comparison studies have been conducted for
the treatment of NSCLC with SABR, to the best of our knowledge, there are not any other
studies comprehensively covering a wide range of different IMRT techniques from various
commercial vendors. In this study, the most up to date treatment planning using FFF beams
to reduce significantly treatment times was used for both fixed beam and VMAT planning.

2.5 Conclusion
In the treatment of early-stage NSCLC patients with SABR, this study has demonstrated
VMAT treatment planning techniques to have the optimal trade-off between dose
conformality and sparing normal tissue, and treatment efficiency. Although all plans were
clinically acceptable, VMAT outperformed HT in all parameters measured, and statistical
superiority was observed in 12 parameters when comparing grouped VMAT and HT
techniques. In the comparison between SS and VMAT techniques, an increase in dose to
the heart, esophagus and bronchus, was observed, although insignificant. VMAT was
dosimetrically advantageous in all other parameters while providing significantly shorter
treatment times than any other modality studied.
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RA and SA VMAT techniques performed comparably; RA displayed significantly sharper
dose fall off while SA optimization was statistically more efficient.
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Chapter 3

3

The potential for respiratory-gated VMAT to reduce
normal lung toxicity in SBRT patients

This chapter is adapted from research paper entitled “Dosimetric planning study of
respiratory-gated volumetric modulated arc therapy for early-stage lung cancer with
stereotactic body radiation therapy” published in Practical Radiation Oncology vol. 5 (3):
pp. 156-61 (2015) by Xhaferllari I, Chen JZ, MacFarlane M, Yu E, Gaede S.

3.1 Introduction
Non-small cell lung cancer (NSCLC) continues to be the leading cause of cancer death.
Twenty percent of NSCLC diagnosed are in early-stage and it continues to rise due to better
diagnostic techniques1. Common treatments for early-stage NSCLC are surgery and
radiation therapy. Patients undergo radiation therapy if they are inoperable or refuse
surgery. To provide inoperable patients comparable treatment, early-stage lung tumors are
treated with strereotactic ablative body radiotherapy (SABR), a technique of high precision
radiation therapy where high doses (54 - 60 Gy) are delivered in fewer fractions (three to
eight)2. Studies have demonstrated SABR to have comparable local control and regional
reoccurrence to surgery3. Local control in 3 years surpasses 90% and the 3-year survival is
84.7% for early-stage NSCLC patients treated with SABR4.
However, in lung cancer radiotherapy, respiratory motion may have large impact on the
dose to both the tumour and the normal lung. Studies have shown the magnitude of motion
is variable and unpredictable between patients and within a patient over treatment days5–9.
Respiratory motion, in conjunction with the complexity of intensity-modulated radiation
therapy (IMRT) delivery, can lead to the interplay effect, caused by the asynchronous
movement of the tumor and the multi-leaf collimator (MLC)10,11. Beam-intensity gradients
are defined by MLC and the target may move in and out of these gradients. This movement
is not accounted for in the treatment planning systems.
In lung radiotherapy, a method of accounting for respiratory motion is to create a full
motion encompassing margin called the internal tumor volume (ITV) with the aid of four69

dimensional computed tomography (4D-CT)12. When motion is considered “significant”,
breathing motion management technique such as respiratory gating, abdominal
compression, voluntary/involuntary breath hold technique, or tumor tracking can be used13.
In recent years, volumetric modulated arc therapy (VMAT) has been implemented in many
centers for the treatment of SABR for early-stage NSCLC and has shown to provide better
normal tissue sparing to critical organs while maintaining proper dose coverage to the
target14. The Varian TrueBeamTM System (Varian Medical Systems, Palo Alto, CA) has an
integrated respiratory gating and motion management system using an external surrogate,
allowing for the delivery of respiratory gated VMAT. To increase treatment efficiency,
respiratory-gated VMAT can be delivered with flattening filter free mode (FFF) for both 6
MV and 10 MV beams, allowing for dose rates four times greater than previously available.
Another feature of the TrueBeamTM System is advanced image guidance, allowing for
gated kV imaging before or during treatment. Typically, prior to respiratory gated VMAT
treatment, a free breathing cone-beam CT is acquired for anatomical verification of patient
setup, followed by orthogonal gated kV imaging to verify the gating window by
comparison with the digital reconstructed radiographs produced during planning.
This paper investigates the potential dosimetric advantage of combining respiratory gating
and VMAT using FFF beams for treating early-stage NSCLC with SABR.

3.2 Materials and Methods
3.2.1

Patient Selection

In this study, 4D-CT scans from twenty early-stage NSCLC patients with respiratory tumor
motion greater than 5 mm peak-to-peak were randomly selected from recent patient data.
Table 3-1 displays the patient demographics and the calculated centroid tumor motion.
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Table 3-1. Patient tumor location, motion, size, and the gating window used in the study.
3D Motion (cm)
Patient

Tumor
location

Sup/Inf Ant/Post Lat

Free
Breathing
ITV size

Gated

(cm3)

(cm3)

ITV size

Gating
window

1

RLL*

3.0

1.3

0.8

22.1

13.2

40% - 60%

2

RLL

3.0

1.3

0.0

17.2

5.6

40% - 70%

3

RLL

2.8

0.8

0.3

22.6

10.7

30% - 60%

4

RLL

2.6

0.7

0.6

4.8

1.6

40% - 70%

5

RLL

1.9

0.5

0.3

35.2

17.2

40% - 70%

6

LLL†

1.7

0.2

0.1

40.9

27.3

30% - 60%

7

RLL

1.6

0.9

0.1

27.7

16.8

40% - 70%

8

RLL

1.6

0.4

0.1

26.7

18.3

30% - 60%

9

LLL

1.4

0.3

0.2

143.1

113.0

30% - 60%

10

RLL

1.3

0.2

0.2

53.1

37.5

40% - 70%

11

RML§

1.2

0.1

0.2

16.2

9.9

40% - 70%

12

RUL‡

1.0

0.9

0.2

16.6

10.3

30% - 60%

13

RLL

1.0

0.2

0.2

17.3

11.6

30% - 60%

14

RLL

0.9

0.6

0.1

97.8

68.7

30% - 70%

15

RML

0.9

0.3

0.1

48.8

31.0

30% - 60%

16

LLL

0.6

0.2

0.2

10.2

6.1

40% - 70%

17

LULll

0.6

0.1

0.2

4.4

3.1

40% - 70%

18

LLL

0.5

0.2

0.1

3.9

2.7

30% - 60%

19

RUL

0.4

0.5

0.2

27.9

16.3

30% - 70%

20

LLL

0.3

0.2

0.7

3.4

2.1

40% - 70%

Abbreviations: *RLL-Right Lower Lobe; †LLL-Left Lower Lobe; §RML-Right Middle
Lobe; ‡RUL-Right Upper Lobe; llLUL- Left Upper Lobe
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3.2.2

Treatment planning

Each patient was retrospectively planned with gated and non-gated VMAT using SmartArc
technique on Pinnacle treatment planning system version 9.0 (Philips Radiation Oncology,
Fitchburg, MA) and the dose was calculated using collapsed cone convolution. SmartArc
is a VMAT optimization system developed by Philips Radiation Oncology Systems in
collaboration with RaySearch Laboratories AB (Stockholm, Sweden)15. The non-gated
VMAT plans were generated using the average intensity projection CT images
encompassed by the entire 4D-CT dataset. The ITV in the non-gated VMAT scenario was
defined as the envelope of the GTV delineated in all 10 phases of the respiratory cycle. The
gated VMAT plans were generated using a subset average of the intensity projection CT
images encompassed by only those phases which lie within the intended gating window.
The gating window was chosen based on the analysis of the 4D-CT images to provide the
optimal trade-off between an increase in treatment time and a decrease in motion, keeping
residual motion in the gating window within 3 mm. The gating window for each patient is
listed in Table 3-1. The ITV, in the gated case, was defined as the envelope of the GTVs
delineated in the phases defined by the subset average CT. For both gated and non-gated
scenarios, a five millimeter margin was added to account for set-up uncertainties, defining
the planning target volume (PTV).
Each VMAT plan consisted of two 225 degree arcs, one clockwise and one
counterclockwise, with beam energy of 10X FFF and a maximum dose rate of 2400
MU/min. The dose prescription was based on the tumor location; for tumors near or
adjacent to the chest wall, a dose of 55 Gy in 5 fractions was prescribed, whereas for all
other cases, a dose of 54 Gy in 3 fractions was prescribed. The prescription was set
according to RTOG 0618, 100% of the dose to 95% volume of the PTV. All dosimetric
parameters satisfied the requirements of our in-house SABR protocol16–18. In order to avoid
dosimetry bias between the gated and non-gated plans, a Pinnacle planning script was
generated and used to optimize all 40 plans. The planning script generated the beams
required according to the location of the target, set IMRT optimization parameters, and
then optimized using Pinnacle’s direct machine parameter optimization (DMPO) for 25
iterations (Appendix A). After the plan was completed, minor adjustments were sometimes
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necessary to satisfy limits of dose to normal structure and target. Any adjustments
performed on one of the patient’s plan were repeated for their other respective plan.

3.2.3

Statistical Analysis

The main normal lung parameters considered in this study were V20Gy, the percent volume
of the normal lung minus the ITV receiving at least 20 Gy and V50%, the absolute volume
of lung minus the ITV receiving at least 50% of the prescription dose. In studies, V20Gy has
shown to be a predictive of pneumonitis19 while V50% is an important parameter used to
control the amount of intermediate dose spillage, and hence, the total volume of potential
irreversible fibrosis16–18. Other common lung parameters considered were: contralateral
V5Gy, the percent volume of contralateral lung receiving at least 5 Gy, MLD, mean normal
lung dose and D2cm, the maximum dose that is 2 cm away from the PTV. D2cm is a useful
parameter representing the extent of dose falloff outside the PTV, which is crucial for lung
SABR18. The total number of monitor units (MU) necessary to deliver each plan was also
compared. Other parameters compared were the maximum dose to nearby critical organs
such as the cord, esophagus, heart, bronchus, and trachea, and the ITV and PTV size.
To test for significance, initially Shapiro-Wilk tests were done to check for normality. If
the significance value is less than 0.05, then the null hypothesis is rejected and the
parameter values were not normally distributed; whereas if it is above 0.05, the null
hypothesis was accepted and the parameter was normally distributed. Based on the
Shapiro-Wilk test, the volumes of the ITV and PTV, and the maximum dose to the trachea
were not normally distributed. Consequently, tests of significance for these parameters
were performed using the Wilcoxon–Mann–Whitney non-parametric test. Paired t-test was
performed for all other parameters.

3.3 Results
For each plan, target coverage and organ sparing was achieved according to the
requirements of our in-house SABR protocol by using a Pinnacle planning script with some
adjustments. However, there were significant differences in the dose distributions due to
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the differences in PTV sizes between the gated and non-gated VMAT plans. The dose
distribution for both gated and non-gated VMAT plans for one patient are shown in Figure
3-1 in the transverse and coronal planes through the isocenter. The volume covered by the
100% of the prescription, 54 Gy, and 50% of the prescription, 27 Gy, is noticeably greater
in the non-gated case than the gated case.

Figure 3-1. Dose distribution for a non-gated VMAT plan (left) and gated VMAT plan
(right) in the transverse and coronal planes. The isodose line of 54 Gy, and 27 Gy are shown
in white and black respectively, while the planning target volume is the black contour.
Figure 3-2 compares V20Gy amongst the 20 patients. The use of gating significantly reduced
V20Gy from (6.05 + 2.06)% to (5.21 + 1.75)% (p=0.00004).
Figure 3-3 compares V50% amongst the 20 patients. The use of gating significantly reduced
V50% from (158.17+61.12) cm3 to (125.71+49.46) cm3 (p=0.00002).
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Figure 3-2. Comparison of the percent of the lung volume receiving at least 20 Gy (V20Gy)
for both the non-gated and gated VMAT plans for all 20 patients.

Figure 3-3. Comparison of the volume of lung receiving 50% of the prescription dose
between gated and non-gated VMAT plans for all 20 patients.
Table 3-2 compares each parameter considered in this study with their respective mean
values and corresponding p-value. A decrease is seen in all the parameters between nongated and gated VMAT plans. A significant p-value was found for the difference of each
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parameter between gated and non-gated VMAT plans except for the maximum dose to
critical structures.
Table 3-2. Mean values and statistics for each of the parameters studied.
Metric

Non gated

Tests of Normality
Gated

p-value
Shapiro-Wilk
Gated

Non - gated

ITV*

32.00 cm3

21.13 cm3

<0.001

0.000

0.000

PTV†

71.61 cm3

50.54 cm3

<0.001

0.000

0.001

D2cm‡

61.38%

59.27%

0.007

0.625

0.197

V20Gy§

6.05%

5.21%

<0.001

0.178

0.292

V50%ll

158.17 cm3

125.71 cm3

<0.001

0.054

0.553

V5Gy¶

14.10%

11.59%

<0.001

0.139

0.159

Cord dose

11.35 Gy

11.19 Gy

0.895

0.006

0.904

14.87 Gy

14.27 Gy

0.278

0.297

0.491

Bronchus dose

15.59 Gy

15.44 Gy

0.814

0.115

0.039

Trachea dose

3.83 Gy

3.44 Gy

0.059

0.000

0.000

Heart dose

18.2 Gy

17.38 Gy

0.121

0.325

0.642

MLD#

455.24 Gy

408.02 Gy

<0.001

0.176

0.667

MU**

3707.7

3434.9

0.003

0.981

0.942

Esophagus
dose

Abbreviations: *ITV - Internal Target Volume; †PTV - Planning Target Volume; ‡D2cm - Percent
ratio of the dose 2 cm away from the PTV to the prescription; §V20Gy - Percent volume of healthy
lung receiving 20 Gy or more; llV50% - Absolute volume of healthy lung receiving 50% of the
prescription; ¶V5Gy - Percent volume of contralateral lung receiving 5 Gy or more; Critical organ
dose – maximum dose to that organ; #MLD - Mean Lung Dose; **MU - Monitor Units
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3.4 Discussion
Several studies have investigated the benefits of VMAT in providing accurate target dose
while sparing normal tissue in lung radiotherapy 20,21. However, one of the largest sources
of dosimetric error in NSCLC treatment, including VMAT, is respiratory motion.
Respiratory gating is one method of managing respiratory motion. Respiratory gated
VMAT is now possible with TrueBeamTM and previous studies have shown that gated
VMAT delivery with TruebeamTM can be performed accurately22,23.
This study is demonstrating the potential clinical benefits of respiratory-gated VMAT with
FFF beams in reducing lung toxicities associated with SABR for early stage lung cancer.
Reducing margins of the target volume by using respiratory gating can aid in sparing of
normal tissue while maintaining clinically feasible treatment times. A predictor for early
toxicity seen in the lung, pneumonitis, is the percent volume of the lung receiving 20 Gy
(V20Gy); the lower the V20Gy, the lower the risk. We have shown the use of respiratory-gated
VMAT can significantly reduce V20Gy and V50% compared to non-gated VMAT, commonly
used in clinics worldwide. It should be taken into account that the ITV in the non-gated
case contains normal lung volume not accounted for in the calculation of V50% and,
therefore, the values received represent an underestimation of the true values in the nongated case. Also, the volume of lung during full breathing cycle is greater than the volume
of lungs in the end-exhale.
In Table 3-2, the max dose of other normal tissues such as cord, esophagus, heart, bronchus,
and trachea decreased in respiratory gated VMAT compared to non-gated VMAT, albeit
not significantly. A greater maximum dose reduction in critical organs was seen in cases
where the tumor was proximal to these critical organs. In all other cases, the reduction in
margin did not result in a significant difference. Otherwise, all the parameters studied have
shown to be significantly decreased when gated VMAT planning is performed. In general,
the doses to critical organs are expected to decrease with respiratory gating because of the
reduction of the PTV volumes with gating. The dose falloff parameter, D2cm, significantly
decreased with gated VMAT, meaning less normal tissue being exposed to higher doses.
Dose spillage or the percent of contralateral lung receiving at least 5 Gy, V5Gy, significantly
decreased with gated VMAT.
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A disadvantage to respiratory gating is increase in the treatment time. However, FFF-based
treatment reduces gated treatment times with higher dose rates. Treatment time was
estimated based on the planning dosimetric values, monitor units, dose rate and gating
window. On average, each non-gated VMAT treatment requires 1.5 minutes whereas gated
VMAT treatment requires 4.7 minutes. However, based on the electronic treatment records
for 30 fractions of patients treated clinically with 10X-FFF SABR VMAT, treatment time
for respiratory gated VMAT was increased by a factor of 2.3 compared to non gated VMAT
delivery. A study by Malinowski et al showed changes in the spatial relationship between
tumour and surrogate marker occurred mostly in 30-minute treatment fractions; however,
as we showed above, typical respiratory gated SABR VMAT treatments with FFF beams
have significantly lower treatments times, a tenth of the values reported in the study24.
Figure 3-2 and Figure 3-3 shows cases of patients, 16, 17, 18, and 20, where gated VMAT
may not be necessary since there is only a slight difference in reduction of normal lung
dose; the p-values for V20 Gy and V50% difference for these four patients are 0.286 and 0.040
respectively. This lack of reduction in normal lung dose may be due to the target in each
of these plans not being located centrally in the lung. Also, the paucity of motion may
contribute, in each of these cases, maximum target motion in any direction is less than 6
mm; there is only one other patient with motion of similar magnitude as seen in Table 1.
The slight increase in sparing of lungs may not outweigh the increase in treatment time
during gated treatment, inferring that gating is not necessary for all patients.
A weakness of this study was that treatment planning for non-gated cases was performed
on the average intensity projection from the full 4D-CT dataset, and not using 4D dose
accumulation. However, a study by Li et al showed that there was no significant difference
in both the target and normal tissue dose distribution using 3D or 4D dose calculation25.
Also, since the definition of normal lung in this study was lung-ITV, we are actually
underestimating the dose to the normal lung, as mentioned earlier, thereby increasing the
necessity for motion management strategies such as respiratory gating.
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3.5 Conclusion
This dosimetric planning study has shown that respiratory gated VMAT using flattening
filter free technology has the potential to reduce dose to normal lung compared to free
breathing VMAT, without greatly compromising treatment delivery time. There was a
significant decrease in normal lung V20Gy and V50%, both of which are important parameters
to consider when minimizing the risk of radiation-induced lung toxicity.
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Chapter 4

4

The use of on-board kV imaging during respiratory gated
VMAT delivery to evaluate the correlation between
tumour motion and external surrogate motion in patientspecific waveforms

This chapter is based on a research paper entitled “The use of on-board kV imaging during
respiratory gated VMAT delivery to evaluate the correlation between tumour motion and
external surrogate motion in patient-specific waveforms” by Xhaferllari I, Stevens T, ElSherif O, Gaede S to be submitted to the Medical Physics journal.

4.1 Introduction
Respiratory motion leads to significant uncertainties in the treatment of thoracic and
abdominal tumors with radiation therapy1. Respiratory gating is one method used to limit
intra-fractional breathing motion, resulting in reduced target margins and radiation-induced
lung toxicities2–4. The gating window can be determined based on either the amplitude or
phase of the periodic external surrogate motion waveform. The gating threshold in
amplitude based gating is defined on motion displacement relative to the baseline, the mean
motion at end-exhale calculated during the learning of the respiratory motion5. Whereas,
gating thresholds in phase gating are defined as two angular positions of the respiratory
waveform5. Of these two techniques, amplitude gating has demonstrated to be more
reliable when tracking irregular respiratory motion over time6–8. Phase gating assumes
constant periodicity in respiratory breathing motion, and can lead to substantial targeting
errors for irregular non-periodic waveforms9. Variabilities in respiratory waveform
characteristic, such as slope and period, lead to discrepancies in the motion displacement
sorted to the same phase during phase-based respiratory gating.
In respiratory gating, predictive filters are employed to control for irregular, non-periodic
breathing by setting a threshold of periodicity for triggering the beam on10. The breathing
waveform recorded during 4D-CT acquisition is used as a reference for radiation treatment.
The threshold applied to the predictive filter aids in restricting inaccurate treatment
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delivery by triggering the beam off when the motion does not match the 4D-CT reference
within the specified threshold.
The main uncertainty in respiratory gated treatment lies in the assumption that an external
surrogate can accurately predict the internal motion of the target. Respiratory gated
treatments are susceptible to baseline changes during treatment and overall variability in
intrafraction tumor motion9. Intrafraction motion variability may invoke a phase shift
between the external trace and the internal target motion. In gated delivery of lung cancer,
this can lead to discrepancies in dose delivery, with some target volumes being on the verge
of under-dosage11,12. Previous studies have investigated the correlation between the motion
of external markers and internal targets during 4D-CT acquisition13–15, before treatment16–
18

, and with the use of ultrasound19 or fiducial markers18,20,21.

Respiratory gated volumetric modulated arc therapy (VMAT) is a method used to treat
early-stage non-small cell lung cancer (NSCLC) with stereotactic ablative body
radiotherapy (SABR). However, the impact of multiple gantry “starts and stops” as well as
multiple dose rate “ramp-ups and ramp-downs” during high dose rate respiratory-gated
VMAT on the internal/external correlation and, subsequently, the dose to the target is
unclear. The increase in treatment delivery complexity may cause latencies in machine
response and recording external motion. The goal of this study is to examine the utility of
using on-board kV imaging to: 1) determine the correlation of external surrogate motion
and internal target motion during ungated, amplitude gated, and phase gated VMAT
delivery using flattening filter free (FFF) beams ; and 2) identify known phase shifts
between the internal and external trace.

4.2 Methods
4.2.1

Study subjects

From our institutional database, five previously treated early-stage NSCLC real patient
breathing (RPB) traces were selected, along with a sinusoidal trace, to represent variable
breathing patterns and a range of motion irregularity. For early-stage NSCLC patients, the
breathing trace was acquired from the Real-Time Position Management (RPM) suite
(Varian Medical Systems, Palo Alto, CA) during CT simulation. The RPM motion trace
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file specifies a flag indicating acquisition of 4D-CT imaging. The portion of the respiratory
motion waveform represented by the 4D-CT acquisition flag was extracted. The gross
target volume, (GTV), was contoured on all ten 4D-CT phases using MIM software version
6.3 (Mim Software Inc., Cleveland, OH). The centroid coordinates of the GTV contour
were identified in each of the 4D-CT phase using MIM software, and the total motion of
the GTV in the superior-inferior direction was calculated based on variability between
phases. The respiratory breathing trace extracted from the RPM system was scaled to the
total calculated motion of the GTV to represent the real-patient full respiratory cycle.
The variability in target displacement at consecutive end-exhalation phases was calculated
in each RPB waveform to determine motion irregularity. High standard deviation in the
end-exhale position represented irregular breathing while low standard deviation
represented periodic, regular breathing. In addition to the five real-patient breathing traces,
a sinusoidal waveform with 1.5 cm peak-to-peak motion, and four second period was
included in the study (patient 6). Variability in motion pattern was defined as periodic for
regular RPB and sinusoidal trace, exhibiting a baseline drift if the position of the baseline
was slowly veering, and defined as baseline shift for patients exhibiting sudden changes in
displacement of the baseline position. Table 4-1 demonstrates characteristics of the patients
analyzed.
Table 4-1. Selected subjects motion characteristics
Centroid tumor
motion (cm)

Standard Deviation (cm)
End-Inhale

Motion
End-exhale Irregularities

1

1.23

0.092

0.017

Periodic

2

1.02

0.254

0.060

Baseline drift

3

0.93

0.219

0.127

Baseline shift

4

0.73

0.168

0.170

Baseline shift

5

0.60

0.300

0.179

Baseline drift

6

1.50

Patient

Periodic
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4.2.2

Treatment planning and delivery

RPB traces were acquired corresponding to previously treated patients from our in-house
respiratory gated SABR protocol. All treatment plans corresponding to these patients were
optimized using SmartArc VMAT technique in Pinnacle Treatment Planning system v9.6
(Philips Medical Systems, Fitchburg, MA) and consisted of two 225⁰ arcs.
The Varian TrueBeam linac version 2.0 with the integrated respiratory gating system,
operating in Research Mode (Varian Medical Systems, Palo Alto, CA), was used for
treatment delivery due to its ability to design customized beam and imaging trajectories.
Here, the axes of the treatment delivery, such as the gantry, collimator, couch, and MLC,
and imaging points are user controlled and programmed as a function of cumulative control
points. Research Mode trajectories were written in an extensible markup language (XML)
and allowed for modification of the partial 225° arcs from the original VMAT treatment
plans. Namely, simultaneous kV imaging was added to the VMAT arc. These plans were
then delivered to the Quasar programmable respiratory motion phantom (Modus Medical
Devices, London, ON). The Quasar programmable respiratory motion phantom contained
a cedar insert with an embedded 3 cm delrin sphere, to simulate healthy lung with a tissuelike tumour. The internal trace was extracted from the superior-inferior motion of the insert.
Meanwhile, the external trace was obtained from the respiratory gating box, placed on a
platform stage with vertical motion (Figure 4-1). The phantom operates using a circular
shaped cam for sinusoidal motion, and another cam for typical respiratory cycle to drive
both the platform stage and insert. The Quasar motion phantom was programmed according
to the real-patient one-dimensional breathing trace derived above. 22
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Figure 4-1. Quasar programmable respiratory motion phantom, depicting the moving
cedar insert with an embedded delrin sphere (internal motion) and the platform stage for
the respiratory gating box (external motion).
Treatment delivery was performed under free breathing ungated, amplitude gated, and
phase gated conditions. Free breathing ungated conditions encompassed 100% duty cycle
via phase gating while respiratory gated conditions encompassed 40% duty cycle at end
exhalation. The free breathing ungated delivery condition was used to test reproducibility
of motion with variability in the phantom. Amplitude gating has shown to perform well
with the lack of consistent periodicity in breathing6–8, whereas phase gating has been shown
to produce errors under irregular motion conditions that can lead to inconsistent triggering
of the beam on and off 8.
The predictive filter defines a threshold within which the respiratory breathing trace should
correspond to the reference breathing trace. Before treatment delivery, the predictive filter
registers amplitude versus respiratory phase data points to define periodicity in the
breathing trace. The threshold of the predictive filter, or quality of gating, applied during
treatment allows the beam to trigger off if the breathing traces falls outside of these limits.
We further investigated the impact of the predictive filter threshold on phase-based gating
acquired with kV imaging. All respiratory phase gated deliveries were repeated with a
predictive filter of 0, 2, 5, and 10% threshold, or as set in the XML treatment file with the
gating quality of 0, 0.02, 0.05, and 0.1.
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4.2.3

Image acquisition

On-board gated kV projections were acquired simultaneously during MV beam-on while
inside the gating window. A dynamic gain fluoroscopy protocol, with an imaging
frequency of 7 frames/second, was designed to maintain low kV dosage while attaining
sufficient imaging data to establish an internal breathing trace. A head and neck clinical
pre-treatment cone-beam CT protocol was used to define imaging parameters. The
fluoroscopic imaging parameters were 100 kVp, 20 mA, with a 20 ms duration of the kV
pulse. A full bow-tie filter was applied.

4.2.4

Analysis of the internal and external trace

The phantom was set-up under static breathing conditions such that the 3-cm delrin sphere
was located at isocenter. The delrin sphere, embedded in cedar, exhibits one-dimensional
motion in the superior-inferior direction or y-orientation in the kV projection. The location
of the delrin sphere was determined by acquiring multiple line profiles from 1-cm left to
1-cm right of the center of the sphere (Figure 4-2). In all the line profiles, the noise and
average intensity in the cedar were determined. The delrin sphere was identified as
consecutive values in the line profile that deviate from the cedar. Profiles affected by the
noise of MV degradation or obstructed from the treatment couch were removed if deviating
by two standard deviations of the centroid mean position. The remaining profiles were
averaged to determine the centroid in the kV projection. The internal trace was defined as
the variability of the centroid position between consecutive projections. Afterward, the
motion trace was manually inspected for projections, or centroid points, deviating from the
programmed motion. These points were removed from further analysis if manual analysis
revealed differing centroid values. The header of the imaging files enclosed the amplitude
of the external surrogate box for each kV projection. The external trace was defined as the
variability in amplitude of the external surrogate box from consecutive kV projections.
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Figure 4-2. Quasar respiratory motion phantom depicting the moving cedar with the
embedded delrin sphere. Centroid of the delrin sphere was calculated based on line profiles
between the dashed lines.
Linear regression was used to compare the accuracy of the external surrogate trace in
predicting the internal trace. Based on this model, correlation of determination, R2, was
determined for all deliveries. The point-to-point root-mean-square-error (RMSE) was
calculated over the waveform of the internal and external motion. The difference in
correlation between free breathing ungated, phase gated, and amplitude gated conditions
for each of the six breathing traces under varying predictive filters were investigated.
The data acquired from the on-board kV imaging was also used to examine the variations
in the residual motion in amplitude and phase based respiratory gated during VMAT
delivery. The length of gating window for the breathing cycle was calculated based on the
time stamp associated with each projection. Displacements in the position at the start and
end of the gating window was analyzed to investigate discrepancies in amplitude associated
with the same phase. The amplitude value of the time stamp associated with the entering
or exiting the gating window in amplitude and phase gating was measured.
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4.2.5

Phase shift

A phase shift of the external surrogate can occur during treatment due to either patient
specific physiology or system latency in machine response to recording the external data
points and triggering respiratory gating. Unfortunately, the Quasar respiratory motion
phantom is unable to decouple the external platform motion from the insert motion.
Therefore, the ability of during treatment kV imaging to identify a phase shift between the
internal and external trace, was investigated by using a second phantom, the Quasar
programmable motion platform (Modus Medical Devices, London, ON), with independent
motion. The external motion trace and, hence, the respiratory gating trigger, were obtained
via the second phantom while the internal trace was obtained via on-board kV imaging of
the Quasar programmable respiratory motion phantom. A sinusoidal motion pattern with a
2-cm peak-to-peak motion and 4 second period, was programmed for both phantoms with
eight known shifts spaced 0.4 seconds apart. The correlation of determination coefficient
in the linear regression statistical test was performed for each experimental set of
respiratory traces. The observed phase shift was calculated by shifting the external trace,
in time, until correlation was maximized.

4.3 Results
4.3.1

Correlation analysis

The calculated internal and external trace along with the programmed breathing pattern for
the ungated, amplitude gated, and phase gated treatment delivery, is displayed in Figure
4-3 for the first 45 seconds of treatment of patient 1. This respiratory trace entailed
repetitive RPB motion with low deviations in the end-exhale position. A correlation of R2
= 0.996, 0.948, 0.973 was achieved for free-breathing ungated, amplitude gated, and phase
gated, respectively.
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Figure 4-3. Computer controlled respiratory breathing trace (solid line), and the internal
target (circle symbol) and external surrogate trace (asterisk symbol) are shown for freebreathing ungated, end-exhale amplitude gated, and phase gated in the first 45 seconds of
treatment delivery. Over the course of the treatment delivery, a correlation of R 2 = 0.996,
0.948, 0.973 was achieved for free-breathing ungated, amplitude, and phase gating,
respectively.
The correlation observed in free breathing ungated treatment delivery, validates the Quasar
motion phantom accuracy in reproducing the computer controlled real patient breathing
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trace, and the automation technique in delineating the internal trace despite MV
degradation, and obstruction from the acrylic of the phantom and treatment couch at some
angles. Regardless of motion irregularities programmed, the correlation in the free
breathing ungated scenario for all patients ranged between R2 = 0.950-0.997 with a mean
of 0.986, as shown in Figure 4-4A. Similarly, for amplitude gated and phase gated
scenarios, correlation ranged between R2 = 0.919-0.987 or a mean of 0.942, and R2 = 0.9590.981 or a mean of 0.974, respectively.
Different predictive filter thresholds were applied during respiratory phase gated delivery.
The correlation coefficient for treatment deliveries with a predictive filter threshold of 0%,
2%, 5%, and 10% ranged between R2 = 0.959 to 0.981, 0.938 to 0.976, 0.890 to 0.975, and
0.890 to 0.975, respectively (Figure 4-4B). The correlation was high for all scenarios
including the sinusoidal case (patient 6) where no variability amongst treatment delivery
techniques was observed. In RPB with high end-exhalation position variability, the MV
and kV beams were not able to trigger due to the periodicity of motion remaining outside
of the threshold. For these breathing traces, only a zero threshold could be used to allow
the MV and kV beam to trigger. This can be observed by the lack of points in Figure 4-4B
for patients 4 and 5.
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Figure 4-4. The coefficient of determination, R2. (A) Free breathing ungated (circle
symbol), amplitude-gated (asterisk symbol), and phase-gated (square symbol). (B) Phasegating with different predictive filter thresholds applied of 0% threshold (circle symbol),
2% threshold (asterisk symbol), 5% threshold (square symbol), and 10% threshold.
The variety of RPB patterns traces is displayed in Figure 4-5 along with the corresponding
linear regression analysis in the free breathing ungated, amplitude gated and phase gated
scenario. Patient 1 (Figure 4-5A) represented a repetitive RPB waveform, patient 2 (Figure
4-5B) represented a baseline drift scenario, and patient 3 (Figure 4-5C) represented an RPB
trace exhibiting baseline shift. The phase-based gated deliveries exhibited a greater range
of motion, approaching the motion magnitude of the free-breathing in Figure 4-5C.
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Figure 4-5. Different programmed motion traces and the corresponding linear regression
analysis for free breathing ungated (circle), amplitude gated (asterisk), and phase gated
(square). A) Patient 1 exhibited a repetitive breathing with a low standard deviation in the
end-exhalation, b) patient 2 exhibited amplitude variation, and c) patient 3 exhibited a
baseline shift and varying periodicity.
The calculated RMSE for the different treatment delivery techniques and the inclusions of
various predictive filters are shown in Figure 4-6. Submillimeter accuracy was found in
all deliveries. The free breathing ungated delivery, with the greatest motion magnitude,
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resulted in the largest error at a range of 0.023 cm to 0.065 cm, whereas the error in the
residual motion in amplitude gating and phase gating resulted in a range of 0.015 cm to
0.024 cm and 0.015 cm to 0.033 cm, respectively (Figure 4-6A). With various predictive
filters the RMSE ranged between 0.015 cm to 0.033 cm, 0.014 cm to 0.026 cm, 0.014 cm
to 0.026 cm, and 0.014 cm to 0.025 cm, for predictive thresholds of 0%, 2%, 5%, and 10%,
respectively (Figure 4-6B).

Figure 4-6. Root mean square error, RMSE, comparing the error between the internal and
external trace during free breathing ungated (circle symbol), amplitude-gated (asterisk
symbol), and phase-gated (square symbol) deliveries. (A); phase-gating with different
predictive filter thresholds of 0% threshold (circle symbol), 2% threshold (asterisk
symbol), 5% threshold (square symbol), and 10% threshold (B).

4.3.2

Residual motion analysis

The length of the gating window during amplitude and phase gated deliveries is shown in
Figure 4-7. The overall deviations with phase gating were lower than with amplitude gating
at 0.276 seconds and 0.757 seconds, respectively.
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Figure 4-7. Variation in the length of the duty cycle during amplitude (diamond) gated,
and phase gated (circle) deliveries. The symbol represents the average while the whiskers
represent the standard deviation.
Irregular, non-periodic motion has been shown to lead to significant variabilities in phase
gating6. On board kV imaging was utilized to compare the amplitude displacement
variability at the entrance and exit of the gating window during amplitude- and phase-based
respiratory gated VMAT, as shown in Figure 4-8. On the contrary to the length of the gating
window, the position variations in the entry and exit of the gating window were less in
amplitude gating than phase gating, shown in Figure 4-8 by small whiskers in the mean
position of amplitude gating. The mean position variations in exiting and entering the
gating window were 0.024 cm and 0.131 cm in amplitude and phase gating, respectively.
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Figure 4-8. The amplitude of motion at entry, left, and exit, right, the gating window in
phase-gating. Diamond and circle symbol represents the mean amplitude when entering
and exiting the gating window, while the whiskers represent the standard deviation.

4.3.3

Determining a phase shift

Known baseline phase shifts between the external surrogate trace and internal target trace
were introduced to investigate the ability of kV imaging to detect such phase shifts. A
second independently programmed phantom was used to trigger the kV and MV beam
while the original phantom’s trace was shifted at 0.4-second intervals. The correlation
coefficient between the internal and external trace for each shift was 0.229 ± 0.14. The
external waveform was shifted until the correlation coefficient was maximized, resulting
in a mean ± standard deviation correlation of 0.974 ± 0.03 (Table 4-2).
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Table 4-2. Programmed shifts between the internal target motion and the external surrogate
marker were measured using the correlation coefficient. Their respective correlation
values are shown.
Correlation of Determination
(R2)

Shift (seconds)
Programmed

Measured

Before shift

After shift

0.4

0.364

0.026

0.915

0.8

0.636

0.027

0.981

1.2

1.182

0.166

0.993

1.6

1.455

0.434

0.989

-0.4

-0.455

0.007

0.994

-0.8

-0.909

0.127

0.997

-1.2

-1.200

0.269

0.995

-1.6

-1.727

0.773

0.929

The results indicated that the kV projections were able to accurately detect any phase shifts
in phase respiratory gating, shown in Figure 4-9, where the programmed and measured
shift are displayed. The correlation between the known shifts and the measured was
determined to be 0.997. Ideally, the slope of the line between the measured and
programmed data points should be one, and the y-intercept should be zero. However, the
values achieved are within the resolution of the imaging, of 0.091 seconds per frame or 11
frames per second.
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Figure 4-9. The programmed shift between the two independent phantoms, and the
measured shift when maximizing the correlation.

4.4 Discussion
To the best of our knowledge, this is the first study that investigated kV imaging as a tool
to evaluate internal target and external surrogate verification during gated VMAT treatment
without the use of fiducial markers. This was accomplished by varying respiratory gating
parameters such as the mode (free breathing ungated, amplitude and phase-gated), and the
predictive filter threshold used in phase gated delivery.
Sinusoidal motion trace, 1.5 cm peak-to-peak and 4 second period, was tested, along with
five RPB waveforms exhibiting repetitive motion, baseline drifts, and baseline shifts with
differing end-exhale deviations. Decreasing correlation between the internal and external
trace could be due to a time delay on the acquisition kV imaging inside the gating window
and/or latencies in recording the external trace. Chugh et al. concluded time delays of over
100 ms can be expected in breathing waveform with period variations23. In all treatment
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delivery scenarios, a high correlation was observed despite increasing deviation in the endexhale and non-periodicity.
Despite a higher correlation between the external surrogate and internal target observed in
phase gating compared to amplitude gating, in Figure 4-3, gated kV images appear to be
acquired outside the end-exhalation during phase-based respiratory gating. Phase gating
relies on sinusoidal approximation based on previous breathing periods. Learning period
of four waveform periods is required to learn the characteristics of the respiratory trace, as
discussed in section 1.5.3 of this thesis. In TrueBeam Research Mode, treatment delivery
was initiated without learning the characteristics of the breathing trace. Consecutively, the
beam triggered outside of the end-exhalation gating in the beginning of the trace, as
observed in phase gating of Figure 4-3.
Clinically, the reference breathing trace recorded during 4D-CT acquisition is used to
provide a histogram of displacement versus phase. This allows for calculations of the
respiratory waveform periodicity. Malone et al. 2014 recommend the use of a 5%-40%
predictive filter for reproducible treatment delivery10. In treatment delivery, a predictive
filter threshold reduces the potential of triggering the MV beam when the patient is outside
the limitations included in the 4D-CT acquisition, i.e. the patient coughs, takes a deeper
breath, or exhibits a lack of periodicity. However, the addition of the predictive filter to
treatment delivery increases treatment delivery complexity, along with high dose rate
respiratory gated VMAT, which in turn can cause latencies in machine response. A strong
correlation was observed in all deliveries where a predictive filter was included. In the
selected group of waveforms analyzed, patients 4 and 5 had the greatest deviations in endexhale position which inhibited the use of a predictive filter during respiratory gating.
Patient 2 was the only study subject that required removal of one to four projections out of
the total 278 - 368 projections acquired after manual verification. The poorer results of the
internal trace can explain the lower correlation values seen in this patient.
Phase gating is susceptible to dosimetric uncertainties due to potentially long treatment
times and due to potential drift occurring with the external surrogate which leads to phase
shifts in the internal and external trace9,11. In SABR treatments that use high dose rates,
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capable with flattening filter free beams, the treatment time can be reduced to 3-4 minutes4
making these patients less vulnerable to baseline drifts. Shifting the external trace along
the internal trace to maximize the correlation coefficient provided the ability to accurately
observe phase shifts. Although only tested for sinusoidal motion, this method can still
provide an approximation of more complex real patient breathing waveforms. Uncertainty
in the phase shift experiment lies in the usage of two independently programmed phantoms,
allowing the study to become prone to additional mechanical errors.
Previous studies have investigated the internal and external correlation via acquisition of
the planning CT dataset13,14, via pre-treatment image verification techniques16–18, during
treatment using fiducial markers and the Mitsubishi Real-Time Radiation Therapy
system16,20,24 or via fluoroscopy in the CyberKnife system19. Most of these studies require
additional imaging dose, but it is important to limit kV exposure time to limit skin dose25.
This study investigated computer customized kV images acquired at specific imaging
points, and the imaging parameters maintained similar to pre-treatment CBCT protocol
while capturing fewer projections.
During treatment, kV imaging can also provide verification of the gating window. The
length of the gating window exhibits more variance in amplitude gating than phase gating
because amplitude gating is based on a threshold for displacement, whereas phase gating
relies on two angular phases in every breathing cycle. Variation in the baseline amplitude
and length of the end-exhale will cause deviations in the length of each gating window in
amplitude gating. Whereas the variations listed above, as well as periodicity of the
respiratory signal, will influence the position of each breathing cycle in phase gating as
shown in Figure 4-6 and Figure 4-7. Recently, studies have demonstrated the capability of
during treatment verification using the on-board MV or kV imaging26–30.
This study was limited to phantom experiments as it was completed using Research mode
of Varian TrueBeam linear accelerators and does not investigate the correlation in patients
during treatment. Patient-specific hysteresis may alter the relationship between the internal
and external targets not accounted for during respiratory gated VMAT delivery31.
However, the method investigated here can provide a tool to triage irregular RPM
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waveforms to make clinical decisions on the use of respiratory gated motion management
if there is a lack of correlation. Clinical use of kV-imaging during gated VMAT delivery
could detect discrepancies in correlation and potentially be accounted for in subsequent
treatment fractions.

4.5 Conclusions
In this study, on-board kV imaging has been validated as a tool that can verify the external
surrogate motion and internal target motion correlation during respiratory gated VMAT.
The technique examined RPB exhibiting regular and irregular motion with different
breathing waveform patterns, considered various gating scenarios, and was able to
accurately detect any phase shifts. Verification of respiratory-gated VMAT delivery is
essential, especially for adaptive radiation therapy, which relies on accurate intrafraction
knowledge of tumour position for accurate dose calculation.
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Chapter 5

5

Investigation of image quality of intrafraction cone beam
CT for 3D verification of respiratory-gated VMAT delivery

The contents of this chapter are in preparation for submission to Physics in Medicine and
Biology entitled “Investigation of image quality of intrafraction cone beam CT for 3D
verification of respiratory-gated VMAT delivery” by Xhaferllari I, Dekker K, Hajdok G,
Gaede S.

5.1 Introduction
Respiratory motion causes a major challenge in the treatment of thoracic and abdominal
cancers with radiation therapy1,2. At the same time, the clinical implementation of
stereotactic ablative body radiotherapy (SABR) in early-stage non-small cell lung cancer
(NSCLC) has led to higher doses per fraction, requiring tight margins3–5. Respiratory
gating is a technique to manage respiratory motion by limiting the radiation beam to
specific portions of the breathing cycle6,7. As a result, high doses are delivered to the target,
while limiting dose to normal tissue. One of the main limitations of respiratory gating is
that it relies on the accuracy of an external surrogate to predict the internal motion of the
target, despite intrafraction variations in respiratory motion8,9. Therefore, treatment dose
verification methods are required to ensure the planned dose distribution are accurately
delivered during respiratory gated radiotherapy.
The application of image-guided radiation therapy (IGRT) improves tumour targeting10.
On-board kV imaging and electronic portal imaging device (EPID) are widely used as a
pre-treatment image-based verification method11. Cone-beam CT (CBCT) can be
reconstructed for volumetric verification when kV or MV planar images are acquired in an
arc. Pre-treatment CBCT portrays patient anatomy before treatment and aids in reducing
patient misalignments. However, CBCT acquired prior to treatment does not guarantee
accurate dose delivery to the target during treatment delivery, especially for moving
targets.
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Continuous imaging through EPID in cine mode has been used for during treatment
verification. However, EPID is limited in the investigation of anatomy alignments by the
field-of-view (FOV) of the treatment beam, especially for SABR treatment delivery with
small field sizes. Recently, intrafraction verification techniques using on-board kV
projections have been investigated for treatment verification of SABR, including
volumetric modulated arc therapy (VMAT)12–15. The benefit of during VMAT imaging is
the ability to reconstruct a volumetric CBCT. However, added imaging dose from the onboard kV unit should be maintained as low as possible16. For during treatment verification,
the added imaging dose is reliant on the treatment session time and the imaging acquisition
mode. Treatment session times are greater during respiratory gated SABR compared to
ungated conventional radiation therapy, due to higher doses per fraction in SABR, and the
restriction of radiation beam delivery to portions of the breathing cycle. The ability to
compute gated-kV imaging concurrent with treatment can help reduce patient exposure and
limit imaging dose for respiratory gated patients. Another limitation of intrafraction kV
imaging is the potential degradation of the kV projections due to MV scatter hitting the kV
detector17–19.
The hypothesis of this study is that gated on-board kV CBCT can be used as a 3D method
to validate the delivery of respiratory-gated VMAT using a programmable respiratory
motion phantom. This was tested by evaluating imaging quality and target visualization
capabilities of during treatment gated on-board kV CBCT while minimizing kV beam-on
time.

5.2 Methods
5.2.1

Quasar Motion phantom

The Quasar programmable respiratory motion phantom (Modus Medical, London, ON)
was used in all on-board kV CBCT reconstructions. It is a dynamic phantom with the
ability to insert different moving components, useful for investigating the impact of motion
on imaging and radiation delivery (Figure 5-1A). For the purpose of this study, a cedar
cylindrical insert, representing lung equivalent electron density with embedded polystyrene
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spheres, representing tumour equivalent electron densities, was added (Figure 5-1B, C).
The polystyrenes spheres ranged in sizes of 3-cm, 2-cm, 1-cm, and 0.5-cm, best
exemplifying detectability properties of different sized lesions typically seen in early-stage
NSCLC treated with SABR. The cedar and polystyrene unit moves in the superior-inferior
(SI) direction by the magnitude specified in the programmed motion trace.

Figure 5-1. Quasar programmable respiratory motion phantom (A). Moving insert
composed of cedar, representing normal lung tissue, and embedded polystyrene spheres,
representing tumour tissues (B). (C) Schematic of the moving insert with various sizes and
locations of polystyrene spheres.

5.2.2

Imaging Acquisitions

Varian TrueBeam linear accelerator v.2.0 (Varian Medical System, Palo Alto, CA) in
Research Mode was used to obtain on-board kV imaging simultaneous to the MV treatment
beam. Research Mode allows for user defined imaging and treatment delivery protocols,
and has the capability of synchronizing image acqusition to treatment delivery. On-board
kV imaging was acquired concurrently to treatment beam delivery of a clinical SABR lung
plan delivered in a 225° partial arc. Ungated and triggered gated kV acquistion projections
were collected with a stationary and moving phantom, respectively. A full bow-tie filter
and a titanium filter were added to compensate for greater attenuation of the x-ray beam at
the center of the FOV by the phantom, and reduce low energy x-rays of the beam,
respectively.
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5.2.2.1

Imaging Parameters

5.2.2.1.1

Treatment Deliveries under static conditions

In the first set of measurements, static conditions were kept to investigate various imaging
parameters on image quality and target detectability, in the absence of respiratory motion.
This included reconstructing a pre-treatment on-board kV CBCT of the phantom in the
absence of MV scatter, based on a current clinical protocol, acquired using a full 360° arc
at 11 frames per second. A reference on-board kV CBCT, in the presence of MV scatter,
was reconstructed using similar parameters to the pre-treatment on-board kV CBCT, but
acquired at 7 frames per second. The acquisition parameters for the reference on-board kV
CBCT were 100 kVp, 20 mA, 20 ms, 7 frames per second, during SABR VMAT with arc
range of 225°, and a kV source to detector distance (SDD) of 150 cm. MV scatter was
added using the SABR-VMAT clinical plan of a previously treated patient. We varied the
energy, tube current, and SDD. All static deliveries and respective test numbers, referred
throughout this paper, are summarized in Table 5-1.
Table 5-1. Imaging parameters of static acquisitions. The reference acquisition has been
bolded.
Test #

Energy

Current

Pulse length

SDD

Frame rate

Arc range

MV

(kVp)

(mA)

(ms)

(cm)

(fr/sec)

(degrees)

scatter

1

100

20

20

150

11

360

No

2

100

20

20

150

7

225

Yes

3

80

20

20

150

7

225

Yes

4

125

20

20

150

7

225

Yes

5

100

10

20

150

7

225

Yes

6

100

40

20

150

7

225

Yes

7

100

20

20

140

7

225

Yes

8

100

20

20

160

7

225

Yes
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5.2.2.1.2

Treatment Deliveries under motion conditions

In the second set of experiments, the motion phantom was enabled during treatment
delivery as kV projections were captured. Three real-patient breathing (RPB) traces were
tested to represent various breathing patterns, depicted by a simplified sinusoidal waveform
in Figure 5-2. The three RPB waveforms were extracted from CT-simulation of previous
patients treated with respiratory gating. Each RPB trace was normalized to the total motion
measured in the 4D-CT dataset. A fast, repetitive RPB trace (Figure 5-2A) with a peak-topeak amplitude of 1.2 cm, was used to represent regular motion. RPB traces with irregular
motion patterns were observed with a baseline drift20 (Figure 5-2B) and a trace with a
baseline shift21 (Figure 5-2C). The baseline drift motion displayed a veering position of the
baseline with a peak-to-peak amplitude of 1.0 cm. Whereas the baseline shift trace
displayed sudden changes in the baseline amplitude of motion, with a peak-to-peak motion
of 0.9 cm. A set of projections were acquired under free breathing ungated conditions,
using a 100% duty cycle, and amplitude- and phase-based gating using a 40% duty cycle
for each RPB. The reference imaging parameters, from acquisition (2) in Table 5-1, were
used for all acquisitions.
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Figure 5-2. Schematic of the different waveforms in a simplified sinusoidal waveform. A)
Fast, repetitive breathing, B) Baseline drift (shown by the red line), C) Baseline shift
(shown by the red step).

5.2.2.2

CBCT reconstruction

In clinical practice, CBCT images are generally reconstructed using the Feldkamp-DavisKress (FDK) algorithm of filtered backprojections22. To simulate clinical application, all
datasets in this study were reconstructed using the FDK algorithm with Hamming filter
applied. Reconstructions were also computed using in-house CT projection code written in
CUDA-C for GPU acceleration on a CPU with intel i7-2600 and GPU of NVIDIA GTX
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780. The reconstructed matrix size was 512x512x384 pixels with isotropic voxel of 0.0517
cm. Therefore, the FOV was 26.5 cm by 26.5 cm. The number of projections per scan
varies with gantry speed, frame rate, treatment modality, and the periodicity of the
respiratory breathing trace. The gantry speed was limited to 6° per second, and the highest
dose rate of 2400 monitor units per minute was used for the treatment beam. The number
of projections acquired in the pre-treatment on-board kV CBCT was 662. The during
treatment on-board kV CBCTs were acquired under static conditions with approximately
311 projections, due to shorter scanning angle and lower frame rate. The during treatment
CBCTs acquired under respiratory motion conditions resulted in 311 projections for the
ungated conditions, and 345 – 397 projections for gated conditions. Acquisitions with MV
scatter resulted in fewer number of projections compared to the pre-treatment on-board kV
CBCT, because a lower kV acquisition frame rate of 7 frames per second was used in
acquisitions with MV scatter compared to 11 frames per second in pre-treatment on-board
kV CBCT projections. CBCT acquired under gated conditions required greater projections
than ungated conditions due to frequent ramp up and down of the dose rate limiting the
gantry speed.
In datasets acquired using imaging parameters expected to lead to a decrease in image
quality (e.g. low mA, low kVp) with respect to the reference acquisition, and the reference
acquisition, [(2), (3), (5), (8)], were reconstructed using an iterative reconstruction
technique to potentially increase image quality. The iterative algorithm applied, OSCTV23, combines ordered subsets convex (OSC) algorithm24,25 and the total variation
minimization (TV) regularization technique26.

5.2.3
5.2.3.1

Evaluation methods
Image Quality

The CBCT datasets were exported into 3D-SlicerRT program for analysis27,28. 3D-Slicer is
a multi-platform free, open source software for visualization and medical imaging
computing. In the stationary phantom measurements, the polystyrene spheres and a 2-cm
sphere region of interest (ROI) in the cedar, were delineated on the reference acquisition
(2). These contours were imported onto the remaining static on-board kV CBCT datasets
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(1) - (6) to remove contouring bias in the analysis process. The contours for on-board kV
CBCT datasets (7) and (8) were delineated separately as these datasets had different image
acquisition geometries. For the respiratory motion induced CBCT datasets, the polystyrene
spheres and the cedar ROI, were delineated individually based on the blur of motion
observed.
Image quality was investigated for all CBCT datasets by calculating the contrast-to-noise
ratio (CNR) between each of the polystyrene spheres and the ROI in the cedar29.
𝐶𝑁𝑅 =

𝜇𝑝 − 𝜇𝑐
𝜎𝑝

(1)

where µp and µc are the mean linear attenuation coefficients of the polystyrene spheres, and
the cedar ROI, respectively, and σp is the standard deviation of the linear attenuation
coefficient of each polystyrene sphere.

5.2.3.2

Target Delineation

In the static acquisitions, target detectability was identified by calculating the full-widthhalf-maximum (FWHM) for each of the polystyrene spheres. The central coronal slice,
shown in the schematic of Figure 5-1C, displays the center through all four spheres. Based
on the geometry of the cedar insert, profiles were calculated to obtain the FWHM.
In the motion induced acquisition, the region of interest delineated in 3D-Slicer was
compared to the static CBCT targets by calculating the volume percent difference (VPD)
for each region of interest12.
𝑉𝑃𝐷 =

|𝑉𝑀 ∪ 𝑉𝑆 − 𝑉𝑀 ∩ 𝑉𝑆 |
𝑉𝑆
× 100%

(2)

where VM represents the volume blur of the polystyrene sphere in the moving phantom
acquisition, and VS represents the respective polystyrene sphere in the stationary phantom
delivery. All static and motion induced treatment deliveries were set-up at isocentre,
inherently shifting the gated delivery targets to the end-exhalation extreme from the static
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target. To limit registration error in the VPD calculation, the gated CBCT images were
retrospectively shifted based on the number of pixels representing 40% of the total
breathing motion.
Statistical analysis was performed using a one-way analysis of variance (ANOVA)
followed by a Tukey’s posthoc test in the statistics package of IBM SPSS v.20 (IBM SPSS
Statistics for Windows, Armonk, NY).

5.3 Results
5.3.1

Effects of Acquisition Parameters on Image Quality

The on-board kV CBCT acquisitions with a static phantom were used to investigate image
quality in the different sized polystyrene spheres. In Figure 5-3, the coronal slice from the
isocentre of the static CBCT reconstructions is shown using the same window and level.
The reconstruction volume was cropped to display only the moving cedar with the
polystyrene spheres. The pretreatment CBCT (labelled no MV) (1) displayed the best
visualization of the spheres. However, each polystyrene sphere was visible in all
reconstructions, except for the 0.5-cm sphere in the 80 kVp (3) CBCT volume.
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Figure 5-3. Coronal slice at isocenter in all the static deliveries. The corresponding
numbers represent the imaging parameters described in the methods section. For visual
purposes, the slice is cropped to only represent the moving insert. The same window level
is used in all eight CBCT images.
The effect of MV scatter on on-board kV CBCT was investigated in polystyrene. Linear
attenuation coefficients in the pre-treatment CBCT (1) and the reference acquisition (2)
were compared by delineating the 2-cm polystyrene sphere. The difference in linear
attenuation coefficient was investigated by subtracting the pre-treatment CBCT (1) from
the reference acquisition (2), shown by the red histograms in Figure 5-4. In polystyrene, a
decrease in the linear attenuation coefficient is observed, with a mean value of 0.027 cm-1,
and spread or standard deviation of 0.01 cm-1. Previous studies have observed a significant
effect of MV scatter on kV imaging18,30, however, the field size in these studies was 10 cm
by 10 cm or greater, whereas this study used a smaller field size of 4.5 cm by 4.2 cm, as
observed in early-stage NSCLC SABR treatment.
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Figure 5-4. Difference in linear attenuation coefficient (µ) values in the polystyrene ROI
between the reference CBCT acquisition in the presence of MV scatter (2), and the pretreatment CBCT acquisition in the absence of MV scatter (1). The difference in linear
attenuation coefficient (µ) values is shown by the red histogram.
The CNR between each polystyrene sphere and cedar ROI displayed the lowest values for
acquisitions with 80 kVp (3), where CNR ranged between 1.8, for the 0.5-cm sphere, to
2.2, for the 1-cm sphere, as shown in Figure 5-5. A significant reduction was found for
volumes acquired with 80 kVp (3) (p = 0.002), and 10 mA (5) (p = 0.006), compared to the
pre-treatment CBCT acquired without MV scatter (1). Similarly, a significant difference
was observed when comparing CNR for 120 kVp (4) and 40 mA (6), to 80 kVp (3) and 10
mA (5) (p < 0.015). Otherwise, no significant difference was observed amongst other
CBCT volumes. For volumes acquired with the reference MV scatter acquisition (2),
compared to the pre-treatment on-board kV CBCT (1), increased tube voltage acquisition
(125 kVp) (4), and increased current acquistion(40 mA) (6), there was a greater
discrepancy between CNR in the larger spheres, 3-cm and 2-cm, compared to the CNR in
the smaller spheres 1-cm, 0.5-cm. The 0.5-cm sphere CNR ranged between 2.9 to 4.0,
whereas the CNR in the 3-cm sphere ranged between 3.7 to 6.4.
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Figure 5-5. Contrast-to-noise ratio (CNR) between each of the polystyrene spheres and a
region of interest in the cedar in CBCT in a stationary phantom.
Similarly, when comparing FWHM, the lower energy (80 kVp) (3) diminished the
visibility of the 0.5-cm lesion (Figure 5-6). For the remaining CBCT datasets, the FWHM
calculation for the 3-cm, 2-cm, 1-cm, and 0.5-cm spheres resulted in a range of 2.96 to 3.02
cm, 1.98 to 2.07 cm, 0.92 to 1.11 cm, and 0.47 to 0.58 cm, respectively. No significant
differences were found amongst different acquisition parameters. On-board kV CBCT
acquired during SABR treatment delivery, resulted in detectability of different sized
lesions for all acquisition parameters explored in this study.
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Figure 5-6. The full-width-half-maximum (FWHM) of all polystyrene spheres in the
centroid slice of the CBCT dataset in a stationary phantom.

5.3.2

Comparison of CBCT reconstruction techniques

The FDK filtered backprojection algorithm is implemented clinically for pre-treatment
CBCT reconstruction. All acquisitions were reconstructed using FDK filtered
backprojection. Iterative reconstruction has recently been shown to improve imaging
quality in lower dose acquisition modes, and in acquisitions with limited projections23. The
reference acquisition (2), projections acquired with a low energy of 80 kVp (3), low current
of 10 mA (5), and 160 SDD (8), were reconstructed using the OSC-TV iterative algorithm.
The coronal slice of the reconstruction in the centroid position comparing FDK to OSCTV, is displayed in Figure 5-7.
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Figure 5-7. Comparison of filtered backprojection (FDK algorithm) and iterative (OSCTV algorithm) reconstruction displayed in the coronal slice at isocenter. The same window
level was used in both datasets.
A significant increase (p<0.001) was observed in the CNR calculations with OSC-TV
compared to FDK (Figure 5-8). The CNR increased by 2.6 times or more in the different
polystyrene spheres for acquisitions with 80 kVp (3). The 0.5-cm sphere in the 80 kVp
CBCT reconstruction (3) was visible and had a FWHM value of 0.53 cm. FWHM
calculations on the iterative reconstructed CBCT datasets did not reveal significant
differences (p>0.05) and all the ROIs were identified. The FWHM for the 3-cm, 2-cm, 1cm, and 0.5-cm polystyrene spheres ranged from 2.97-3.00 cm, 1.98 – 2.01 cm, 0.94-1.01
cm, and 0.43 – 0.53 cm, respectively. Iterative reconstruction with OSC-TV demonstrates
the potential to reduce imaging dose while maintaining detectability of various sized
lesions.
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Figure 5-8. Comparison of contrast-to-noise ratio (CNR) between filtered back projection
(FDK algorithm) and iterative reconstruction (OSC-TV algorithm) for every polystyrene
sphere.

5.3.3

Target Motion Analysis

Figure 5-9 demonstrates the coronal slice of the on-board kV CBCT for the static (reference
imaging protocol), and the RPB trace exhibiting a baseline drift under free breathing
ungated, amplitude and phase gated conditions. Blurring is observed among all polystyrene
spheres in the free breathing ungated image, where the visualization for 0.5-cm and 1-cm
spheres was difficult.

Figure 5-9. Coronal slice at isocenter comparing static, free breathing ungated, amplitude
gated and phase gated delivery for the RPB waveform with a baseline drift
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Image quality was quantified by the CNR between the delineated polystyrene spheres and
a ROI in the cedar (Table 5-2). A significantly lower CNR was observed for the free
breathing ungated conditions encompassing the full blur of motion, compared to amplitude
gating (p=0.001) and phase gating (p<0.001). However, amplitude gating and phase gating
did not reveal significant differences (p>0.05).
Detectability of different sized regions of interest was investigated by comparing the VPD
between the motion induced acquisition and the static reference (2) on-board kV CBCT
(Table 5-2). Similar to the CNR calculations, the VPD improved in respiratory gated
deliveries compared to free breathing ungated conditions, albeit not significant (p>0.05).
However, in the baseline drift RPB, the VPD decreased in the free breathing ungated
conditions compared to gated conditions for the 0.5-cm sphere. The delineation of the 0.5cm polystyrene sphere was difficult in all CBCT datasets due to respiratory motion
artifacts. A significant decrease was observed when comparing the CNR of the 0.5-cm
sphere to the 2-cm sphere (p = 0.014) and the 3-cm sphere (p=0.028). This resulted in a
significant increase of the VPD for the 0.5-cm sphere compared to the remaining
polystyrene spheres (p<0.05).
Table 5-2. Contrast-to-noise ratio (CNR), and volume percent difference (VPD)
calculation for each polystyrene sphere amongst the different RPB traces and treatment
delivery conditions.
Motion
Polystyrene Management
sphere
3-cm

2-cm

Fast, regular RPB
trace

Baseline drift
RPB

Baseline Shift
RPB

CNR

VPD

CNR

VPD

CNR

VPD

Ungated

2.5

27.6

2.1

15.8

2.1

20.6

Amplitude

3.0

16.6

3.8

15.8

3.0

9.2

Phase

3.2

12.0

3.3

12.1

2.9

12.9

Ungated

2.1

32.7

1.7

25.9

2.5

18.7

Amplitude

2.9

24.8

3.7

18.5

3.2

15.3

Phase

3.1

20.9

3.9

18.3

3.6

16.5

120

1-cm

0.5-cm

Ungated

1.8

52.3

1.5

43.4

1.9

43.0

Amplitude

2.3

34.8

2.1

38.5

2.7

22.0

Phase

2.7

17.6

3.2

32.8

2.7

35.8

Ungated

1.8

142.0

1.1

41.7

1.9

66.1

Amplitude

1.9

85.6

2.7

78.8

2.5

48.9

Phase

3.0

57.8

1.5

57.8

1.9

65.5

5.4 Discussion
Current clinical practice relies on on-board kV CBCT acquired prior to treatment for proper
patient set-up and verification. However, early-stage NSCLC patients are susceptible to
intrafraction motion variations not accounted for in pre-treatment verification8,9. The
objective of this study was to evaluate imaging quality and target visibility of intrafraction
on-board kV CBCT, and to investigate the influence of respiratory motion on gated and
free breathing CBCT in a respiratory motion phantom study. High visibility and imaging
quality is required to allow for usability of on-board kV CBCT acquired during treatment.
Despite results in literature regarding the negative effects of MV scatter from the treatment
beam on during treatment kV-CBCT reconstruction18,30, we observed no significant
differences in image quality and target visibility in CBCTs reconstructed in the presence
of MV scatter compared to pre-treatment CBCT. Smaller field sizes in SABR treatment
delivery minimize degradation in on-board kV CBCT from MV scatter, compared to
studies where field sizes of 10 cm x 10 cm or greater were used.
Respiratory motion artifacts were minimized through the use of gated on-board kV CBCT
acquisition. This acquisition mode, restricts on-board kV acquisition to specific portions
of motion in the phantom, limiting imaging dose. A significant decrease was observed in
CNR between the free breathing ungated and respiratory gated on-board kV CBCT. For
very small targets, respiratory motion, introduced motion artifacts in both gated and
ungated CBCT, causing uncertainty in delineating the 0.5-cm spheres. A limitation in this
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study was potential retrospective registration misalignment between the gated and static
on-board kV CBCT calculations introducing uncertainties in the VPD calculations. These
registration errors can be reduced by acquiring a subset average 4D-CT dataset to represent
the gating window used during treatment delivery. The subset average 4D-CT can be
applied to verify respiratory gated treatment delivery.
Li et al. described a clinical application of gated on-board kV CBCT in patients by
acquiring kV fluoroscopy during a treatment session, and retrospectively removing all
projections acquired while the treatment beam is turned off15. This significantly increases
imaging dose due to the increased length of a respiratory gated treatment session. Kincaid
et al. investigated gated CBCT acquisition as a method to remove target blurring by
limiting the MV exposure and shifting the treatment jaws to block the MV beam31. The
CNR values reported were comparable to the measurements in this study. Our study
evaluated image quality while maintaining low imaging dose exposure with 124 mAs in
the free breathing ungated acquisition, and a range of 138 mAs to 159 mAs in the
respiratory gated on-board kV CBCT, compared to 1478 mAs reported by Kincaid et al.31.
The application of iterative reconstruction in on-board kV CBCT can further increase
image quality and target detectability. In this study, various real patient breathing motion
irregularities investigated did not lead to a significant difference amongst CNR and VPD,
as expected during gated delivery.
Imaging dose and potential wear-and-tear on the on-board kV unit was limited by acquiring
kV projections as triggered gated acquisitions in TrueBeam Research Mode. This modality
is currently not available in clinical mode but potential implementation could easily allow
translation to gated on-board kV CBCT to early-stage NSCLC patients. In this patient
group, gated CBCT will reduce motion artifacts, and limit imaging dose and MV
degradation. Future work will investigate the role of intrafraction CBCT for usability in
adaptive radiotherapy.

5.5 Conclusions
Intrafraction on-board kV CBCT acquired during gated VMAT SABR treatment can
provide during treatment verification. In this study, CBCT potentially tarnished by MV
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scatter during a partial arc delivery was observed to show insignificant differences
compared to CBCT acquired without MV scatter using similar imaging parameters. In a
motion induced thoracic phantom, intrafraction respiratory gated CBCT quality was
significantly improved compared to free breathing ungated CBCT. This intrafraction
treatment verification method can positively impact adaptive radiotherapy applications.
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Chapter 6
“It always seems impossible until it is done” – Nelson Mandela

Summary, Conclusion, and Future Work

6

6.1 Summary
The overall goal of this thesis was to optimize radiation therapy planning and delivery of
respiratory gated IMRT and VMAT for early-stage NSCLC patients treated with SABR.
This goal led to the formulation of the following research objectives:


To compare different IMRT treatment delivery techniques to deduce the most
optimal trade-off between treatment efficiency, tumour dose conformality and
healthy tissue sparing when treating early-stage NSCLC with SABR.



To evaluate the potential reduction of radiation induced lung toxicity through the
use of respiratory gated VMAT, when treating patients that exhibit significant
respiratory-induced tumour motion.



To determine if on-board kV imaging can be used as a tool to validate respiratory
gated VMAT delivery by investigating the correlation of the external surrogate
motion to the internal target motion, and by determining potential phase shifts.



To optimize imaging parameters of volumetric CBCT acquired by synchronizing
kV imaging with respiratory-gated VMAT delivery to provide 3D verification of
correct tumour targeting

In the following subsections, an overview of Chapters 2-5 of the thesis will be provided,
along with resulting conclusions from each study and impact on the above objectives.

6.1.1

Dosimetric planning comparison of IMRT techniques for early
stage non-small cell lung cancer treated by SABR

In Chapter 2, various IMRT techniques were compared for the treatment of early-stage
NSCLC with SABR. This was accomplished by retrospectively planning ten patients with
three fixed beam techniques (step-and-shoot low and high modulation, and sliding
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window), two VMAT techniques (SmartArc and RapidArc), and Helical Tomotherapy
with three different fan beam widths (1-cm, 2.5-cm, and 5-cm). The Eclipse v11.3
treatment planning system employed the Acuros XB dose calculation algorithm and was
used to compute sliding window fixed beam IMRT and RapidArc VMAT. High and low
modulation step-and-shoot fixed beam plans and SmartArc VMAT were computed with
Pinnacle v9.1 treatment planning system that uses collapsed cone convolution dose
calculation algorithm. All HT treatment plans were planned in TomoPlan v.3.1.1, which
employs a convolution/superposition dose calculation algorithm. Fixed-beam and VMAT
plans were generated using 10MV FFF x-ray beams with a maximum dose rate of 2400
MU/min, while HT plans were generated with 6MV beams with a maximum dose rate of
600 MU/min. A comprehensive analysis was completed by comparing various parameters
grouped into tumour dose conformality, dose volume histograms and indices, and treatment
efficiency (i.e. minimization of MUs, MLC travel distance, treatment time delivery).
VMAT treatment plans resulted in significantly lower contralateral lung V5Gy (p < 0.05)
compared to the HT plans, and significantly lower mean lung dose (p<0.006) compared to
HT-5cm treatment plans. Increased MLC leaf travel used to form intensity gradients in the
beam can lead to potential degradation of the MLC carriage over time. SmartArc resulted
in the least MLC leaf travel, while a significant difference was found between high
modulation step-and-shoot and the remainder of the delivery techniques. Treatment
efficiency was evaluated by calculating treatment delivery “beam on” time and a
significant difference was found amongst HT and fixed-beam plans compared to VMAT
modalities (p<0.001).
Further comparison was completed by grouping the most efficient techniques from each
modality, both step-and-shoot plans, VMAT plans, and HT 2.5-cm and 5-cm. VMAT
outperformed HT, with statistical superiority observed in 11 parameters. In the comparison
between step-and-shoot and VMAT techniques, an increase in dose to the heart, esophagus
and bronchus was observed in the VMAT plans, although insignificant. VMAT showed
significantly improved treatment efficiency and was dosimetrically advantageous for all
other parameters.
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In the comparison between the two VMAT techniques, SmartArc resulted in a significant
reduction in the total monitor units (p = 0.05), whereas a significant decrease was observed
in the dose fall-off parameter, D2cm, (p=0.05), in RapidArc treatment plans. Otherwise,
RapidArc and SmartArc performed comparably. Although all techniques had clinically
acceptable treatment plans, VMAT was dosimetrically advantageous in treating early-stage
NSCLC with SABR as it provided the optimal trade-off between dose conformality and
sparing of normal tissue, and treatment efficiency. Based on the results of this study,
VMAT is recommended in treatment planning of early-stage NSCLC patients treated by
SABR.

6.1.2

Assessing the potential to reduce normal lung toxicity in
SABR patients using respiratory-gated VMAT

In Chapter 3, VMAT enhanced by respiratory gating was assessed for tumour motion of 5
mm or more, identified as significant by the AAPM task group 761. Twenty patients were
retrospectively planned using both the free breathing “untagged average” CT scan and the
“subset average” 4D-CT data set, to represent non-gated and respiratory gated scenarios,
respectively. The ITV in the non-gated plans was defined as the envelope of the GTVs
delineated in all 10 phases of the respiratory cycle. In the gated plans, ITV encompassed
only end-exhalation phases included in the subset average. Treatment planning was
computed with 10MV-FFF x-ray beams using Pinnacle v.9.0 treatment planning software.
Pinnacle scripts were developed to optimize all 40 plans in order to minimize dosimetric
bias in treatment planning. Minor adjustments were sometimes necessary to fulfill dose
limits to critical structures. The main parameters analyzed were V20Gy, predictive of
radiation induced pneumonitis in healthy lung tissue2, and V50%, parameter used to control
intermediate dose spillage and total volume of potential irreversible fibrosis3–5.
There was a significant decrease in V20Gy, from (6.05 +/- 2.06)% to (5.25 +/- 1.75)%
(p=0.00009) and V50% from (158.17 +/- 61.12) cm3 to (125.71 +/- 49.46) cm3 (p=0.00002)
in the gated plans. Also, there was a significant decrease in contralateral lung V5Gy, D2cm,
MLD and total MU. However, non-centrally located lesions with motion less than 6 mm
did not result in a significant difference in V20Gy (p=0.286) whilst a significant reduction
was observed for V50% (p=0.04). Respiratory gated treatment delivery increased treatment
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time by approximately a factor of 2.3 compared to non-gated VMAT delivery, and the
application of respiratory gating should be limited only to patients with significant motion.
The results of this study affirmed significant reduction of potential radiation induced lung
toxicity, whilst previous studies resulted in safe delivery of respiratory gated VMAT in
TrueBeam linacs6,7. This provides the foreground information to enable the clinical
introduction of respiratory gated VMAT in the clinic for tumours with significant
respiratory motion.

6.1.3

On-board kV imaging during respiratory gated VMAT delivery
to verify the correlation between internal tumour motion and
external surrogate motion in patient-specific waveforms

In Chapter 4, a method to investigate respiratory gated delivery uncertainties was
evaluated. Respiratory gated delivery relies on the accuracy of the external surrogate
marker to predict the correct internal target motion. Challenges arise when the internal
motion is out of phase with the external surrogate motion, or when there are latencies in
machine response or recording of the external motion. Several other studies have
investigated the correlation in respiratory gating during 4D-CT acquisition8–10, before
treatment11–13, and with the use of ultrasound14 or fiducial markers13,15,16. Treatment
delivery complexity is enhanced by combining respiratory gating with high dose rate
VMAT, due to additional degrees of freedom, such as varying dose rates, and multiple
pauses of the gantry motion. The goal was to evaluate on-board kV imaging as a tool to
determine the internal and external correlation, and to detect phase shifts during respiratory
gated VMAT delivery. The Quasar respiratory motion phantom, which contains a hollow
body and drives a 3-cm delrin “tumour” sphere embedded in a cedar cylinder, was utilized
to represent a tumour surrounded by normal lung tissue. This study was completed in
TrueBeam Research Mode v.2.0 software to allow for computer customized kV
fluoroscopy that was triggered only within the treatment beam gating window. VMAT
treatment plans were delivered whilst the phantom motion was programmed using a simple
sinusoidal conditions and five real-patient breathing conditions exhibiting variable
respiratory motion, as characterized during 4D-CT acquisition. Treatment delivery was
performed under free breathing non-gated, amplitude gated, and phase gated conditions.
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For phase gating, the impact of various motion predictive algorithms was evaluated. The
moving delrin target was automatically delineated in all kV projections and compared to
the external platform (surrogate) motion integrated into the Quasar phantom. The external
and internal correlation was evaluated by linear regression analysis; highest discrepancy
(R2 = 0.919), however still a high correlation, was observed during amplitude-based gating
for waveforms exhibiting amplitude variations. High correlation coefficients were
observed in all deliveries, with a range of R2 = 0.950-0.997, 0.919-0.987, and 0.959-0.981
in non-gated, amplitude and phase gated, respectively. Similarly, the correlation coefficient
for treatment deliveries with a predictive filter threshold of 0%, 2%, 5%, and 10% ranged
between R2 = 0.959 to 0.981, 0.938 to 0.976, 0.890 to 0.975, and 0.890 to 0.975,
respectively. Submillimeter accuracy was found amongst the external and internal trace in
all deliveries. During treatment on-board kV imaging provides for a tool to verify
respiratory gated treatment.
Two independently programmed phantoms were used to determine if on-board kV imaging
technique can accurately identify known artificial phase shifts. The motion of the external
surrogate, from the second phantom, was shifted at intervals of 0.4 seconds in a sinusoidal
waveform with a four second period, to the internal motion of the Quasar motion phantom.
Retrospectively, shifts were measured by maximising the correlation coefficient. The mean
correlation increased from 0.229 ± 0.14 to 0.974 ± 0.03 after shifting the respiratory trace
of the original phantom. The measured and known shifts did not reveal a significant
difference (p=0.899, R2=0.997).
This study was completed using TrueBeam Research Mode, and was limited to respiratory
motion phantoms. However, real-patient breathing waveforms of various irregularity and
various gated treatment delivery modes were programmed and assessed. In all scenarios,
during treatment on-board kV imaging method was validated as a way to determine the
correlation between the internal tumour motion and external marker motion during gated
VMAT delivery. It can also be used to determine potential phase shifts between the motions
of the tumour and the external surrogate marker.
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Intrafraction on-board kV imaging will be useful in daily triaging of patients and allow for
clinical decisions to be made on the use of respiratory gated motion management on a
patient-specific basis. Also, clinical use of kV-imaging during gated VMAT delivery could
be used for adaptive radiation therapy where any discrepancy detected in a daily beam
delivery may be accounted for in subsequent treatment fractions.

6.1.4

Investigation of image quality of intrafraction cone beam CT
for 3D verification of respiratory-gated VMAT delivery

Chapter 4 provided a two-dimensional verification of respiratory gated delivery, whereas
in Chapter 5, intra- treatment CBCT was assessed as a three-dimensional treatment
verification tool. The main goal of this study was to assess detection of different size
targets, and image quality in intrafraction CBCT that is influenced by MV scatter. The
range of the targets examined, 0.5-cm to 3-cm in diameter, coincide with typical lesion size
in early-stage NSCLC patients. A “reference” CBCT of a stationary phantom was
reconstructed using on-board kV-projections acquired simultaneously during MV
treatment delivery of a 225° partial arc VMAT SABR treatment, using imaging parameters
of 100 kVp, 20 mA, 20 ms and source to detector distance of 150 cm. Image quality and
detectability were compared between this CBCT, and CBCT acquisition using a 360° arc
acquired without MV scatter degradation. Then, imaging parameters were varied in order
to evaluate image quality and detection of the targets while reducing imaging dose. For the
static phantom, variable energy (80 kVp and 125 kVp), current (10 mA and 40 mA), and
the source to detector distance (140 cm and 160 cm) were considered. Each acquisition was
reconstructed using filtered back projection with a hamming filter. Imaging quality was
defined as the improvement in the contrast-to-noise ratio (CNR), whereas detectability was
defined by calculating the full-width-half-maximum (FWHM) of each of the spherical
targets.
A significant reduction in image quality was found in reconstructed CBCTs with 80 kVp
and 10 mA compared to the CBCT acquired without MV scatter contribution, the high
energy of 125 kVp acquisition, and high current 40 mA acquisition. However, no
significant difference was observed in image quality between the CBCT acquired with the
reference imaging parameters with and without MV scatter. All targets were identified with
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the exception of the 0.5-cm sphere in the 80 kVp acquisition. The reference acquisition,
along with three sets of acquisitions obtained using low energy (80 kVp), low current (10
mA), and the greatest distance between the kV source and the detector (160 cm), were
reconstructed using OSC-TV algorithm for iterative CT reconstruction. CNR significantly
improved in all deliveries reconstructed with iterative reconstruction. No significant
difference was observed in image detectability with all targets accurately identified.
Real patient breathing traces with periodic motion, motion exhibiting a baseline drift, and
motion with a baseline shift were programmed on the Quasar motion phantom with cedar
insert embedded with polystyrene “tumour” spheres. For each motion scenario, projections
were acquired using the reference imaging parameters during a free breathing non-gated,
amplitude gated, and phase gated VMAT delivery during SABR. Respiratory motion
induced artifacts in the detection of the different targets and image quality were examined.
Detection of the target was identified as the volume percent difference (VPD) between
respiratory motion targets, and static targets obtained with reference imaging parameters.
A significantly lower CNR was measured in free breathing ungated conditions
encompassing the full blur of motion, compared to amplitude gating (p=0.001) and phase
gating (p<0.001), whereas, amplitude gating and phase gating did not reveal significant
differences (p>0.05).
This study has provided for verification of respiratory gated CBCT during treatment
delivery. In most of the CBCT reconstructions, the smallest target at 0.5-cm remained
visible, despite MV degradation on the acquired projections. Tarnished visibility was
observed in free-breathing ungated on-board kV CBCT, but triggered respiratory gated onboard kV CBCT reduced motion artifact. Intrafraction volumetric datasets can be applied
to respiratory gated SABR patients with potential applicability in adaptive radiotherapy.
Adapting treatment dose distribution based on intrafraction CBCT will allow for accurate
presentation of the true anatomy.
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6.2 Future work
6.2.1
6.2.1.1

Simultaneous kV and MV imaging during treatment
Three dimensional motion calculation during respiratory
gated delivery

In Chapter 4, internal and external correlation was investigated using only on-board kV
imaging in two-dimensions. Interlaced MV imaging can provide for a three dimensional
tracking of the respiratory trace during respiratory gated VMAT delivery. The EPID
detector is located perpendicular to the kV detector and can acquire imaging at 90°
simultaneous to on-board kV imaging. Customized kV imaging points can be triggered as
a function of cumulative dose, while simultaneously, cine MV imaging can be acquired.
Real patient breathing is predominantly in the superior-inferior (SI) direction, however in
40% of the treatments, motion is dominant in the anterior-posterior (AP) direction or the
right-left (RL) direction17. Simultaneous kV and MV imaging, will provide a three
dimensional position of the target in space. Consecutive acquisitions can be used to extract
the respiratory trace in the SI, AP, and RL of the internal target to compare to the external
surrogate box location in respiratory gated treatment delivery.

6.2.1.2

Simultaneous portal dosimetry and image verification

The synchronous kV and MV imaging technique described above can be used for any
treatment verification, and is not limited to respiratory gating based delivery. The on-board
kV imaging allows for an anatomical verification to ensure patients are properly aligned,
whereas, the interlaced MV imaging permits for a dosimetric verification of the true dose
delivered to the target. In TrueBeam Research Mode, continuous MV can be acquired in
dosimetry mode, while kV radiographic projections are programmed every 1° of gantry
rotation. The integrated MV image is a beams-eye-view (BEV) overlap of the exit fluence.
Portal images can be calibrated as defined by 1 calibrated unit (CU) is equal to 1 Gy for
10x10 cm field size at 100 cm source-to-imager-distance18. The MV portal images can be
compared to treatment dose distribution for variations in treatment dose delivery. Whereas,
the simultaneous kV projections can be reconstructed, as described in Chapter 5, to allow
for anatomical verification to the planning CT.
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Ren et al19 discussed the combination of kV and MV imaging as a target verification tool
by reconstructing volumetric imaging during treatment by the use of a priori information.
The technique described increased the number of projections acquired, leading to improved
image contrast while maintaining low imaging dose low in a non-clinical format. Whereas,
the study being suggested here, includes the combination of kV and MV imaging for a
dosimetric and anatomical intrafraction verification.

6.2.2

MV scatter characterization during kV acquisition

Chapters 4 and 5 exploit kV imaging as an intrafraction treatment verification method.
However, the implementation of kV imaging, simultaneous with active MV treatment
beams, cannot ignore the impact of the MV scatter and potential head leakage to the kV
detector and, hence, the resulting image degradation. Wallace et al. investigated the kV
signal to the kV detector as a ratio to the MV signal scattered to the kV detector in various
frequencies of the kV source, and patient sizes20. We have performed preliminary work to
quantify the scattered dose to the kV detector from the MV source. A 10X FFF beam with
8 cm by 8 cm field size was used to deliver 3000 MU while the kV source to detector
distance was 100 cm, located perpendicular to the MV beam. Transmission of the kV
source was reduced by placing a lead block in the path of kV source and limiting the
imaging parameters to 40 kVp, and 0.4 mA. Patient scatter of the treatment beam was
simulated using the Quasar motion phantom (Modus Medical Devices, London, ON).
Scattered dose was measured using ten optically stimulated luminescence dosimeters
(OSLD), placed linearly along the on-board kV detector (Figure 6-1).
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Figure 6-1. Scattered dose to the kV detector experimental setup.
The exposed OSLD were read using microStar InLight Reader (Landauer Inc, Glenwood,
IL). The dose measured to the OSLD ranged between 1.04 cGy at the top of the detector,
to 3.55 cGy at the bottom of the kV detector, with the center of the detector receiving 2.75
cGy, Figure 6-2.

Figure 6-2. Scattered dose to the kV detector ranged between 1.04 at the top, to 3.55 cGy
at the bottom of the detector.
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In Appendix B, a theoretical calculation of the estimated fraction of dose detected by a
pixel in the kV detector was presented. According to the calculations, 3000 MU delivery
will lead to 0.52 cGy to the kV detector at the centroid pixel, approximately 5 times less
than measured in the OSLD experiment, 2.75 cGy. Despite the discrepancy between the
calculated and measured values, both are low in comparison to the dose at isocentre, 3000
MU. The scattering volume in the measurements was a phantom composed of different
density material, such as acrylic, cedar, and delrin, whereas the calculations were based on
mimicking beam calibration by using a water phantom with isocentre at 5-cm depth. Also,
in the calculated value of Appendix B, charged particle equilibrium was assumed, and in
the measured values, the OSLD were placed directly on the kV detector without a buildup layer. Other potential sources for discrepancy in the measured values are head scatter,
secondary scatter of photons, OSLD energy dependence, and backscatter from the
treatment couch.
Although this preliminary work provides an estimation, a more accurate Monte Carlo
calculation that accounts for the different spectra of kV energies and MV energies is
required. The MV scatter can be characterized based on the kV detector material and
thickness, and the kV and MV beam pulse rate. This information may be used to
retrospectively remove MV scatter from kV projections and improve image quality.
Studies have investigated removing the MV scatter by the read-out of unexposed frames
between kV exposures through external hardware21,22, interlacing kV projections in
Research Mode without impact from the MV beam23, and by using a lead collimator on the
kV source to estimate MV scatter24.

6.2.3

Clinical implementation of intrafraction kV imaging

A main clinical limitation in results of chapters 4 and 5 is the inability to trigger kV imaging
solely in the gating window in clinical operation mode. Both studies were completed using
TrueBeam Research mode only, which allows for user defined imaging trajectories but is
not approved for clinical use.
Current clinical implementation of intrafraction kV imaging can be achieved through single
projection images triggered at the entry or exit of the gating window, or fluoroscopy
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throughout the entire treatment session, regardless of MV beam-on or -off. Triggered kV
imaging at the entry or exit of the gating window will not supply a treatment verification
simultaneous to the treatment MV beam, whereas, kV fluoroscopy will. However, the
current kV fluoroscopy mode does not decipher between MV beam-on or -off with kV
imaging continuously acquiring. Therefore, the imaging dose in kV fluoroscopy could be
unacceptably high during respiratory gated delivery depending on the treatment time and
the duty cycle. Also, projections acquired outside of the gating window are not useful for
intrafraction verification but could be utilized to deduce accurate volumetric
reconstructions absent of MV degradation.

6.2.3.1

Adaptive radiotherapy application

Future upgrades to include advanced imaging in clinical mode by allowing respiratory
gated triggered kV will permit the implementation of methods examined in Chapters 4 and
5 to be translated into intrafraction verifications for early-stage SABR patients. Early-stage
NSCLC patients treated with VMAT will be enrolled in the study, and will undergo
respiratory gated kV imaging. Based on the projections, the external marker motion will
be retrospectively correlated to the internal target motion. This analysis will provide a
respiratory gated treatment verification. The kV projections acquired, will be reconstruct
into during treatment gated-CBCT. Gated-CBCT and the planned dose distribution can be
overlapped to certify accurate dose delivery throughout a treatment course. CBCT acquired
for all treatments will monitor day-to-day variations and provide a dataset to re-optimize
treatment planning for subsequent treatments. This process can help eliminate the need to
re-acquire 4D-CT simulation for treatment planning.

6.2.3.2

Radiation induced lung toxicities in respiratory gated SABR
patients

Chapters 3 of this thesis discussed potential reduction in radiation induced lung toxicity
using respiratory gated VMAT. While in Chapter 5, image quality and target detectability
of intrafraction gated and ungated CBCT was investigated. During gated treatment, CBCTs
can be used for retrospective dose calculation to provide accurate dose-volume parameters
for clinical outcomes research. Occurrence of radiation induced pneumonitis and
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irreversible fibrosis can be investigated in these patients by acquiring CT scans at 3 months,
6 months, 12 months, and 24 months following radiation therapy. A future study in earlystage NSCLC patients can involve correlating volumes of pneumonitis and irreversible
fibrosis observed in follow-up scans and respective doses to these volumes in the
intrafraction CBCT.

6.2.3.3

Modelling on-board kV imaging in treatment planning
system

The pitfalls of intratreatment kV imaging is the additional dose to the patient and the wear
and tear on the kV tube and detector. Currently, acceptance testing and commissioning is
computed during the installation of the on-board kV imaging unit to determine localization,
and imaging quality for different anatomical sites25. Quality assurance is performed at
frequency dependent on the test to ensure the imaging unit operates safely and
reproducibly25. In this future works study, the spectrum of kV energies will be modelled
based on acquisition of protocols for various anatomical sites. The half value layer will be
measured using Unfors RaySafe Xi Mam detector (Unfors RaySafe Inc. Cleveland, OH)
while the computed tomography dose index (CTDI) will be measured using Unfors
RaySafe Xi transparent detector. The treatment planning system can be adapted for low
energy kernels to allow accurate dose calculation through the beam characteristics in the
anatomical site of kV imaging protocols. Modelling the kV beam in the treatment planning
system will allow for the imaging dose to be accounted for. This will, in turn, result in
adaptation of the treatment plan accordingly.

6.3 Conclusions
The main findings of this thesis are summarized as follows


VMAT, RapidArc and SmartArc, are dosimetrically advantageous in treating earlystage NSCLC with SABR compared to fixed-beam and helical tomotherapy while
providing significantly shorter treatment times.
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Respiratory-gated VMAT using flattening filter free technology has the potential to
reduce the dose to normal lung, and lower the potential for inducing pneumonitis,
and irreversible fibrotic volume when respiratory motion is a concern.



On-board kV imaging was used to verify the external surrogate motion and internal
target motion correlation during respiratory gated VMAT delivery. The technique
was used in real-patient breathing traces exhibiting regular and irregular motion,
and in a sinusoidal trace. All treatment deliveries resulted in a high correlation
coefficient. Known artificial phase shifts were also accurately identified with onboard kV imaging.



Intrafraction CBCT can provide high quality images and detectability despite the
presence of MV scatter. Respiratory gated CBCT, acquired by customized kV
imaging synchronously to respiratory-gated VMAT delivery, increases image
quality by reducing the blur of motion compared to free breathing ungated CBCT.

The results of this thesis will provide the application of respiratory gated on-board kV
imaging simultaneous to treatment beam delivery as a method to validate respiratory gated
VMAT delivery while potentially enhancing clinical benefits of respiratory gating in earlystage NSCLC patients.
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Appendices
A. Appendix A – Automated IMRT planning
Treatment plans in Chapter 1 and 2 optimized in Pinnacle treatment planning systems
(Philips Radiation Oncology, Fitchburg, USA) were computed using planning scripts to
remove bias and optimize efficiency. Planning scripts produced for early-stage NSCLC are
based on previous scripts written for different sites, such as head and neck. This appendix
is adapted from previous publication titled “Automated IMRT planning with regional
optimization using planning scripts” published in the in the Journal of Applied Clinical
Medical Physics vol 14(1):4052 (2013) by Xhaferllari I, Wong E, Bzdusek K, Lock M, and
Chen J.

A.1. Introduction
Intensity-modulated radiation therapy (IMRT) has become a standard technique in
radiation therapy to provide more conformal dose distribution to improve tumor control
probability and/or to reduce radiation toxicities. Currently, more than half of every disease
site uses IMRT1–4. For some simple cases, such as localized prostate cancer or whole breast
irradiation, various class solutions or protocols can be developed to generate an IMRT plan
efficiently5. However, for complicated cases such as some of head and neck cancers, it is
still time-consuming to generate optimized IMRT plans. Besides requirements of accurate
delineations of various target volumes and organs at risk (OAR), it is often required to
generate additional IMRT optimization structures such as dose limiting ring structures,
manually selecting beam directions and energies, IMRT objectives and associated weights.
These parameters are generally adjusted manually during the optimization process with
trial and error approach, including adding additional IMRT objectives to reduce various
cold and hot spots in the dose distribution.
There are on-going research activities to find more efficient ways for IMRT planning6–12.
Multicriteria optimization technique13–20 has been introduced into IMRT planning in order
to help solve issues faced with single objective planning where a weight for each objective
needs to be set before the plan can be optimized. However, currently, it is still timeconsuming with multicriteria optimization to generate and navigate through a large number
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of plans in Pareto surface. Recently, multicriteria optimization has been commercialized in
RaySearch Laboratories planning system (RaySearch Laboratories, Stockholm, Sweden)21.
Regional optimization22 is an effective way to improve IMRT plans by emphasizing
specific region of interests to help create high-dose gradients between target volumes and
critical structures during optimization using relatively high importance factors on small
region of interests. In this study, we present an iterative method that can be incorporated in
clinical process to improve IMRT plan quality and efficiency. Specifically, we have
implemented regional optimization in a simple iterative algorithm in a commercial
treatment planning system (Pinnacle, Philips Radiation Oncology, Fitchburg, MA). The
regional optimization we implemented is based on region of interest (ROI), and is not
voxel-based, as in the original paper22. Our method is based on automatically generated
cold and hot regions in the plan. In this work, we demonstrate that such an iterative
algorithm is applicable to clinical sites that are generally more challenging in IMRT
planning. The method was applied to three clinical sites: head and neck, prostate with
pelvic nodes, and anal canal cancers, where we evaluated its efficacies and time savings.
In principal, this method can also be used for other sites to automate IMRT planning
processes using planning scripts in treatment planning systems.

A.2. Material and Methods
A.2.1.

Overview

For each clinical site, a class solution was first developed manually based on a group of
clinical cases. The class solution provides standard beam parameters such as number of
beams, their energies, directions, collimator angles, jaw positions, and initial IMRT
objectives and corresponding weights. After a class solution was developed for a clinical
site, the entire optimization process was incorporated in a planning script. The planning
script includes the major activities shown in Figure A-1. For the purpose of providing
concrete methodologies, we will explain each of the optimization steps using the National
Cancer Institute of Canada Clinical Trials Group head and neck clinical protocol (NCIC
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CTG HN.6) as an example. This is a good clinical site to illustrate how to automate regional
IMRT optimization with many OARs and multiple target volumes.

Figure A 1. An overview of the steps completed by each script for a clinical site

A.2.2.

Check required regions of interest

The IMRT scripts require basic regions of interests (ROIs) to be defined, such as all clinical
target volumes (CTVs) and all organs at risk (OARs). For example, for the NCIC CTG
HN.6, the following ROIs are required: CTV70, CTV63 and/or CTV56, where 70, 63, and
56 are the prescription dose in units of Gray for each volume, with intended doses delivered
in 35 fractions. Other required ROIs are: cord, brain_stem, right parotid (rt_parotid), left
parotid (lt_parotid), larynx, mandible, rt_cochlea, lt_cochlea, oral_cavity, and one for the
body contour (external). Standard nomenclature is required by the script.
It is important to ensure all the required ROIs are present, so that the script can set proper
IMRT objectives for these ROIs. The script will check for the required dose matrix and
ROIs. If any of the ROIs are missing, it will display names of missing ROIs, in order for a
user to add or correct the names of required ROIs. If all the required ROIs are present, the
script will set standard colors for ROIs to facilitate quality assurance.
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A.2.3.

Generate additional contours

After checking for the required ROIs, the iterative algorithm will generate various derived
contours such as planning target volume (PTV) for each CTV, planning organ-at-risk
volumes (PRVs) for required OARs, and various dose-limiting ring structures for IMRT
optimization purpose. For the head and neck IMRT clinical trial, Table A-1 gives a
summary of all the contours generated.
Table A-1. Summary of all the contours generate for HN6 clinical trial
Contour name

Explanations

PTV70

Planning target volumes for

PTV63

70, 63 and 56 Gy prescription

PTV56

doses

Contour name
TPTV
cord_prv
brainstem_prv

Explanations
Total sum of all PTVs
Planning risk volumes for cord
and brainstem with a 5 cm
uniform margin

modPTV70

PTVs that exclude cord_prv,

rt_parotid_opt

modPTV63

brainstem_prv and not closer

lt_parotid_opt

modPTV56

to the external contour by 5

external_5mm

Parotid volumes avoiding PTVs

Body contour with a 5 mm margin

mm
optPTV63

Optimization PTVs, avoiding

ring70

1 cm ring around PTV70

optPTV56

overlap volumes with higher

ring63

1 cm ring around ring70, and

prescription doses
optPTV63_m

PTV63

Optimization PTVs, avoiding

ring56

overlap volumes with higher
optPTV56_m

1 cm ring around ring63, and
PTV56

prescription doses with a 1 cm

ring50

1 cm ring around ring56

margin

The script generates derived ROIs for OARs, such as cord_prv and brainstem_prv with 5
mm margin from cord and brain stem, respectively. Other generated PTVs are modPTV70,
modPTV63, and/or modPTV56 that exclude cord_prv, brainstem_prv, and are away from
skin by a 5 mm margin. Their purposes are to limit the dose to spinal cord and brain stem
to within tolerance and reducing skin dose. Also, it generates optPTV63 and/or optPTV56
that avoids overlapping with higher dose PTVs, such as optPTV63 = modPTV63 modPTV70 for optimization purpose. Rings with 1 cm uniform margin around PTVs
and/or other rings, such as ring70, ring63, and/or ring56, are created for creating a more
conformal dose distribution by specifying a maximum dose in each ring structure. In order
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to reduce dose to critical structures such as the parotids, rt_parotid_opt and lt_parotid_opt
are generated that avoid the PTVs so that more realistic objectives for IMRT optimization
can be set. Total sum of the PTVs, TPTV, is generated in order to help define optimal beam
geometries.

A.2.4.

Add beams

A summary of the six different fields used for HN.6 with their respective couch, gantry,
and collimator angles is given in Table A-2. Beams are added according to the class
solution with fixed jaw sizes based on the PTV coverage and OAR sparing to reduce local
minimum problem in IMRT optimization and to improve delivery accuracy and efficiency.
TPTV (defined previously) is used to adjust beam geometry that covers the desired
volumes. Beam geometry is set by setting the collimator, gantry, and couch angles, and
setting the jaw sizes. The jaw sizes for LAO and RAO fields in Table A-2 were set to cover
the total PTV with 8 mm margin, but it is limited to less than 14.5 cm in order to avoid
beam splitting on Varian linacs. Thus, only the side of TPTV where beam direction is along
the boundary of TPTV and parotids is made sure to be covered by the fields so that the
field edge can provide higher dose gradient between TPTV and parotids. This jaw size is
also set to avoid junction of the multileaf collimator (MLC) inside the fields to reduce
delivery uncertainty. However, two noncoplanar beams, LSAO and RSAO, are added to
cover the whole TPTV with fixed jaw size to avoid beam splitting and to provide dose
gradients required for both sides of TPTV. The use of noncoplanar beams is to cover lower
neck nodes but avoid irradiation to shoulders. The advantage of using fixed jaw size for
large IMRT target volumes in the head and neck was discussed in a recent publication23.
As shown in Figure A-2, two posterior oblique fields cover the PTVs only from one side
and shield part of the post neck region with only 2 cm jaw position from central axis for
easier MLC segmentation to reduce dose to spinal cord and brain stem.
After the beam geometry is defined, the proper dose prescription is set. In the case of HN.6,
the prescription dose is 70 Gy in 35 fractions to a reference point at the center of GTV. The
script will check for the position of the isocenter; this isocenter will be used in all beams.
The isodose lines will also be set using standard percentages of prescription with standard
colors.
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A similar procedure was carried out to implement class solutions for the high risk prostate
cancer and anal canal cancer cases.
Table A-2. Summary of beams generated for HN. 6
Gantry angle

Collimator

Couch angle

angle
LSAO (left superior anterior oblique)

75 ˚

0˚

15 ˚

LAO (left anterior oblique)

15 ˚

15 ˚

0˚

LPO (left posterior oblique)

148 ˚

350 ˚

0˚

RPO (right posterior oblique)

218 ˚

10 ˚

0˚

RAO (right anterior oblique)

285 ˚

0˚

345 ˚

345 ˚

350 ˚

0˚

RSAO

(right

superior

anterior

oblique)

Figure A 2. Jaw positions for IMRT fields are fixed in the scripts to reduce probability of
local minimum to avoid beam splitting for more accurate and efficient radiation delivery
147

A.2.5.

Initial optimization

IMRT parameters are set in the script, including the maximum number of iterations, the
maximum number of control points, minimum segment MU, and area. Then, IMRT
objectives and their respective weights are set for the initial optimization using direct
machine parameter optimization (DMPO) in Pinnacle. The IMRT objectives used for HN.6
are given in Table A-3. Higher weights are given to minimum dose of CTVs and modified
or optimization PTVs (modPTV70, optPTV63. and optPTV56) to ensure proper dose
coverage of CTVs and PTVs that are away from skin by 5 mm. However, we specified
lower maximum doses with low weights to the original PTVs to ensure that MLC will open
around PTVs, since part of PTVs may be too close or outside patient skin. This will ensure
sufficient skin flashing without unnecessary high skin dose. If any CTV is right on the skin,
bolus will be used to make sure proper dose coverage. After IMRT objectives are specified,
the dose is calculated and the first optimization is then started.
Table A-3. Some of the IMRT objectives set for the first optimization for HN.6
ROI name

Objective type

Dose (cGy)

Weight

CTV56

Minimum dose

5700

100

CTV63

Minimum dose

6350

100

CTV70

Minimum dose

7100

10

modPTV70

Maximum dose

7690

100

modPTV70

Minimum dose

7000

65

optPTV63

Maximum dose

6720

70

optPTV63

Minimum dose

6450

80

optPTV63_m

Uniform dose

6550

5

optPTV56

Minimum dose

5700

100

optPTV56_m

Maximum dose

6125

100

optPTV56_m

Uniform dose

5650

1

PTV56

Minimum dose

2800

1

PTV63

Minimum dose

3200

1

PTV70

Minimum dose

3000

30

brainstem

Maximum dose

5000

100
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brainstem_prv

Maximum dose

5500

33

cord

Maximum dose

4000

100

cord_prv

Maximum dose

4500

70

mandible

Maximum dose

7000

100

lt_parotid_opt

Maximum EUD

2350

20

ring50

Maximum dose

5000

10

ring56

Maximum dose

5600

100

ring63

Maximum dose

6300

50

ring70

Maximum dose

7000

100

Regional optimization

We implemented the regional optimization to reduce hot and cold spots in IMRT dose
distributions automatically in a simple iterative manner.

A.2.6.1.

Generating regional cold and hot spots

After initial IMRT optimization and the final dose calculation using collapsed cone
convolution for the first pass, various isodose lines related to the minimum doses to PTVs,
maximum doses inside or outside PTVs are converted to contours in the iterative algorithm.
Then, the corresponding cold or hot spots in each region are generated, such as in HN.6,
cold56, cold63, cold70 for cold spot in optTV56, optPTV63, and modPTV70, respectively.
Each cold spot is automatically generated in the script by subtracting the required minimum
isodose line (converted to contour) from the target volume. For example, cold70 =
modPTV70 - 70 Gy isodose line. Similarly, hot56, hot63, hot70, hot_out_70 is the hot spot
in optPTV56, optPTV63, PTV70, and outside PTV70, respectively, and they are generated
automatically by the script. For example, hot63 = maximum isodose line allowed in PTV63
- PTV70 - ring70. The reason to subtract higher dose ring ROIs is to avoid conflict with
minimum dose coverage of higher dose PTVs. The regional cold and hot spots for HN.6
clinical protocol are listed in Table A-4 with their relations to various ROIs and isodose
lines. Similar cold and hot spots based on the prescription of each PTV are added for
prostate with pelvic nodes and anal canal cases.
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Table A-4. Summary of regional cold and hot spots for HN.6 clinical protocol.
ROI name

Relation to ROI of isodose lines

hot_out_70

70 Gy isodose line – PTV70 – ring70

hot63

69.3 Gy isodose line – PTV70 – ring70

hot56

61.6 Gy isodose line – PTV70 – PTV63 – ring70 – ring 63

hot70

75.6 Gy isodose line

cold70

modPTV70 – 70 Gy isodose line

cold63

optPTV63 - 63 Gy isodose line

cold56

optPTV56 - 56 Gy isodose line

A.2.6.2.

Iterative optimization with regional cold and hot spots

IMRT objectives for these cold and hot spots are then added for regional optimization in
the scripts — for example, objectives listed in Table A-5 for HN.6 protocol. The IMRT
plan is then continually optimized with these added regional objectives based on previously
optimized and segmented plan using DMPO. In this re-optimization, only MLC segment
shape and weights are re-optimized. The HN.6 script uses 20 iterations. The generation of
various hot or cold spots and re-optimization can be repeated multiple times until an
optimal plan is achieved.
Table A-5. Summary of objectives set for the regional optimization for HN.6 clinical
protocol
ROI name

Objective type

Dose (cGy)

Weight

hot_out_70

Maximum dose

6800

100

hot63

Maximum dose

6650

50

hot56

Maximum dose

5880

5

hot70

Maximum dose

7350

1

cold70

Minimum dose

700

100

cold63

Minimum dose

6300

50

cold56

Minimum dose

5600

10
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A.3. Results
The method has been implemented and tested for three clinical sites: a clinical trial protocol
for head and neck cancer, prostate cancer with pelvic nodes, and anal canal cancer. Figure
A-3 shows DVH comparison for a head and neck case between a previously manually
optimized clinical plan and the automatically optimized IMRT plan using the automatic
iterative method. A manually optimized plan was used for comparison in this study and the
plan was previously optimized by an experienced dosimetrist for clinical use. As shown in
Figure A-3, the automatically generated plan has lower dose to the three most sensitive
critical structures: brainstem, spinal cord, and the left and right parotids with similar PTV
coverage. The comparison of dose distributions on an axial slice is shown in Figure A-4,
showing fewer hot spots in the automatically optimized plan.
As an example, the effect of regional optimization is shown in Figure A-5 for comparison
of dose distributions before and after regional optimization using the cold and hot spots for
a head and neck case.

Figure A-3. DVH comparison for a head and neck case between manually (dashed line)
and automatically generated plans (solid line).
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Figure A-4. Comparison of dose distribution on a transverse slice for a head and neck case
between manually generated IMRT plan and automatically generated IMRT plan using the
iterative method. Red shaded volume is PTV70 covered by 70 Gy isodose line in blue, and
green shaded volume is PTV63 covered by 63 Gy isodose line in black.

Figure A-5. Comparison of dose distribution on the coronal slice for a head and neck case
before (left) and after (right) automated regional optimization. Shaded volumes are PTV70
(blue), PTV63 (green), and PTV56 (red), respectively.
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Table A-6. Estimated time required to generate IMRT plans
Manual Planning

Automated Planning

Head and Neck

> 4 hours

~ 8 minutes

Anal Canal

> 2 hours

~ 6 minutes

> 1.5 hours

~ 6 minutes

Prostate with pelvic nodes

The time required to run the planning script on a Pinnacle thin client using computation
server with 4 quad core 2.9 GHz CPU is listed in Table A-6. The estimated minimum time
required for manual planning includes time needed to generate various derived contours,
set up beams, dose prescription, manually and repeatedly adjust IMRT objectives, and
running IMRT optimization. It shows that the iterative method implemented here as a script
can save significant time in IMRT planning. These IMRT planning scripts are used
clinically in our center for more than 500 clinical cases since they were implemented
clinically in 2010. They include at least 300 head and neck cases, 180 prostate cases, and
20 anal canal cases. It should be noted that after using automated planning scripts, most
cases will be tweaked by dosimetrists to see if further improvements can be made.
However, most tweaking just needs a few more passes of the continuous optimization that
usually take less than an hour. The estimated time saved in planning for each case is at least
2 hours for head and neck, and 1 hour for anal canal or prostate with pelvic nodes,
depending on the experience of the planner.

A.4. Discussion
The present work implemented planning scripts for complex IMRT cases that automated
most aspects of plan optimization which otherwise required continual manual input by a
planner. We used Pinnacle planning script to automate the regional optimization in an
iterative manner; however, the concept can be used in other planning systems, as well.
Automated IMRT planning script was recently published for optimization of breast
radiotherapy with tangential beams5. Here, we present an automated planning process for
more complicated head and neck, prostate with pelvic nodes, and anal canal cases. It also
includes the method to automatically reduce various cold and hot spots in the optimization
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process. To our knowledge, such implementation for more complex IMRT cases has not
been published before. Since the focus of this paper is on the methodology, we only present
one example for each clinical site, even though the scripts have been used clinically for
more than 500 cases. The thorough statistical analysis of these clinical cases will be
presented in a separate paper.
Since many IMRT planning steps are included in our IMRT planning scripts, they generally
save many hours in the IMRT planning process. It also helps implement clinical protocols,
in-house standards, using standard dose prescriptions, standard margin for PTVs, standard
derived region of interests (ROIs), such as modPTVs, optPTVs, cord_prv, and
brainstem_prv, as well as standard color scheme for ROIs and isodose lines. The planning
script can reduce variations of plan quality due to different experience of planners. The
planning scripts can be improved during clinical use, incorporating new techniques learned
in practice.
For many complicated cases, the IMRT planning scripts provide only a good starting point;
an optimal plan still requires a planner to fine-tune the automatically generated plan to
adapt the plan for individual situation. Also, the class solution does not consider geometry
variations across patients; therefore, it requires fine-tuning for each individual patient. Such
fine-tuning includes modifying IMRT objectives and their weights. Occasionally, beam
parameters may also need to be modified, such as gantry or collimator angles. In future
work we will investigate the impact of adjusting IMRT objectives and weights during the
iterative optimization process. The regional optimization method presented in this paper
may also be combined with priority-based IMRT optimization method24.

A.5. Conclusions
We have developed IMRT planning scripts for a few clinical sites to automate most of
IMRT planning process. In particular, regional optimization has been implemented in an
iterative algorithm to reduce hot or cold spots during the optimization process, especially
important for complex cases. We demonstrated that this is particularly useful in IMRT
planning for head and neck and prostate with pelvic nodes. We have shown that automated
iterative inverse planning improves IMRT planning efficiency substantially.
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B. Appendix B - Estimation of MV scatter contribution to kV
detector
The dose due to the scattered MV beam at a voxel of the kV detector was characterized
based on theory from a paper titled “Compton scatter imaging of a transverse scatter and
attenuations” by Battista JJ, Santon LW, and Bronskill MJ published in Physics in
Medicine and Biology, 1977, vol. 22 (2), pp 229-2441.

*

100

kV detector

*

95

(b)
Φ0, E0
P

Water

Δφ

L
d

φ

(a)

l

D

(c)
*units in cm

Figure B.1. Schematic of Compton scattering to pixels (a, b, or c) of the on-board kV detector. All
symbols and parameter values are defined in the Table below.
The dose scattered to 3 sample voxels (a,b,c) of the cesium iodide array scintillator on the
amorphous silicon flat panel detector was calculated for a non-divergent beam incident on
a cubic water phantom. The geometry of the setup mimics beam calibration of monitor
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units to dose at 100 cm source-to-axis distance (SAD), with a 10 cm x 10 cm field size at
5 cm depth in water:
𝐷𝑖𝑠𝑜 = 𝑀𝑈 ×

1.00 𝑐𝐺𝑦
𝑀𝑈

Voxel ‘P’, located at the center of the phantom, was used to represent a typical scattering
element of the scattering volume (blue). The scattering contribution was calculated at
voxels on the kV detector located in the center (a), top center (b), and bottom center (c), as
shown in Figure B.1.
The fluence of photons (i.e. per cm2) scattered by a voxel at P with area, a, and thickness,
z, then arrive at a pixel area (d2) on the kV detector panel was deduced as follows:

𝑣𝑜𝑥𝑒𝑙
Φ𝑑𝑒𝑡

=

Φ𝑖𝑠𝑜

𝑑𝜎
𝑑Ω 𝜌𝑒 𝑑𝑎 𝑑𝑧 𝑓2
𝑑Ω
𝑑2

(1)

where, assuming charge particle equilibrium (CPE), the isocentric fluence is:
Φ𝑖𝑠𝑜 =

𝐷𝑖𝑠𝑜
⁄𝐸0 (𝜇𝑒𝑛 )
𝜌

(2)
𝐻2 𝑂

The scattering Compton cross section is given by (Attix et al. 1986, equation 7.14)2:
𝑑𝜎

=
𝑑Ω

𝑟02 𝐸1 2 𝐸0

𝐸1

2

𝐸0

(𝐸 ) (𝐸 +
0

1

− 𝑠𝑖𝑛2 𝜙)

(3)

Where (Attix et al. 1986, equation 7.8)2:
𝐸1 =

𝐸0
(𝐸
⁄
1+ 0 𝑚0 𝑐 2 )(1−𝑐𝑜𝑠𝜙)

(4)

The solid angle subtended by a detector pixel of size d at distance L from isocentre is:
𝑑2

𝑑Ω = ( 𝐿2 )

(5)

The attenuation factor of the scattered photons is:
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(6)

𝑓2 = exp [− ∫ 𝜇(𝐸1 , 𝑙) 𝑑𝑙]

Next we consider the radiation scattered by all the voxels (like P) contained in the exposed
region of the water phantom. We make the simplifying assumption that they are all well
represented by the typical voxel at P. In reality, each scattering point has a different primary
attenuation, scattering angle, solid angle, and secondary attenuation. We estimate the total
scattered fluence reaching the detector pixel as follows:
𝑣𝑜𝑙𝑢𝑚𝑒
𝑣𝑜𝑥𝑒𝑙
Φ𝑑𝑒𝑡
= Φ𝑑𝑒𝑡

𝑑𝐴 𝑑𝑍
𝑑𝑎 𝑑𝑧

(7)

where dA is the non-divergent beam’s cross-sectional area and dZ is the phantom overall
thickness.
Assuming the detector material (det) is thick enough to achieve CPE, the absorbed dose at
the detector voxel, related to pixel signal, is then given by:
𝜇𝑒𝑛
𝑣𝑜𝑙𝑢𝑚𝑒
𝐷𝑑𝑒𝑡 = ( )
Φ𝑑𝑒𝑡
𝐸1
𝜌 𝑑𝑒𝑡

(8)

Our ultimate step is to determine the “scatter-to-primary” ratio between the dose absorbed
by pixels of the kV detector (assuming enough thickness to achieve CPE) and the isocentric
reference dose:

𝐷𝑑𝑒𝑡
𝜇𝑒𝑛
𝑑𝜎
𝜇𝑒𝑛
= 𝐸1 ( )
𝑑Ω 𝜌𝑒 𝑓2 𝑑𝐴 𝑑𝑍 ⁄𝐸0 ( )
𝐷𝑖𝑠𝑜
𝜌 𝑑𝑒𝑡 𝑑Ω
𝜌 𝐻

𝑑2

(9)

2𝑂

All parameters and units used in the calculation are summarized below:
𝑣𝑜𝑥𝑒𝑙
Φ𝑑𝑒𝑡

Photon fluence due to scatter events originating in a small voxel at P (cm-2).

𝑣𝑜𝑙𝑢𝑚𝑒
Φ𝑑𝑒𝑡

Photon fluence due to scatter events originating from all P-like voxels in the
exposed phantom volume (cm-2).
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𝑑𝑎

Cross sectional area of the voxel P (cm2). Assumption: Area 1 cm x 1 cm.

𝑑𝑧

Thickness of the voxel P (cm). Assumption: 1 cm.
Cross sectional area of the incident beam (cm2).

𝑑𝐴
Assumption: field size 10 cm x 10 cm of a non-divergent beam.
𝑑𝑍

Thickness of the scattering phantom volume (cm). Assumption: 10 cm.

Φ0

Photon fluence rate at isocenter of the incident beam (cm-2).

𝐷𝑖𝑠𝑜

Dose to water at isocenter (cGy).
Energy of incident photons. Assumption: 10 MV x-ray beam. Assumption: Effective

𝐸0

1

monoenergetic source, with mean energy was calculated: 10 × 3 = 3.333 𝑀𝑒𝑉

𝜇
( )
𝜌 𝐻

Mass attenuation coefficient of water (cm2/g).

2𝑂

𝐷𝑑𝑒𝑡
𝐸1
(

𝜇𝑒𝑛
)
𝜌 𝑑𝑒𝑡

Dose at the kV detector voxel (cGy).
Energy of scattered photon.
Mass energy absorption coefficient of the cesium iodide scintillator on the kV
detector (cm2/g).

𝑓2

Scattered beam attenuation factor.

𝑙

Scattered photon path length in the phantom (cm). For the central voxel (a) of the
detector, l = 5 cm, whereas for the top (b) and bottom (c) voxel, calculated based on
the size of the kV detector, D, and scattering angle, 𝜙.

𝑑𝜎
𝑑Ω

Klein-Nishina differential cross-section for the incident beam (cm2 e-1 sr-1).
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𝑒2

𝑟0

Classical electron radius: 𝑟0 =

𝜙

Photon scattering angle (radians). For the central voxel (a) of the detector, 𝜙 = 2 ,

𝑚0 𝑐 2

= 2.818 𝑥 10−13 cm.
𝜋

whereas for the top (b) and bottom (c) voxel, calculated based on the size of the kV
𝐷/2⁄
𝐿)

detector, D, and the distance from to kV detector, L: 𝜙 = 𝑡𝑎𝑛−1 (
𝑚0 𝑐 2
𝑑Ω

Rest energy of an electron is 0.511 MeV
Solid angle to the kV detector (sr).

d

Size of the height, width, or thickness of the voxel at the kV detector (cm)

L

Scattered photon path length to the voxel in the kV detector (cm).

𝜌𝑒

Electron density of water:
𝜌𝑒 = 3.343 𝑥 10−23 (𝑒 𝑔−1 )(𝑒 𝑔−1 ) × 0.9982 (𝑔 𝑐𝑚−3 )
= 3.337 𝑥 10−23 3370 (𝑒 𝑐𝑚−3 )

The dose scattered to the central voxel (a), top voxel (b), and bottom voxel (c) on the kV
detector per unit isocentric dose was 1.74 x 10-4, 1.73 x 10-4, 1.54 x 10-4, respectively, or
0.0174%, 0.0173%, and 0.0154%. This calculation provided for an estimation of the dose
ratio to the kV detector. Intra-fractional imaging synchronous to the MV beam, as
investigated in Chapters 3 and 4 of this thesis, is tarnished by the MV scatter acquired at
the kV detector. Further analysis to characterize the MV scatter in the kV detector, as
described in Section 6.2.2 of Chapter 6, can aid in improving image quality in during
treatment imaging.
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